---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description. Covers Product description and Place of product in therapy. 543 evidence topics quoted from 229 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Submission planned; NDA submission planned for 2027

> “In November 2023, we initiated OPERA-01, our pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC. We have completed enrollment and anticipate top-line results for this trial in the first quarter of 2027, expect to submit the new drug application (NDA) in 2027”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

> “2027: Anticipated submission of New Drug Application for potential approval of palazestrant as a monotherapy in 2/3L ER+/HER2-MBC and preparations for commercial launch”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.1-3"></a>

##### Launch: Anticipated in 2028

> “if successful, anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch in 2028.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

> “2028: Potential FDA approval and U.S. commercial launch of palazestrant”
> “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.1-4"></a>

##### OPERA-01 top-line data expected in the first quarter of 2027 (November 2026)

> “On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027”
> “Beyond preparing for the potential approval and commercialization of palazestrant”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.1-5"></a>

##### OPERA-01 enrollment completed and top-line timing moved to the first quarter of 2027 (August 2026)

> “Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027”
> “Importantly, enrollment in our pivotal OPERA-01 Phase 3 trial is complete and we now expect to report top-line data in the first quarter of 2027”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="topic-2.1.1-6"></a>

##### Earlier guidance: top-line data in fall 2026 and launch in 2027 (May 2026)

> “Report top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in second- and third-line ER+/HER2- metastatic breast cancer in the fall of 2026.”
> “we believe that we are well-positioned to continue our transformation into a fully integrated oncology company with our first anticipated commercial launch next year.”

Source: [Olema Oncology first quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-first-quarter-2026-financial-and)

<a id="topic-2.1.1-7"></a>

##### Earlier guidance: top-line data in fall 2026, NDA in 2027, and approval and launch in late 2027 (March 2026)

> “We anticipate top-line results for this trial in the fall of 2026, expect to submit the NDA in 2027, and, if successful, anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch in late 2027.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

> “Transformation into a fully-integrated oncology company underway in preparation for the Company’s first potential commercial launch in late 2027”

Source: [Olema Oncology fourth quarter and full year 2025 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-fourth-quarter-and-full-year-2025)

<a id="topic-2.1.1-8"></a>

##### Earlier guidance: top-line data in the second half of 2026 (August 2025)

> “OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025”

Source: [Olema Oncology second quarter 2025 results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2025-financial-and)

<a id="topic-2.1.1-9"></a>

##### Earlier guidance: top-line data in 2026 and launch in 2027 (May 2025)

> “we are focused on rapidly advancing our OPERA-01 and OPERA-02 pivotal trials with top-line data from OPERA-01 anticipated in 2026 and a potential commercial launch in 2027.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.1.1-10"></a>

##### Earlier guidance: top-line data in 2026 (December 2024)

> “We remain on track to share topline data from OPERA-01 in 2026”

Source: [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)

<a id="topic-2.1.1-11"></a>

##### Fast Track designation, July 2022

> “July 21, 2022”
> “today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250”
> “for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor.”

Source: [Olema Oncology Fast Track designation announcement (2022)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-receives-fda-fast-track-designation-op-1250)

<a id="topic-2.1.1-12"></a>

##### Fast Track designation: eligibility for priority review, accelerated approval, and rolling submission

> “In July 2022, we were granted FDA Fast Track designation for palazestrant for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.”
> “NDAs submitted for Fast Track designated drugs may qualify for priority review, accelerated approval and rolling submission under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.1-13"></a>

##### Dose of 90 mg once daily selected in alignment with FDA, May 2025

> “90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib”
> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial in second- and third-line estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”
> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.1.1-14"></a>

##### OPERA-01: first participant dosed in November 2023

> “OPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023”

Source: [Olema Oncology SABCS 2023 combination results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-demonstrates-attractive)

<a id="topic-2.1.1-15"></a>

##### OPERA-02: initiated in the third quarter of 2025

> “In the third quarter of 2025, we initiated OPERA-02, the pivotal Phase 3 clinical trial of palazestrant in combination with ribociclib in patients with frontline advanced or metastatic ER+/HER2- breast cancer.”
> “The trial is currently enrolling, and is expected to enroll approximately 1,000 patients, half of whom will receive palazestrant plus ribociclib; the other half will receive letrozole, a standard-of-care aromatase inhibitor, plus ribociclib.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

> “Initiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer”

Source: [Olema Oncology third quarter 2025 results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2025-financial-and)

<a id="topic-2.1.1-16"></a>

##### OPERA-02: enrollment ongoing, November 2026

> “Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136”
> “It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.1-17"></a>

##### Stage of development by setting

> “Monotherapy: Phase 3”
> “In Combination: Phase 3; multiple studies in Phase 1/2”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.1-18"></a>

##### Partnership: Novartis clinical collaboration for ribociclib and alpelisib combinations (2020, amended 2022 and 2023)

> “Olema first signed a clinical collaboration and supply agreement with Novartis in July 2020, the agreement was amended and restated in January 2022, and focuses on the evaluation of the safety, tolerability and efficacy of palazestrant in combination with Novartis’ proprietary cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor ribociclib and/or Novartis’ proprietary phosphatidylinositol 3-kinase (PI3Ka) inhibitor alpelisib in patients with metastatic ER+ breast cancer.”
> “The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.”

Source: [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)

<a id="topic-2.1.1-19"></a>

##### Partnership: Novartis ribociclib supply for OPERA-02 (2024)

> “Under the terms of the agreement, Novartis will provide Olema with ribociclib drug supply for the planned, Olema-sponsored, Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer. All clinical data and inventions from the trial will be jointly owned while Olema maintains global commercial and marketing rights to palazestrant.”

Source: [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)

<a id="topic-2.1.1-20"></a>

##### Partnership: Novartis right of first negotiation

> “We granted Novartis a right of first negotiation with respect to (a) the grant to any person or entity any right, license or sublicense to exploit palazestrant, in any field or territory, other than to third party service providers, or (b) the sale or other transfer to any person or entity of palazestrant and any related assets, each referred to herein as an Olema Compound Transaction.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.1-21"></a>

##### Partnership: Pfizer palbociclib (2020) and atirmociclib (2025) agreements

> “Under the terms of the agreement, Pfizer will supply atirmociclib for use in the Phase 1b/2 study and Olema will lead the conduct of the study. All clinical data and inventions relating to the combined use of atirmociclib and palazestrant resulting from the study will be jointly owned, with Olema maintaining full global commercial and marketing rights to palazestrant.”
> “This announcement represents Olema’s second clinical trial agreement with Pfizer. The companies’ previous agreement was established in November 2020 to evaluate palazestrant in combination with palbociclib (IBRANCE®) in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer.”

Source: [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)

<a id="topic-2.1.1-22"></a>

##### Patents: composition of matter to 2036; pending applications to 2040 to 2046

> “The 20-year term for these patents expires in 2036. In the United States, it is uncertain whether any PTE will be available, and if so, how much.”
> “Additional patent applications are pending, including applications that relate to dosing regimens and treatment of particular cancers, formulations, and additional combination therapies, including combination therapy with ribociclib, among other patent applications, and, if granted, will have 20-year terms that expire between 2040 and 2046.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.1-23"></a>

##### Regulatory status outside the United States

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Olema Oncology

> “Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.)”
> “Nov. 12, 2026”

Source: [Olema Oncology corporate name change announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-corporate-name-change)

<a id="topic-2.1.2.1-2"></a>

###### Development code and nonproprietary name

> “Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class: complete estrogen receptor antagonist and selective estrogen receptor degrader

> “Here, we describe our discovery of the investigational drug OP-1250 (palazestrant). OP-1250 is a potent complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that is active in both WT and mutESR1 breast cancer tumors.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

> “Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD).”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.2.1-5"></a>

###### International nonproprietary name: proposed in 2022

> “Proposed INN: List 128”
> “palazestrantum”
> “antiestrogen, antineoplastic”
> “C28H36FN3O”
> “2092925-89-6”

Source: [WHO Proposed INN List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

<a id="topic-2.1.2.1-6"></a>

###### International nonproprietary name: recommended in 2023

> “WHO Drug Information, Vol. 37, No. 3, 2023”
> “Recommended INN: List 90”
> “palazestrantum”

Source: [WHO Recommended INN List 90 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl90.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Commercial dosage form and strength

No evidence found.

<a id="topic-2.1.2.2-2"></a>

###### Capsules given fasted in the phase 1/2 monotherapy study

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.2-3"></a>

###### Daily doses studied in dose escalation

> “The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.2-4"></a>

###### Capsule formulation and gastrointestinal events; tablet formulation in ongoing studies

> “the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events. Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.2-5"></a>

###### Tablet formulation in OPERA-01

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”
> “Expected to reduce rate and grade of nausea and vomiting”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.2-6"></a>

###### Capsules in the ribociclib combination analysis

> “Palazestrant was administered in capsules and in fasting state in this analysis.”

Source: [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)

<a id="topic-2.1.2.2-7"></a>

###### Doses in the phase 3 trials: 90 mg and 120 mg once daily in OPERA-01 Part 1; 90 mg once daily in OPERA-02

> “Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

> “Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS class

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### WHO ATC code

No evidence found.

<a id="topic-2.1.2.4-3"></a>

###### WHO INN classification: antiestrogen, antineoplastic

> “antiestrogen, antineoplastic”

Source: [WHO Proposed INN List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

<a id="topic-2.1.2.4-4"></a>

###### NCI Thesaurus: complete estrogen receptor antagonist

> “Complete Estrogen Receptor Antagonist”
> “An orally available, small molecule antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1) and a selective ER degrader (SERD), with potential antineoplastic activity.”

Source: [NCI Thesaurus (2026)](https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C176877)

<a id="topic-2.1.2.4-5"></a>

###### Company classification: CERAN and SERD

> “Mechanism of Action”
> “Complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD)”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Approved indication

No evidence found.

<a id="topic-2.1.2.5-2"></a>

###### Indication sought in the planned NDA: monotherapy in second- and third-line ER+/HER2- metastatic breast cancer

> “2027: Anticipated submission of New Drug Application for potential approval of palazestrant as a monotherapy in 2/3L ER+/HER2-MBC and preparations for commercial launch”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.5-3"></a>

###### Fast Track population

> “Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-2.1.2.5-4"></a>

###### Population of the pivotal trial OPERA-01

> “A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

> “Completed enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with second or third-line estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC).”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="topic-2.1.2.5-5"></a>

###### Second indication under study: first line in combination with ribociclib

> “Turning to our pivotal Phase 3 OPERA-02 trial in first-line metastatic breast cancer, momentum continues to build.”
> “We believe that palazestrant, in combination with ribociclib, is well positioned to become the new standard of care in this setting.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Complete estrogen receptor antagonist and selective estrogen receptor degrader

> “Palazestrant (OP-1250) is a novel oral, complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both transcriptional activation function domains, AF1 and AF2, required for the estradiol-generated transcriptional activity of ER”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.1-2"></a>

###### Blockade of AF1 and AF2 compared with selective estrogen receptor modulators

> “Selective estrogen receptor modulators (SERMs) block only the AF2 domain, leaving the AF1 domain active and capable of gene transcription. Palazestrant is a complete ER antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both AF1 and AF2 domains to completely block ER-driven transcriptional activity.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.1-3"></a>

###### Rationale for blocking both activation functions

> “Transcription via AF1 in the N terminus is hormone-independent and can be promoted by a range of growth factors. For complete inhibition of ER-driven transcription, both AF1 and AF2 must be blocked.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.1-4"></a>

###### Absence of agonist activity

> “OP-1250, like fulvestrant, has no agonist activity on the ER and completely blocks estrogen-induced transcriptional activity.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-5"></a>

###### Inhibition of AF1-dependent activity in uterine cells

> “Elacestrant demonstrated partial agonist activity, with maximum response of 24%; imlunestrant, fulvestrant, and OP-1250 did not induce measurable AP activity.”
> “imlunestrant, fulvestrant, and OP-1250 completely inhibited activity with IC50 values of 32, 9.4, and 6.4 nmol/L, respectively”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-6"></a>

###### Estrogen receptor degradation in breast cancer cells

> “OP-1250 degrades ERα with comparable potency to fulvestrant (DC50 0.52 nmol/L and 0.56 nmol/L, respectively; Emax 62% and 69%, respectively)”
> “OP-1250 treatment reduced ERα protein levels by 63% relative to vehicle in MCF7 and 72% in CAMA-1 cells”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-7"></a>

###### Proteasome-dependent degradation

> “In MCF7 cells, degradation of ERα by OP-1250 was observed as early as 2 hours after treatment, levels reduced in a time-dependent manner, and degradation was blocked by treatment with the proteasome inhibitor MG-132”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-8"></a>

###### Antagonism of residual receptor after degradation

> “Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant”
> “However, the presence of residual ER protein has been detected in vitro with these treatments”
> “Therefore, palazestrant demonstrates robust CERAN activity that completely blocks ER-induced transcription, ensuring full inhibition of any residually available ER remaining from its SERD activity.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.6.1-9"></a>

###### Receptor selectivity

> “OP-1250 demonstrated no agonist-like cross-reactivity on glucocorticoid, progesterone, or androgen receptors. Inhibition of agonist-induced androgen receptor transcriptional activity was detected only at >1 μmol/L OP-1250”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-10"></a>

###### Ligand-binding domain conformation

> “Structural biology studies confirmed the binding of 21 in ERα and the resulting movement of H12, consistent with an antagonist receptor conformation.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.1-11"></a>

###### Activity against ESR1 Y537S and D538G mutant receptors

> “In AP assays conducted with mutant Ishikawa cells, OP-1250 displayed favorable potency against both mutants, comparable to that of fulvestrant”
> “In both AP and proliferation assays, CERANs showed reduced potency in the mutant cell lines relative to wild-type.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-12"></a>

###### Antiproliferative potency in estrogen-stimulated cells

> “OP-1250 demonstrated a promising efficacy profile, with IC50 values of 1.4–1.6 nmol/L and favorable Emax values.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.1-13"></a>

###### Corepressor NCoR1 recruitment

> “Palazestrant and fulvestrant, complete ER antagonists, induced a strong increase in luminescence, indicating potent recruitment of NCoR1 to ERα (Figure 3B).”
> “Palazestrant induces strong NCoR1–ERα recruitment at low concentrations (~1 nM).”
> “4OH-tamoxifen, lasofoxifene and vepdegestrant do not reach a maximum effect (Emax ) of 100% indicating incomplete recruitment.”

Source: [Barratt et al. (2026)](https://olema.com/wp-content/uploads/2026/04/Olema_AACR_2026_Poster-2950_Final-Digital-Poster.pdf)

<a id="topic-2.1.2.6.1-14"></a>

###### Company summary of the NCoR1 findings

> “In a split-luciferase assay, palazestrant was shown to fully recruit the corepressor, NCoR1, enabling complete estrogen receptor (ER) antagonism.”

Source: [Olema Oncology AACR 2026 preclinical data announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-preclinical-data-palazestrant-and-op)

<a id="topic-2.1.2.6.1-15"></a>

###### Earlier hypothesis for AF1 inhibition

> “While the mechanism of AF1 inhibition by CERANs such as OP-1250 has not been determined, we hypothesize that this may occur through recruitment of ER corepressor proteins such as NCoR, as suggested previously”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Reduction of ESR1 variant mutations in circulating tumor DNA

> “were reduced from 106 mutations detected at baseline (in 64 patients with detectable mutations at baseline) to 37 mutations (in 21 patients) after 2 treatment cycles of palazestrant treatment”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-2"></a>

###### Clinical benefit by change in ESR1 mutations

> “In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-3"></a>

###### Ki67 and estrogen receptor expression in tumor samples

> “Palazestrant treatment was associated with significantly reduced Ki67 levels from 29.2% (N = 18) to 20.4% (N = 12); P = 0.041”
> “resulted in a numerical decrease in ERα Allred score from 6.67 (N = 18) to 5.17 (N = 12); P = 0.13”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-4"></a>

###### Exposure relative to the preclinical efficacy threshold

> “resulted in palazestrant concentrations above the predicted efficacy threshold of 226 ng/mL (Fig. 3), indicating complete inhibition of the ER”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-5"></a>

###### Target engagement in a patient-derived xenograft

> “OP-1250 reduced Ki67 levels in a dose-dependent manner, in line with observed tumor growth inhibition”
> “At both the 5 and 10 mg/kg doses, nuclear ERα staining was reduced by approximately 75%, compared with the vehicle group, confirming target engagement”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-6"></a>

###### Uterine wet weight assay

> “E2 and tamoxifen significantly increased UWW, while OP-1250 and fulvestrant did not. OP-1250 and fulvestrant inhibited E2-induced increases in weight, with OP-1250 displaying dose-dependent inhibition as low as 0.01 mg/kg”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-7"></a>

###### Reversal of estrogen-induced transcription

> “OP-1250 treatment reversed E2-induced changes in transcriptional activity of known estrogen response genes within 6 hours”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-8"></a>

###### Suppression of PGR and GREB1 expression

> “Palazestrant consistently downregulates PGR and GREB1 expression in both ESR1 wild-type (MCF7, CAMA-1) and mutant (ST941C) breast cancer models (Figure 6A-F).”

Source: [Barratt et al. (2026)](https://olema.com/wp-content/uploads/2026/04/Olema_AACR_2026_Poster-2950_Final-Digital-Poster.pdf)

<a id="topic-2.1.2.6.2-9"></a>

###### ESR1 wild-type xenograft

> “OP-1250 doses ≥3 mg/kg shrank tumors and outperformed fulvestrant, which did not lead to appreciable tumor shrinkage.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-10"></a>

###### ESR1 Y537S patient-derived xenografts

> “In this model, OP-1250 doses of ≥1 mg/kg outperformed fulvestrant, and all treatments led to tumor growth inhibition; 10 and 30 mg/kg doses led to tumor shrinkage below starting volume in all treated animals”
> “Both OP-1250 doses outperformed elacestrant, with greatest tumor growth inhibition with 10 mg/kg OP-1250.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-11"></a>

###### Intracranial xenograft model

> “4 of 8 animals in the OP-1250 monotherapy group and 6 of 8 in the OP-1250 + ribociclib group lacked detectable tumor at study day 100.”
> “OP-1250 treatment (monotherapy or in combination with ribociclib) resulted in all 8 animals alive at study day 100 and 6 alive 50 days after cessation of dosing.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-12"></a>

###### Preclinical combination with CDK4/6 inhibitors

> “The 10 mg/kg dose of OP-1250, which leads to plasma concentrations similar to those measured in clinical studies, outperformed 75 mg/kg monotherapy doses of both CDK4/6 inhibitors and resulted in tumor shrinkage. Combination treatment resulted in more pronounced and consistent tumor shrinkage across doses, with all but one animal achieving >50% reduction in tumor volume”
> “addition of OP-1250 to either CDK4/6 inhibitor extended animal survival”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

<a id="topic-2.1.2.6.2-13"></a>

###### QTcF in the phase 1/2 monotherapy study

> “There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-14"></a>

###### Planned electrocardiogram analysis

> “The Corrected QT interval according to Fridericia’s formula (QTcF) and heart rate (HR) from electrocardiogram (ECG) data analysis will be conducted based on methodology recommended in the ICH E14 guideline”
> “Descriptive statistics (for the average of the triplicate measurements) at baseline and the maximum of post-baseline as well as changes from baseline will be summarized for QTcF and HR.”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="topic-2.1.2.6.2-15"></a>

###### Bradycardia at the recommended phase 2 dose

> “TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.2-16"></a>

###### Bradycardia during dose escalation

> “Four patients experienced grade 1 asymptomatic bradycardia; 1 of these 4 was found to have a prior history of asymptomatic bradycardia. One patient was in the 120 mg cohort, 1 patient was in the 210 mg cohort, and 2 patients were in the 300 mg cohort.”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.6.2-17"></a>

###### QTcF in combination with ribociclib

> “No QTcF values of >500 ms were observed at any time point.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.6.2-18"></a>

###### hERG inhibition in vitro

> “did not inhibit the human ether a-go-go related gene (hERG) protein at 30 μM and hence does not carry cardiac arrhythmia liability”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption and time to peak concentration

> “Single-dose and steady-state PK analyses (cycles 1 and 2, day 1) showed that palazestrant was readily bioavailable and demonstrated rapid absorption with a median Tmax of approximately 4 h”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-2"></a>

###### Dose proportionality

> “Palazestrant also showed linear PK with a dose-proportional exposure in the dose range of 30 mg/day to 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-3"></a>

###### Accumulation, peak-to-trough fluctuation, and effective half-life

> “Steady-state PK profiles showed limited peak-to-trough fluctuation (range, 1.89–2.51), with an accumulation ratio of approximately 3 for Cmax (range, 1.96–3.55) and of approximately 4 for AUC0–24 (range, 3.63–5.20), and an effective half-life of approximately 70 h (range, 50.5 h to 77.2 h).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-4"></a>

###### Terminal half-life

> “Overall, palazestrant showed biphasic elimination in the distribution phase, which was similar to that observed with 120 mg palazestrant in healthy volunteers (data on file), confirming the 8-day terminal half-life.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-5"></a>

###### Distribution and support for once-daily dosing

> “PK analyses showed that palazestrant was readily bioavailable and rapidly absorbed (reaching peak concentration after 4 h), with extensive tissue distribution, dose-proportional exposure, and a long half-life of approximately 8 days. These PK characteristics support once-daily dosing.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-6"></a>

###### Steady-state exposure at the recommended phase 2 dose

> “The steady-state geometric mean AUC0–24 was 4030 and 9210 h*ng/mL for 60 and 120 mg dose cohorts, respectively”
> “At the RP2D of 120 mg (n = 73), the geometric mean Cmax at steady state was 541 ng/mL, and the geometric mean Cavg was 384 ng/mL, showing sustained concentrations above the predicted efficacy threshold”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-7"></a>

###### Steady-state pharmacokinetic parameters at 60, 90, and 120 mg

| Dose, once daily | Tmax,ss, h, median [min–max] | Cmin,ss, ng/mL, GeoMean (GeoCV%) | Cmax,ss, ng/mL, GeoMean (GeoCV%) | Cavg,ss, ng/mL, GeoMean (GeoCV%) | AUC0–24,ss, ng*h/mL, GeoMean (GeoCV%) | Accumulation ratio, Cmax,ss | Accumulation ratio, AUC0–24,ss |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 60 mg | “4.0” “[1.00–6.00]” | “116 (50.3)” | “241 (47.1)” | “168 (45.2)” | “4030” | “2.25 (57.5)” | “2.94 (51.0)” |
| 90 mg | “4.0” “[1.00–6.00]” | “213 (92.7)” | “460 (77.4)” | “322 (82.1)” | “7720” | “3.55 (34.7)” | “5.12 (41.3)” |
| 120 mg | “4.0” “[1.00–6.00]” | “276 (41.6)” | “541 (37.4)” | “384 (37.9)” | “9210” | “1.96 (19.6)” | “4.76 (43.1)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-8"></a>

###### Posted steady-state AUC by dose in the registry results

| Dose, once daily | Participants analyzed | AUC0–24 at steady state, ng/mL*h, geometric mean | Geometric coefficient of variation |
| --- | --- | --- | --- |
| 30 mg | “5” | “1956” | “33.0” |
| 60 mg | “26” | “4014” | “46.2” |
| 90 mg | “6” | “7668” | “82.4” |
| 120 mg | “77” | “9163” | “38.1” |
| 150 mg | “2” | “12580” | “27.3” |
| 210 mg | “6” | “22439” | “47.2” |
| 300 mg | “6” | “25438” | “40.2” |

Source: [ClinicalTrials.gov NCT04505826 results](https://clinicaltrials.gov/study/NCT04505826?tab=results)

<a id="topic-2.1.2.6.3-9"></a>

###### Effective half-life by dose during dose escalation

| Dose, once daily | t1/2eff, h, GeoMean | GeoCV% |
| --- | --- | --- |
| 30 mg | “54.7” | “(26.0)” |
| 60 mg | “63.4” | “(29.2)” |
| 90 mg | “72.7” | “(54.1)” |
| 120 mg | “68.8” | “(54.7)” |
| 150 mg | “61.6” | “(23.6)” |
| 210 mg | “57.3” | “(109.9)” |
| 300 mg | “51.0” | “(61.7)” |

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.6.3-10"></a>

###### Time to peak concentration during dose escalation

> “OP-1250 is readily bioavailable with a median tmax ranging between 2 and 4 hours”
> “Dose-proportional increases in OP-1250 exposures (mean Cmax and AUC0–24) were observed across all evaluated doses after single and multiple doses”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.6.3-11"></a>

###### Terminal half-life and peak-to-trough variability at the dose selection analysis

> “Mean terminal half-life (t1/2)=8 days, supporting once-daily dosing”
> “Steady-state plasma levels showed minimal peak-to-trough variability, allowing complete inhibition of the ER for the full dosing interval”

Source: [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)

<a id="topic-2.1.2.6.3-12"></a>

###### Exposure at 90 mg and 120 mg in combination with ribociclib

> “Palazestrant doses of 90 mg and 120 mg had overlapping exposure when in combination with ribociclib”
> “Steady-state plasma concentrations at both 90 mg and 120 mg doses exceeded the predicted efficacious threshold”
> “There was no clinically significant difference in exposure between 90 mg and 120 mg doses.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.6.3-13"></a>

###### Plasma protein binding across species

> “Compound 21 is highly plasma protein-bound (>99%) across all species, including humans. Plasma free drug percentages in mouse/rat/dog/cyno/hu are 0.06/0.24/0.04/0.13/0.08, respectively.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.3-14"></a>

###### Nonclinical oral half-life

> “Compound 21 is orally bioavailable and has low clearance and a long half-life in the mouse, rat, dog, and monkey”
> “The half-lives after a single oral dose in the mouse, rat, dog, and monkey were 10, 16, 106, and 34 h, respectively.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.3-15"></a>

###### Nonclinical single oral dose pharmacokinetics

| Species | Oral dose, mg/kg | Tmax, h | T1/2, h | Oral bioavailability, F (%) |
| --- | --- | --- | --- | --- |
| Mouse | “5” | “1” | “10” | “72” |
| Rat | “5” | “1.5” | “16” | “55” |
| Dog | “10” | “1.5” | “106” | “89” |
| Monkey | “10” | “8” | “34” | “44.4” |

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.3-16"></a>

###### Brain and tumor concentrations in mice

> “OP-1250 demonstrated plasma exposures well above levels needed for complete ER saturation at Ctrough, robust brain penetrance with brain/plasma ratios >1, and tumor accumulation.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information, boxed warning, contraindications, and REMS

> “We have never completed a pivotal clinical trial or submitted an NDA to the FDA or similar drug approval filings to comparable foreign authorities.”
> “For example, the most common side effects we have seen in patients treated with palazestrant in our clinical trials are nausea, fatigue, vomiting, constipation, headaches, and neutropenia.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.2.7.1-2"></a>

###### Treatment-emergent and treatment-related adverse events: phase 1/2 monotherapy at 60 and 120 mg

> “Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%).”
> “Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]).”
> “Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Adverse event, n (%) | 60 mg, any grade (n = 30) | 120 mg, any grade (n = 86) | 120 mg, grade 3 | 120 mg, grade 4 |
| --- | --- | --- | --- | --- |
| TEAE: nausea | “14 (46.7)” | “54 (62.8)” | “3 (3.5)” | “0” |
| TEAE: vomiting | “5 (16.7)” | “25 (29.1)” | “4 (4.7)” | “0” |
| TEAE: fatigue | “13 (43.3)” | “22 (25.6)” | “3 (3.5)” | “0” |
| TEAE: neutropenia | “2 (6.7)” | “21 (24.4)” | “3 (3.5)” | “6 (7.0)” |
| TEAE: headache | “7 (23.3)” | “17 (19.8)” | “0” | “0” |
| TEAE: constipation | “6 (20.0)” | “15 (17.4)” | “0” | “0” |
| TEAE: diarrhea | “6 (20.0)” | “12 (14.0)” | “0” | “0” |
| TRAE: nausea | “10 (33.3)” | “47 (54.7)” | “3 (3.5)” | “0” |
| TRAE: vomiting | “3 (10.0)” | “21 (24.4)” | “2 (2.3)” | “0” |
| TRAE: fatigue | “9 (30.0)” | “17 (19.8)” | “2 (2.3)” | “0” |
| TRAE: neutropenia | “0” | “18 (20.9)” | “3 (3.5)” | “5 (5.8)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-3"></a>

###### Adverse events by dose: posted registry results of the phase 1/2 trial

| Adverse event, affected/at risk (%) | 60 mg QD | 90 mg QD | 120 mg QD | 300 mg QD |
| --- | --- | --- | --- | --- |
| Total serious adverse events | “4/33 (12.12%)” | “2/6 (33.33%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Febrile neutropenia (serious) | “0/33 (0.00%)” | “0/6 (0.00%)” | “2/83 (2.41%)” | “1/7 (14.29%)” |
| Nausea | “14/33 (42.42%)” | “2/6 (33.33%)” | “55/83 (66.27%)” | “6/7 (85.71%)” |
| Vomiting | “5/33 (15.15%)” | “1/6 (16.67%)” | “24/83 (28.92%)” | “5/7 (71.43%)” |
| Diarrhoea | “6/33 (18.18%)” | “0/6 (0.00%)” | “14/83 (16.87%)” | “1/7 (14.29%)” |
| Fatigue | “13/33 (39.39%)” | “0/6 (0.00%)” | “24/83 (28.92%)” | “4/7 (57.14%)” |
| Neutrophil count decreased | “2/33 (6.06%)” | “0/6 (0.00%)” | “16/83 (19.28%)” | “2/7 (28.57%)” |
| Alanine aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “11/83 (13.25%)” | “1/7 (14.29%)” |
| Aspartate aminotransferase increased | “0/33 (0.00%)” | “0/6 (0.00%)” | “13/83 (15.66%)” | “0/7 (0.00%)” |
| Sinus bradycardia | “0/33 (0.00%)” | “0/6 (0.00%)” | “7/83 (8.43%)” | “2/7 (28.57%)” |
| Photopsia | “0/33 (0.00%)” | “2/6 (33.33%)” | “5/83 (6.02%)” | “3/7 (42.86%)” |

Source: [ClinicalTrials.gov NCT04505826 results](https://clinicaltrials.gov/study/NCT04505826?tab=results)

<a id="topic-2.1.2.7.1-4"></a>

###### Neutropenia: phase 1/2 monotherapy

> “Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.”
> “Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia.”
> “While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.”
> “The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).”
> “Neutropenia, albeit at a lower frequency, has also been reported with fulvestrant, with grade ≥ 3 neutropenia observed in 1% to 2% of patients receiving fulvestrant monotherapy and rates of febrile neutropenia of 0 to 1% [30, 31].”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Of the 86 patients treated, events of Grade 4 neutropenia were observed in six patients, occurring approximately 4–6 weeks into therapy.”
> “All six patients had prior exposure to CDK4/6 inhibitors.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.7.1-5"></a>

###### Neutropenia: blood count monitoring in ongoing trials

> “All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-6"></a>

###### Adverse events including neutropenia: combination with ribociclib

| Related TEAE, n (%) | 120 mg + ribociclib, all grades (n = 56) | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg + ribociclib, all grades (n = 16) | 90 mg, grade 3 | 90 mg, grade 4 |
| --- | --- | --- | --- | --- | --- | --- |
| Neutropenia | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| WBC decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

> “2 patients had a dose reduction of palazestrant only; 1 due to nausea and 1 due to neutropenia”
> “8 patients had a dose reduction of both treatments; 23 patients had a dose reduction of ribociclib.”
> “The most common cause for dose reduction was neutropenia.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.7.1-7"></a>

###### Adverse events including neutropenia: combination with palbociclib

| TEAE, n (%) | All grades (N = 46) | Grade 3 | Grade 4 |
| --- | --- | --- | --- |
| Neutropenia | “40 (87)” | “28 (61)” | “5 (11)” |
| Nausea | “26 (57)” | “0” | “0” |
| Vomiting | “17 (37)” | “0” | “0” |
| Anemia | “12 (26)” | “1 (2)” | “0” |
| Diarrhea | “11 (24)” | “0” | “0” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

> “Neutropenia incidence was similar to the PALOMA-3 study; it was reversible in all patients and the timing was generally consistent with the palbociclib-related neutropenia.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.7.1-8"></a>

###### Bradycardia and photopsia: phase 1/2 monotherapy

> “TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.”
> “Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively) [25, 28, 29].”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-9"></a>

###### QTc interval: monotherapy and combination with ribociclib

> “There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.”
> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “No QTcF values of >500 ms were observed at any time point.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

> “Screening QTcF <450 ms, resting heart rate 50-90 beats/min”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

> “Significant cardiovascular disease”
> “Significant ECG abnormalities”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="topic-2.1.2.7.1-10"></a>

###### Gastrointestinal toxicity: nausea, vomiting, and diarrhea

> “The most frequently reported TRAEs were gastrointestinal events and fatigue, which have also been commonly reported with SERDs and selective ER covalent antagonists (SERCAs) [24–27].”
> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”
> “In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”
> “Expected to reduce rate and grade of nausea and vomiting”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.7.1-11"></a>

###### Hepatic laboratory abnormalities

> “In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).”
> “Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| TEAE, 120 mg (n = 83) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All (%) |
| --- | --- | --- | --- | --- | --- |
| AST increased | “10” | “2” | “1” | “0” | “13 (16%)” |

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.7.1-12"></a>

###### Venous thromboembolism

> “Patients were excluded from all phases of the study if they had impaired cardiac function, cerebral vascular disease, or a recent thromboembolic event”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “History of a pulmonary embolism, or deep venous thrombosis within the last 6 months, or subject has an increased risk of thrombosis as determined by the investigator.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

> “Cerebral vascular disease, pulmonary embolism, DVT <6 months prior to the first dose of study drug, or increased risk of thrombosis”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.7.1-13"></a>

###### Discontinuations due to adverse events: phase 1/2 monotherapy

> “Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.7.1-14"></a>

###### Safety assessments and independent data monitoring in OPERA-01

> “Safety and tolerability (AEs, SAEs, dose modifications, clinical laboratory parameters, ECGs, performance status, and vital sign measurements)”
> “Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.”
> “An independent data monitoring committee (IDMC), comprising medical and statistical representatives not involved in the trial, is monitoring the safety, efficacy, and conduct of the trial.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.7.1-15"></a>

###### Class context: dyslipidemia and embryo-fetal toxicity with elacestrant

> “5.1 Dyslipidemia Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively.”
> “Monitor lipid profile prior to starting and periodically while taking ORSERDU.”
> “Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.1.2.7.1-16"></a>

###### Class context: QTc prolongation and bradycardia with camizestrant

> “ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death”
> “ETCAMAH causes a decrease in heart rate.”
> “In SERENA-6, bradycardia adverse events occurred in 8% of patients treated with ETCAMAH.”
> “Visual disturbances include: photopsia, blurred vision, visual field defect, decreased visual acuity, visual impairment, diplopia, photophobia and visual perseveration.”

Source: [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)

<a id="topic-2.1.2.7.1-17"></a>

###### Class context: QTc prolongation with vepdegestrant

> “In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients.”
> “Perform an ECG prior to initiation of treatment with VEPPANU, and do not initiate VEPPANU in patients with QTc >470 msec.”

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age range studied and older adults

> “18 Years and older”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Age, years; median (range) | “59.5 (30–81)” | “61.0 (32–85)” | “61.0 (30–85)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
| --- | --- | --- | --- |
| Median age, yrs (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.8-2"></a>

###### Men: eligibility and enrollment

> “Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Female, n (%) | “30 (100)” | “86 (100)” | “116 (100)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Characteristic, n (%) | Total (N = 46) |
| --- | --- |
| Female sex | “45 (98)” |
| Premenopausal | “4 (9)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Premenopausal women: ovarian suppression and enrollment

> “Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Female participants can be pre-, peri- or postmenopausal.”
> “Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Childbearing potential: yes, n (%) | “0” | “7 (8.1)” | “7 (6.0)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “The reproductive status of female participants has been reported as having a childbearing potential (yes vs no)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
| --- | --- | --- | --- |
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.8-4"></a>

###### Pregnancy, lactation, and contraception requirements in clinical trials

> “Willingness to use effective contraception”
> “Pregnancy or breastfeeding”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

> “Males and females of childbearing age must be willing to use effective contraception during the study and for 90 days or longer, following the last dose of study treatment”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.8-5"></a>

###### Nonclinical reproductive and developmental toxicology

No evidence found.

<a id="topic-2.1.2.8-6"></a>

###### Class context: embryo-fetal toxicity with imlunestrant

> “In an animal reproduction study, oral administration of imlunestrant to pregnant rats during the period of organogenesis led to embryo-fetal mortality and structural abnormalities at maternal exposures that were below the human exposure at the recommended dose based on AUC.”
> “Advise females of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose.”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

###### Hepatic impairment: trial exclusion criteria

> “a clinically significant history of liver disease consistent with Child–Pugh class B or C”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Adequate hepatic function”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

> “Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis (eg, hepatitis B or hepatitis C virus), current alcohol abuse, or cirrhosis.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

> “Adequate hematologic, renal, hepatic, and coagulation function”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.8-8"></a>

###### Renal impairment: trial exclusion criteria

> “Adequate renal function”
> “Significant renal disease”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="topic-2.1.2.8-9"></a>

###### Hepatic and renal impairment: dedicated pharmacokinetic studies

No evidence found.

<a id="topic-2.1.2.8-10"></a>

###### Central nervous system metastases: phase 2 cohort and exclusion from OPERA-01

> “Cohort A will enroll subjects with measurable disease without evidence of Central Nervous System (CNS) metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases.”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

> “Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and CNS metastases (exploratory cohort, not included in this report).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Palazestrant has demonstrated activity in both ESR1-wild type (ESR1-wt) and ESR1-mutated (ESR1-mut) preclinical models as well as central nervous system (CNS) penetration and demonstrated antitumor activity in brain metastasis models.”
> “CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression that requires immediate CNS-directed treatment”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.8-11"></a>

###### Race of participants in the phase 1/2 monotherapy trial

| Race, n (%) | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| White | “23 (76.7)” | “70 (81.4)” | “93 (80.2)” |
| Black or African American | “1 (3.3)” | “7 (8.1)” | “8 (6.9)” |
| Asian | “1 (3.3)” | “3 (3.5)” | “4 (3.4)” |
| Not reported/Other | “5 (16.7)” | “6 (7.0)” | “11 (9.5)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Palazestrant

<a id="topic-2.1.2.9.1-1"></a>

###### Strong CYP3A4 inhibitors and inducers in the phase 1/2 study

> “any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.9.1-2"></a>

###### Medications with a known risk of QT prolongation

> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.9.1-3"></a>

###### Proton pump inhibitors and antiemetics

> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.9.1-4"></a>

###### CYP3A4 metabolism and sensitivity to inhibition

> “Ribociclib is a strong inhibitor of CYP3A4. While palazestrant is metabolized by CYP3A4, it is not sensitive to CYP3A4 inhibition.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.1-5"></a>

###### Effect of ribociclib on palazestrant trough concentrations

> “Steady-state trough values overlapped between the combination and single agent palazestrant, with a small increase in mean exposure (Table 4). The effect of ribociclib on the exposure of palazestrant is not clinically meaningful.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.1-6"></a>

###### Dose-normalized palazestrant trough concentrations with and without ribociclib

| Study | Dose-normalized steady-state trough, geometric mean (geometric SD); n | 90% confidence interval |
| --- | --- | --- |
| OP-1250-001, single agent | “2.49 (48%); 172” | “[2.35, 2.64]” |
| OP-1250-003, combination with ribociclib | “3.35 (61%); 25” | “[2.77, 4.06]” |

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.1-7"></a>

###### Ribociclib and palazestrant exposure at the September 2024 data cutoff

> “Steady-state trough values between the combination and single-agent palazestrant were overlapping.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-2.1.2.9.1-8"></a>

###### Ribociclib and palazestrant exposure at the July 2025 data cutoff

> “Ribociclib had no clinically meaningful effect on palazestrant exposure”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.9.1-9"></a>

###### Effect of palbociclib on palazestrant exposure

> “Palbociclib 125 mg did not affect palazestrant (30-120 mg) exposure parameters.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Palazestrant on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### CYP3A4 inhibition and induction

> “Ribociclib is metabolized mainly by CYP3A4. Palazestrant is not a CYP3A4 inhibitor or inducer.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### In vitro CYP3A4 and transporter inhibition

> “Low risk of transporter inhibition by compound 21 was determined by in vitro P-gp and BCRP assays (IC50 = 4 and >5 μM, respectively). No inhibitory activity was observed for the CYP 3A4 isoform (IC50 > 10 μM).”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.9.2-3"></a>

###### Ribociclib exposure with palazestrant 30 to 120 mg

> “Ribociclib 600 mg exposure is not affected by palazestrant doses ranging from 30 to 120 mg.”
> “When administered in combination with palazestrant, ribociclib exposure was within the reported range of the 600 mg dose single agent exposures at steady state.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.2-4"></a>

###### Steady-state ribociclib parameters with and without palazestrant

| Steady-state parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
| --- | --- | --- |
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.2-5"></a>

###### Ribociclib exposure at the September 2024 data cutoff

> “Palazestrant did not affect ribociclib 600 mg exposure when compared with published concentrations for single-agent ribociclib.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-2.1.2.9.2-6"></a>

###### Ribociclib exposure at the July 2025 data cutoff

> “No significant drug-drug interaction was observed between palazestrant and ribociclib”
> “Palazestrant had no clinically meaningful effect on ribociclib 600 mg steady-state exposure when compared with published concentrations for single-agent ribociclib.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.9.2-7"></a>

###### Palbociclib exposure with palazestrant

> “There was no effect of palazestrant (30-120 mg) on palbociclib 125 mg exposure parameters.”
> “AUC(0-24)and Cmax ratios of combination therapy to monotherapy ranged from 96% to 107%.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.9.2-8"></a>

###### Company summary of the palbociclib interaction data

> “There was no observed drug-drug interaction between palazestrant and palbociclib, and there was no induced metabolism or increase in exposure of either palbociclib or palazestrant when administered in combination.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dose levels in dose escalation

> “The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-2"></a>

###### Maximum tolerated dose

> “Palazestrant doses of up to 300 mg/day resulted in no DLTs, and the MTD was not reached.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-3"></a>

###### Doses selected for dose expansion

> “both the 60 mg/day and 120 mg/day doses were selected for further study in the dose-expansion phase (phase 1b)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-4"></a>

###### Recommended phase 2 dose of 120 mg

> “Based on the tolerable safety profile, favorable PK, and encouraging antitumor activity shown in the phase 1 portion of the study, the 120 mg/day dose was chosen as the RP2D.”
> “Limited data were available for patients treated with 90 mg palazestrant, as only 6 patients were enrolled during dose escalation.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose reductions during dose escalation

> “Six patients had dose reductions”
> “2 patients at 210 mg dose had reductions: 1 patient to 120 mg and 1 patient to 60 mg”
> “4 patients at 300 mg dose had reductions: 3 patients to 120 mg and 1 patient to 60 mg”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.10.1-6"></a>

###### Dose modification for neutropenia in the monotherapy study

> “these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-7"></a>

###### Reduced dose levels after grade 4 neutropenia

> “Of these patients, three had a dose interruption with recovery and subsequent dose reduction (two continued at 90 mg and one continued at 60 mg) without any recurrence, and three had dose discontinuation followed by recovery.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.10.1-8"></a>

###### Blood count monitoring and dose modification in ongoing studies

> “All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.1-9"></a>

###### OPERA-01 dose selection design

> “In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET”
> “The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.”
> “In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.10.1-10"></a>

###### OPERA-01 registry dosing

> “Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-2.1.2.10.1-11"></a>

###### Dose selected with the FDA for the phase 3 trials

> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial”
> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.1.2.10.1-12"></a>

###### Phase 3 dose as monotherapy and with ribociclib

> “The phase 3 dose of palazestrant as monotherapy or in combination with ribociclib is 90 mg QD.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.10.1-13"></a>

###### OPERA-02 registry dosing

> “Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.”
> “Participants will be treated with ribociclib 600 mg once daily on Days 1-21 of a 4-week (28 day) cycle.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-2.1.2.10.1-14"></a>

###### OPERA-02 dose rationale

> “This data supports the OPERA-02 study evaluating 90 mg once-daily palazestrant in combination with 600 mg ribociclib for the first-line treatment of ER+, HER2− ABC.”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-2.1.2.10.1-15"></a>

###### Dosing with palbociclib

> “Patients received 30, 60, 90, or 120 mg palazestrant QD plus 125 mg palbociclib PO QD on days 1–21 of each 28-day treatment cycle.”
> “Dose-expansion (ongoing) patients receive 120 mg palazestrant plus 125 mg palbociclib QD.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.10.1-16"></a>

###### Dose reductions with palbociclib

> “No patients had dose reduction of palazestrant for neutropenia. Eleven patients had dose reduction of palbociclib for neutropenia.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.10.1-17"></a>

###### Dosing with ribociclib in dose escalation

> “palazestrant at 30, 60, and 120 mg once daily plus ribociclib 600 mg once daily on days 1–21 of each 28-day treatment cycle (Figure 2). The RP2D of palazestrant was 120 mg in combination with ribociclib.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.10.1-18"></a>

###### Dose reductions with ribociclib

> “2 patients had a dose reduction of palazestrant only; 1 due to nausea and 1 due to neutropenia”
> “8 patients had a dose reduction of both treatments; 23 patients had a dose reduction of ribociclib. The most common cause for dose reduction was neutropenia.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route, frequency, and cycle length in the phase 1/2 study

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.2-2"></a>

###### Fasting requirement with the capsule formulation

> “In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.2-3"></a>

###### Tablet formulation and administration with food in ongoing studies

> “Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.2-4"></a>

###### Tablet formulation in OPERA-01

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.10.2-5"></a>

###### Treatment duration in the phase 1/2 study

> “Palazestrant treatment was continued until intolerable toxicity, disease progression, study/treatment withdrawal, or death.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.10.2-6"></a>

###### Cycle length and treatment duration in OPERA-01

> “All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.10.2-7"></a>

###### Once-daily schedule in the OPERA-01 registry record

> “Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial launch preparation underway (November 2026)

> “increased manufacturing and clinical supply activities in support of advancing clinical programs and early preparations for the potential commercialization of palazestrant and higher personnel related costs.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

> “Supported by a strong balance sheet, we are intently focused on execution in the second half of the year as we ramp preparations for our first potential commercial launch of palazestrant as a monotherapy”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="topic-2.1.2.11-2"></a>

###### Commercial planning, supply and distribution, and field force

> “Commercial launch planning began in 2025”
> “Early commercial leadership build expected to begin in 2026”
> “Establishing manufacturing supply and distribution for commercial use”
> “Anticipated targeted field force of ~75–100 reps”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.1.2.11-3"></a>

###### No existing sales force or distribution capability

> “We have never commercialized a product candidate and we currently do not have, and have never had, a sales force, or distribution or marketing capabilities. In order to commercialize any product candidates, if approved, we must build marketing, sales, supply, distribution, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market palazestrant, OP-3136, or any future product candidates we may develop.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.2.11-4"></a>

###### Worldwide commercialization rights

> “We own full worldwide development and commercialization rights to both palazestrant and OP-3136.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Manufacturing by contract manufacturing organizations, including commercial supply

> “We currently do not own or operate any manufacturing facilities. We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations (CMOs) to produce palazestrant and OP-3136 for non-clinical and clinical testing, as well as for commercial manufacture if palazestrant or OP-3136 receives marketing approval.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.11-6"></a>

###### Specialty pharmacy or distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Gonadotropin-releasing hormone or LHRH agonists for premenopausal women and men

> “Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

> “GnRH agonist requested for premenopausal women and for men.”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

> “Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

> “Male and pre- or peri-menopausal female participants must be willing to take a gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) agonist”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Combination partners under study: CDK4/6, CDK4, PI3Kα, and mTOR inhibitors

> “In combination, we are investigating palazestrant in multiple Phase 1/2 studies with CDK4/6 inhibitors (palbociclib or ribociclib), a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor (alpelisib), a mechanistic target of rapamycin (mTOR) inhibitor (everolimus), and a CDK4 inhibitor (atirmociclib).”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.12-3"></a>

###### Ribociclib: dosing and pharmacokinetic compatibility

> “Here we present the data for 72 patients: 56 patients received 120 mg QD palazestrant and 16 patients received 90 mg QD palazestrant, all with 600 mg of ribociclib.”
> “Safety was consistent with the known safety profiles of each drug; palazestrant and ribociclib did not demonstrate any drug-drug interactions.”
> “The phase 3 dose of palazestrant as monotherapy or in combination with ribociclib is 90 mg QD.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

> “Ribociclib is a strong inhibitor of CYP3A4.”
> “Palazestrant is not a CYP3A4 inhibitor or inducer.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

> “90 mg QD palazestrant”
> “600 mg ribociclib (3 weeks on/1 week off)”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Palbociclib: dosing and pharmacokinetic compatibility

> “Palazestrant 120 mg in combination with palbociclib 125 mg was well tolerated.”
> “No drug-drug interaction between palazestrant and palbociclib was observed, in agreement with previous reports.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.12-5"></a>

###### Antiemetics and proton pump inhibitors

> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”
> “Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue [26].”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.12-6"></a>

###### Colony-stimulating factors for neutropenia

> “While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.12-7"></a>

###### Medications not permitted: QT-prolonging drugs and strong CYP3A4 inhibitors or inducers

> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”
> “any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.12-8"></a>

###### Washout of prior anticancer therapies

> “Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Fulvestrant, <28 days prior ET, CDK4/6i, everolimus, tacrolimus, alpelisib, or PARP inhibitors, <14 days prior Any investigational cancer therapy, <28 days or 5 half-lives (whichever is shorter) prior”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.12-9"></a>

###### Bone-modifying agents

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Palazestrant on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### MIPS Quality ID 453: systemic cancer-directed therapy in the last 14 days of life

> “Percentage of patients who died from cancer receiving systemic cancer-directed therapy in the last 14 days of life.”
> “Do not include supportive care therapies (e.g., growth factors, bisphosphonates, RANK ligand inhibitors, nausea medications or fluids if these are not given in association with”
> “Hormonal therapies and steroids are not included in this systemic cancer directed therapy definition.”

Source: [CMS Quality ID 453 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_453_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

###### MIPS Quality ID 457: hospice admission for less than 3 days before death

> “Percentage of patients who died from cancer and admitted to hospice and spent less than 3 days there.”

Source: [CMS Quality ID 457 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_457_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

###### MIPS Quality ID 143: pain intensity quantified

> “Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified.”
> “Patient on oral chemotherapy on or within 30 days before denominator eligible encounter: M1433”

Source: [CMS Quality ID 143 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_143_MIPSCQM.pdf)

<a id="topic-2.1.2.13-4"></a>

###### MIPS Quality ID 144: plan of care for pain

> “Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain.”
> “Patient on oral chemotherapy during the performance period: M1435”

Source: [CMS Quality ID 144 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_144_MIPSCQM.pdf)

<a id="topic-2.1.2.13-5"></a>

###### MIPS Quality ID 047: advance care plan

> “Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan.”

Source: [CMS Quality ID 047 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_047_MIPSCQM.pdf)

<a id="topic-2.1.2.13-6"></a>

###### Enhancing Oncology Model: episodes with hormonal therapy only and quality strategy

> “Unlike OCM, EOM focuses on beneficiaries receiving systemic initiating cancer therapy, and will not include beneficiaries who receive hormonal therapy only.”
> “Subject to certain exceptions, EOM includes the following seven cancer types for beneficiaries undergoing systemic initiating cancer therapy: high-risk breast cancer, chronic leukemia, small intestine/colorectal cancer, lung cancer, lymphoma, multiple myeloma, and high-intensity prostate cancer.”
> “The EOM quality strategy focuses on measures from the following domains: patient experience, avoidable acute care utilization, management of symptoms and toxicity, management of psychosocial health, and management of end-of-life care.”

Source: [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)

<a id="topic-2.1.2.13-7"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Palazestrant: class, dosing, and OPERA-01 population

> “Palazestrant is a next-generation, orally bioavailable complete estrogen receptor antagonist (CERAN) and SERD with potent activity targeting the ER”
> “Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant”
> “In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.”
> “OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.”
> “trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.14-2"></a>

###### Palazestrant: phase 1/2 formulation, efficacy, and comparison with other estrogen receptor-targeting agents

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.”
> “Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue”
> “At 120 mg/day, the median progression-free survival was 4.8 months (95% CI, 3.5–7.1) overall and 5.6 months (95% CI, 4.8–NE) among patients with cancers with ESR1 mutations.”
> “Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively)”
> “The CERAN/SERD mechanism of action of palazestrant is shared by fulvestrant, camizestrant and imlunestrant”
> “Elacestrant, which is a selective ER modulator (SERM) and SERD, does not completely shut down ER signaling due to being an partial agonist and was also more active in cancers harboring ESR1 mutations”
> “although a direct comparison has not been performed”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.14-3"></a>

###### Palazestrant: competing estrogen receptor-targeting products named by the sponsor

> “Our lead product candidate, palazestrant, is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD)”
> “if we are successful in developing palazestrant, it may compete against existing products and product candidates in development, to the extent any such product candidates are approved, for the treatment of ER+ breast cancer, including fulvestrant, marketed as Faslodex® by AstraZeneca PLC”
> “camizestrant, marketed as ETCAMAH® by AstraZeneca PLC”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.2.14-4"></a>

###### Elacestrant (Orserdu): indication, regimen, EMERALD efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test” “with disease progression following at least one line of endocrine therapy” |
| Mechanism | “Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα).” |
| Recommended dosage | “The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs.” |
| Dosage forms and strengths | “Tablets: Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) and 86 mg (equivalent to 100 mg elacestrant hydrochloride)” |
| Pivotal trial | “The efficacy of ORSERDU was evaluated in EMERALD (NCT03778931), a randomized, open-label, active-controlled, multicenter trial that enrolled 478 postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer of which 228 patients had ESR1 mutations.” |
| Prior therapy required | “Patients were required to have disease progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.” |
| Median PFS, ESR1-mutated, ORSERDU (N = 115), months (95% CI) | “3.8 (2.2, 7.3)” |
| Median PFS, ESR1-mutated, fulvestrant or an aromatase inhibitor (N = 113), months (95% CI) | “1.9 (1.9, 2.1)” |
| PFS hazard ratio, ESR1-mutated (95% CI) | “0.55 (0.39, 0.77)” |
| Population without ESR1 mutations | “An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.” |
| Warnings and precautions | “Dyslipidemia: ORSERDU may cause hypercholesterolemia and hypertriglyceridemia.” “Embryo-Fetal Toxicity: ORSERDU can cause fetal harm.” |

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Elacestrant: EMERALD progression-free survival in all patients and in patients with ESR1 mutation

> “PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).”
> “Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.1.2.14-6"></a>

###### Elacestrant (Orserdu): wholesale acquisition cost at launch

| Strength | NDC | Pack size | WAC (as of date of commercial availability) | Date of commercial availability |
| --- | --- | --- | --- | --- |
| 86 mg | “72187010103” | “30 tablets” | “$7,123.00” | “2/3/2023” |
| 345 mg | “72187010203” | “30 tablets” | “$21,369.00” | “2/3/2023” |

Source: [Vermont Attorney General Orserdu report (2023)](https://ago.vermont.gov/sites/ago/files/2023-11/VT-high-cost-prescription-drug-reporting%20Orserdu.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Imlunestrant (Inluriyo): indications, regimen, EMBER-3 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication, monotherapy | “as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy” |
| Indication, combination | “in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy” |
| Mechanism | “Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα.” |
| Recommended dosage | “The recommended dosage of INLURIYO, as monotherapy or in combination with abemaciclib, is 400 mg orally once daily until disease progression or unacceptable toxicity.” |
| Administration | “Take on an empty stomach at least 2 hours before food or 1 hour after food” |
| Dosage forms and strengths | “INLURIYO tablets contain 200 mg imlunestrant” |
| Pivotal trial | “The efficacy of INLURIYO was evaluated in EMBER-3 (NCT04975308), a randomized, open-label, active-controlled, multicenter trial that enrolled 874 adult patients with ER+, HER2- locally advanced or metastatic breast cancer of which 323 patients had ESR1 mutations (ESR1m), who were previously treated with an aromatase inhibitor either alone or in combination with a CDK4/6 inhibitor.” |
| Median PFS, ESR1m, INLURIYO (N=138), months (95% CI) | “5.5 (3.9, 7.4)” |
| Median PFS, ESR1m, fulvestrant or exemestane (N=118), months (95% CI) | “3.8 (3.7, 5.5)” |
| PFS hazard ratio, ESR1m (95% CI) | “0.62 (0.46, 0.82)” |
| Overall population | “A statistically significant difference in PFS in the overall population was not observed” |
| Median PFS, ESR1m, INLURIYO + abemaciclib (N=67) compared with INLURIYO (N=92), exploratory, months (95% CI) | “11.1 (7.4, 13.7)” “5.5 (3.8, 7.2)” |
| PFS hazard ratio, ESR1m, INLURIYO + abemaciclib compared with INLURIYO (95% CI) | “0.53 (0.35, 0.80)” |
| Warnings and precautions | “Embryo-Fetal Toxicity: INLURIYO can cause fetal harm.” |

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Imlunestrant (Inluriyo): wholesale acquisition cost

| Strength and dosage form | NDC | Pack size | Wholesale acquisition cost |
| --- | --- | --- | --- |
| 200 mg tablet | “0002-1717-28” | “28” | “$11,250.00” |
| 200 mg tablet | “0002-1717-56” | “56” | “$22,500.00” |

Source: [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf)

> “Lilly USA, LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.”
> “Accessed on 09/26/2025.”

Source: [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Vepdegestrant (Veppanu): indication, regimen, VERITAC-2 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.” |
| Mechanism | “Vepdegestrant is a heterobifunctional protein degrader that binds to estrogen receptor (ER) and the E3 ligase cereblon (CRBN).” |
| Recommended dosage | “The recommended dosage of VEPPANU is 200 mg taken orally once daily with food” |
| Dosage forms and strengths | “Tablets: 100 mg and 200 mg” |
| Prior therapy required | “Patients were required to have disease progression on 1 to 2 prior lines of endocrine therapy, including 1 line with a CDK4/6 inhibitor.” |
| Exclusions | “Patients were excluded if they had received chemotherapy for advanced or metastatic disease or fulvestrant in any line of therapy” |
| Randomized comparison | “Patients were randomized 1:1 to receive VEPPANU 200 mg orally once daily (N=313), or fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and then once monthly thereafter (N=311).” |
| Median PFS, ESR1-mutated, VEPPANU (N=136), months (95% CI) | “5.0 (3.7, 7.4)” |
| Median PFS, ESR1-mutated, fulvestrant (N=134), months (95% CI) | “2.1 (1.9, 3.5)” |
| PFS hazard ratio, ESR1-mutated (95% CI) | “0.57 (0.42, 0.77)” |
| Warnings and precautions | “VEPPANU can cause QT (QTc) interval prolongation” “In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients.” |

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Camizestrant (Etcamah): indication, regimen, SERENA-6 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test” |
| Approval pathway | “This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation” |
| Mechanism | “Camizestrant is an estrogen receptor (ER) antagonist.” |
| Recommended dosage | “The recommended dosage of ETCAMAH is 75 mg orally once daily, with or without food, until disease progression or unacceptable toxicity” |
| Dosage forms and strengths | “Tablets: 75 mg.” |
| Pivotal trial setting | “The ESR1 mutation status was assessed by ctDNA testing during first-line treatment with an AI in combination with a CDK4/6 inhibitor.” |
| Median PFS, ETCAMAH plus a CDK4/6 inhibitor (N = 157), months (95% CI) | “16.0 (12.7, 18.2)” |
| Median PFS, AI plus a CDK4/6 inhibitor (N = 158), months (95% CI) | “9.2 (7.2, 9.5)” |
| PFS hazard ratio (95% CI) | “0.44 (0.31, 0.60)” |
| Boxed warning | “ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death” |
| Warnings and precautions | “Bradycardia: Monitor heart rate more frequently during the first 30 days.” |

Source: [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Fulvestrant (Faslodex): indications, regimen, CONFIRM efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication, monotherapy after endocrine therapy | “HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.” |
| Indication, combination | “HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.” |
| Mechanism | “Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.” |
| Recommended dosage | “FASLODEX 500 mg should be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.” |
| Dosage forms and strengths | “FASLODEX, an injection for intramuscular administration, is supplied as 250 mg/5 mL fulvestrant.” |
| Pivotal trial after endocrine therapy | “A randomized, double-blind, controlled clinical trial (CONFIRM, NCT00099437) was completed in 736 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.” |
| PFS hazard ratio, 500 mg compared with 250 mg (95% CI) | “0.80 (0.68-0.94)” |
| Warnings and precautions | “Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use.” “Injection Site Reaction: Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve.” |

Source: [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

###### Capivasertib (Truqap): indication, regimen, CAPItello-291 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-authorized test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.” |
| Mechanism | “Capivasertib is an inhibitor of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3) and inhibits phosphorylation of downstream AKT substrates.” |
| Recommended dosage | “The recommended dosage of TRUQAP, in combination with fulvestrant, is 400 mg orally twice daily (approximately 12 hours apart) with or without food, for 4 days followed by 3 days off.” |
| Dosage forms and strengths | “Tablets: 160 mg and 200 mg” |
| Pivotal trial | “The efficacy of TRUQAP with fulvestrant was evaluated in CAPItello-291 (NCT04305496), a randomized, double-blind, placebo-controlled, multicenter trial that enrolled 708 adult patients with locally advanced (inoperable) or metastatic HR-positive, HER2-negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) breast cancer of which 289 patients had tumors with eligible PIK3CA/AKT1/PTEN-alterations.” |
| Median PFS, altered tumors, TRUQAP with fulvestrant (N=155), months (95% CI) | “7.3 (5.5, 9.0)” |
| Median PFS, altered tumors, placebo with fulvestrant (N=134), months (95% CI) | “3.1 (2.0, 3.7)” |
| PFS hazard ratio, altered tumors (95% CI) | “0.50 (0.38, 0.65)” |
| Overall survival | “At the prespecified final analysis of OS, there was no significant difference in OS between the TRUQAP with fulvestrant arm and the placebo with fulvestrant arm, with HR 0.83 (95% CI: 0.63, 1.10) in the PIK3CA/AKT1/PTEN-altered subgroup.” |
| Warnings and precautions | “Hyperglycemia: TRUQAP can cause severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes.” “Diarrhea: TRUQAP caused diarrhea in most patients.” “Cutaneous Adverse Reactions: Monitor for signs and symptoms of cutaneous adverse reactions.” |

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

###### Capivasertib: CAPItello-291 progression-free survival in the overall and AKT pathway-altered populations

> “In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).”
> “In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).”
> “Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.1.2.14-14"></a>

###### Capivasertib (Truqap): wholesale acquisition cost of blister packs

| Product | NDC | Order quantity | WAC price |
| --- | --- | --- | --- |
| 160 mg tablets, 4 x 16 blister pack | “00310-9500-02” | “1 Blister Package (4x16)” | “$22,922.00” |
| 200 mg tablets, 4 x 16 blister pack | “00310-9501-02” | “1 Blister Package (4x16)” | “$22,922.00” |

Source: [AstraZeneca Truqap blister pack availability notice (2024)](https://associationdatabase.com/aws/MSHO/asset_manager/get_file/909026)

<a id="topic-2.1.2.14-15"></a>

###### Gedatolisib (Revtorpyk): indication, regimen, VIKTORIA-1 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “REVTORPYK is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.” |
| Mechanism | “Gedatolisib is a kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT.” |
| Recommended dosage | “The recommended dosage of REVTORPYK is 180 mg as an intravenous infusion over 30 minutes once weekly on Days 1, 8, and 15 of every 28-day cycle, in combination with fulvestrant, with or without palbociclib, until disease progression or unacceptable toxicity.” |
| Dosage forms and strengths | “REVTORPYK is supplied as a sterile, white to off-white lyophilized powder for injection containing 180 mg gedatolisib in a single-dose vial for reconstitution and further dilution.” |
| Prior therapy required | “All patients were required to have progression on or after treatment with a CDK4/6 inhibitor and a non-steroidal aromatase inhibitor (AI) therapy.” |
| Median PFS, REVTORPYK + fulvestrant + palbociclib (N=131), months (95% CI) | “9.3 (7.2, 16.6)” |
| Median PFS, REVTORPYK + fulvestrant (N=130), months (95% CI) | “7.4 (5.5, 9.9)” |
| Median PFS, fulvestrant (N=131), months (95% CI) | “2.0 (1.8, 2.3)” |
| Warnings and precautions | “REVTORPYK can cause severe stomatitis, including ulcers and oral mucositis.” “In Study 1 of VIKTORIA-1, stomatitis occurred in 72% of patients treated with REVTORPYK with fulvestrant and palbociclib, including Grade 3 events in 22% of patients.” “Hyperglycemia: REVTORPYK can cause severe hyperglycemia.” |

Source: [Revtorpyk prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219908Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-16"></a>

###### Gedatolisib: VIKTORIA-1 progression-free survival hazard ratios and discontinuation

> “The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).”
> “Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.1.2.14-17"></a>

###### Gedatolisib (Revtorpyk): wholesale acquisition cost

> “of REVTORPYK, which has been reported to the drug pricing compendia, is $10,000 per vial, or $30,000 per 28-day cycle of treatment.”

Source: [Celcuity Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1603454/000119312526450161/celc-20260930.htm)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Hormone receptor-positive and HER2-positive tumor definitions

> “HR+ means that tumor cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumors.”
> “HER2+ means that tumor cells make high levels of a protein called HER2/neu, which has been shown to be associated with certain aggressive types of breast cancer.”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.1-2"></a>

###### Estrogen receptor-positive threshold: ASCO/CAP guideline

> “Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.”
> “However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive.”
> “Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.”
> “A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.”

Source: [Allison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928404/)

<a id="topic-2.2.1.1-3"></a>

###### HER2 status: ASCO/CAP guideline

> “The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.”
> “This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.”

Source: [Wolff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37284804/)

<a id="topic-2.2.1.1-4"></a>

###### Intrinsic subtypes and their hormone receptor surrogates

> “Four out of five breast cancers test positive for hormone (estrogen and/or progesterone) receptors (HR+) and are generally classified as either Luminal A (70%) or Luminal B (9%) based on the presence of HER2/ERBB2.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.1-5"></a>

###### Advanced breast cancer: international consensus definition

> “In the ABC guidelines, advanced breast cancer is defined as comprising both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC), which includes both distant recurrent disease and stage IV at diagnosis”
> “Advanced/metastatic breast cancer is still an incurable disease for the vast majority of patients.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.1-6"></a>

###### Distant stage and stage IV classification

> “distant stage, cancer that has spread to distant organs and/or lymph nodes, including nodes above the collarbone.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

> “If a patient presents with M1 disease before receiving neoadjuvant systemic therapy, the stage is Stage IV and remains Stage IV regardless of response to neoadjuvant therapy.”

Source: [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)

<a id="topic-2.2.1.1-7"></a>

###### De novo and recurrent metastatic disease

> “Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.1-8"></a>

###### Previously treated disease: endocrine resistance definitions

> “Primary endocrine resistance is defined as relapse while on the first two years of adjuvant endocrine therapy for early breast cancer, or progressive disease within the first six months of first line endocrine therapy-based treatment for advanced breast cancer.”
> “Secondary or acquired endocrine resistance encompasses all remaining clinical situations of endocrine resistance.”
> “The first subgroup, early acquired endocrine resistance , includes relapse while receiving endocrine therapy but after the first two years, relapse within one year of completing adjuvant endocrine therapy, or progressive disease occurring after at least six months, but less than twelve months, of first line endocrine therapy-based treatment for advanced breast cancer.”
> “The second subgroup, late acquired endocrine resistance , is defined as relapse more than twelve months after completing adjuvant endocrine therapy, or progressive disease after at least twelve months of first line endocrine therapy-based treatment for advanced breast cancer.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.1-9"></a>

###### Risk factors: U.S. summary

> “Most women who develop breast cancer have no known risk factors. Approximately 30% of cases can be attributed to potentially modifiable risk factors, such as excess body weight (postmenopausal breast cancer), physical inactivity, and alcohol consumption.”
> “The strongest risk factors are a personal or family history of breast cancer or a personal history of lesions associated with risk (e.g., DCIS, proliferative lesions with atypia); high-dose radiation to the chest; or certain inherited genetic variations (e.g., BRCA1 or BRCA2 gene mutations).”
> “Genetic variations in BRCA1 and BRCA2 account for 5% to 10% of all female breast cancers and 15% to 20% of familial breast cancers.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.1-10"></a>

###### Risk factors: hormone receptor-positive disease and reproductive history

> “Risk increases immediately following childbirth, but decreases for hormone-receptor positive disease after two decades, with an additional reduction among women who are young at first childbirth and/or have more children.”
> “Note: Relative risk for some factors vary by breast cancer molecular subtype.”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.1-11"></a>

###### Risk factors: NCI health professional summary

> “Increasing age is the most important risk factor for most cancers.”
> “Of all women with breast cancer, 5% to 10% may have a germline pathogenic variant in the BRCA1 and BRCA2 genes.”

Source: [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

<a id="topic-2.2.1.2.1-1"></a>

###### U.S. estimated new cases and deaths, 2026

> “In the US in 2026, there will be an estimated 321,910 new cases of invasive breast cancer diagnosed in women and 2,670 cases in men, with an additional 60,730 cases of ductal carcinoma in situ (DCIS) diagnosed in women (Table 1).”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-2"></a>

###### U.S. incidence rate of female breast cancer per 100,000

> “The rate of new cases of female breast cancer was 132.5 per 100,000 women per year.”
> “Approximately 13.0 percent of women will be diagnosed with female breast cancer at some point during their lifetime, based on 2021–2023 data.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.2.1-3"></a>

###### U.S. incidence rate of HR-positive/HER2-negative breast cancer per 100,000

> “The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 92.9 new cases per 100,000 women, based on 2019–2023 cases.”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.2.1-4"></a>

###### U.S. share of cases that are HR-positive/HER2-negative, SEER 21, 2019 to 2023

| Subtype | Percent of cases |
| --- | --- |
| HR+/HER2- | “70%” |
| HR-/HER2- | “11%” |
| HR+/HER2+ | “9%” |
| HR-/HER2+ | “4%” |
| Unknown | “6%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.2.1-5"></a>

###### U.S. share of cases that are HR-positive/HER2-negative, by race and ethnicity

> “HR+/HER2- breast cancer is the most common subtype in every racial and ethnic group, with the highest proportion (73%) among White women and lowest in Black women (59%).”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.2.1-6"></a>

###### U.S. stage distribution at diagnosis, SEER 21

| Stage at diagnosis | Percent of cases |
| --- | --- |
| Localized | “64%” |
| Regional | “27%” |
| Distant | “6%” |
| Unknown | “2%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.2.1-7"></a>

###### U.S. incidence trends, all stages and distant stage

> “The incidence of invasive female breast cancer has been increasing since the mid-2000s; from 2013 to 2022, the rate increased by 1% per year on average, with a steeper pace in women younger than 50 years (1.4% per year)”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

> “Although distant-stage disease rates also increased by 1.1% per year, this likely reflects improved staging because the rate of unstaged disease decreased by a similar magnitude (1.4% per year).”

Source: [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)

<a id="topic-2.2.1.2.1-8"></a>

###### U.S. annual new metastatic diagnoses, de novo and recurrent

> “The backcalculation method also estimates 50,344 new diagnoses of MBC in 2013, of which 12,966 (26%) are de novo and 37,378 (74%) recurrences, thus 3 in 4 are undocumented diagnoses of MBC.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.2.1-9"></a>

###### U.S. new metastatic female breast cancer cases, 2018 estimate and 2025 projection

| Measure | Breast (female) |
| --- | --- |
| Number of new metastatic cancer cases, de novo (observed), 2018 | “15 800” |
| Number of new metastatic cancer cases, de novo and recurrence (estimated), 2018 | “46 666” |
| Projected number of new metastatic (de novo and recurrence) cancer cases, 2025 | “52 126” |

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

<a id="topic-2.2.1.2.1-10"></a>

###### Risk of distant recurrence after 5 years of adjuvant endocrine therapy for ER-positive disease

> “Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years.”
> “Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1–3), and 34% with four to nine nodes involved (T1N4–9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1–3, and 41% with T2N4–9.”

Source: [Pan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5734609/)

<a id="topic-2.2.1.2.1-11"></a>

###### Worldwide incidence, GLOBOCAN 2024

> “With an estimated 2.4 million new cases and 694,000 deaths, female breast cancer is the second most commonly diagnosed cancer and the fourth leading cause of cancer death in 2024, accounting for 11.8% of all cases and 7.1% of all deaths”
> “Incidence rates are elevated in Australia/New Zealand, Northern America, and Northern Europe (90–102 per 100,000) and are approximately three times higher than those in Eastern Africa, South Central Asia, and Middle Africa (29–33 per 100,000;”

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.2.1-12"></a>

###### Worldwide incidence by human development index

> “Incidence rates are 60% greater in higher versus lower HDI countries (54.1 vs. 33.6 per 100,000), whereas mortality rates are 26% greater in lower HDI countries (14.7 vs. 11.7 per 100,000;”

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

Additional sources: [Daily et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33750642/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. women living with breast cancer, all stages

> “In 2023, there were an estimated 4,238,585 women living with female breast cancer in the United States.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.2.2-2"></a>

###### U.S. women living with metastatic breast cancer, 2013 and 2017

> “In 2013, the last year with observed data, we estimate a prevalence of MBC of 138,622 of which 38,897 (28%) are survivors who were initially diagnosed with de novo stage IV disease and 99,725 (72%) survivors initially diagnosed with stage I–III BC who later progressed to MBC”
> “We project that by 1/1/2017 there will be 154,794 women living with MBC in the United States.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.2.2-3"></a>

###### U.S. women living with metastatic breast cancer: duration since metastatic diagnosis

> “Although the largest majority of prevalent cases are women who have been living with metastatic disease for 2 years or less (40%), one third (34%) have lived for 5 years or more with MBC”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.2.2-4"></a>

###### U.S. individuals living with metastatic female breast cancer, 2018 estimate and 2025 projection

| Measure | Breast (female) |
| --- | --- |
| Number living with metastatic disease on January 1, 2018, de novo (observed) | “54 117” |
| Number living with metastatic disease on January 1, 2018, de novo and recurrence (estimated) | “140 230” |
| Projected number living with metastatic disease (de novo and recurrence) on January 1, 2025 | “169 347” |

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

> “Almost 30% of individuals diagnosed with metastatic melanoma and one-fifth of individuals diagnosed with metastatic colorectal or metastatic breast cancer are estimated to have been living with metastatic disease for 10 or more years”
> “The number of individuals living with metastatic cancer is projected to increase from 2019 to 2025 for breast, bladder, colorectal, and prostate cancer”

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

<a id="topic-2.2.1.2.2-5"></a>

###### U.S. share of women living with metastatic disease first diagnosed at stage I to III

> “Notably, a recent study estimated that 61% of women living with metastatic breast cancer were originally diagnosed with stage I–III disease.”

Source: [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)

<a id="topic-2.2.1.2.2-6"></a>

###### U.S. prevalence of previously treated ER-positive HER2-negative advanced disease

No evidence found.

<a id="topic-2.2.1.2.2-7"></a>

###### Worldwide 5-year prevalence of breast cancer by continent, GLOBOCAN 2024

| Continent | 5-year prevalent cases | Percent |
| --- | --- | --- |
| Asia | “3 291 849” | “40.3%” |
| Europe | “2 208 013” | “27.1%” |
| Northern America | “1 373 135” | “16.8%” |
| Latin America and the Caribbean | “670 478” | “8.2%” |
| Africa | “491 878” | “6.0%” |
| Oceania | “126 982” | “1.6%” |

Source: [International Agency for Research on Cancer GLOBOCAN breast fact sheet (2026)](https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### U.S. breast cancer deaths, 2026

> “An estimated 42,670 breast cancer deaths (42,140 in women, 530 in men) will occur in 2026.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

> “Breast cancer is the second leading cause of cancer death in women, after lung cancer.”
> “Breast cancer death rates have been decreasing steadily since 1989, for an overall decline of 44% through 2023.”

Source: [American Cancer Society Key Statistics for Breast Cancer (2026)](https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html)

<a id="topic-2.2.1.3-2"></a>

###### U.S. death rate and age at death

> “The death rate was 18.9 per 100,000 women per year based on 2020–2024, age-adjusted.”
> “The percent of female breast cancer deaths is highest among women aged 65–74.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.3-3"></a>

###### Contribution of metastatic disease treatment to the decline in U.S. mortality

> “A recent modeling study estimated that most of the reduction in mortality is attributable to advances in the treatment of stage I–III disease (47%) and metastatic disease (29%), with an additional 25% associated with earlier detection through screening.”

Source: [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)

<a id="topic-2.2.1.3-4"></a>

###### U.S. 5-year relative survival by stage at diagnosis, SEER 21, 2016 to 2022

| Stage at diagnosis | 5-year relative survival |
| --- | --- |
| Localized | “100.0%” |
| Regional | “87.5%” |
| Distant | “33.8%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.3-5"></a>

###### U.S. 5-year relative survival for HR-positive/HER2-negative disease by stage, SEER 21, 2016 to 2022

| Subtype | Localized | Regional | Distant |
| --- | --- | --- | --- |
| HR+/HER2- | “100.0%” | “91.1%” | “38.1%” |
| HR-/HER2- | “92.8%” | “68.3%” | “14.9%” |
| HR+/HER2+ | “99.5%” | “91.5%” | “48.7%” |
| HR-/HER2+ | “97.8%” | “86.4%” | “43.1%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

> “While breast cancer subtype affects survival, stage at diagnosis may be the most powerful factor in determining survival outcome.”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.3-6"></a>

###### Goals of treatment for metastatic disease

> “Treatment of metastatic disease is palliative in intent. Goals of treatment include prolonging life and improving quality of life.”
> “The longest median survival outcomes have been observed in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor–positive metastatic breast cancer, and less favorable outcomes have been observed in patients with metastatic triple-negative breast cancer (TNBC).”

Source: [National Cancer Institute Breast Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/breast/hp/breast-treatment-pdq)

<a id="topic-2.2.1.3-7"></a>

###### U.S. survival after de novo metastatic diagnosis over time

> “Median relative survival time increased from 22.3 to 38.7 months and from 19.1 to 29.7 months for women diagnosed between ages 15–49 and 50–64, respectively, during 1992–1994 versus 2005–2012.”
> “Despite a poor prognosis there is a small but meaningful percent of these cases who survive 10-years or more; more than 11% of women diagnosed between 2000–2004 under the age of 64 years survived 10 years or more.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.3-8"></a>

###### U.S. breast cancer-specific survival in de novo HR-positive/HER2-negative metastatic disease before and after CDK4/6 inhibitors

> “In the unadjusted analysis of patients with HR+/HER2− mBC, BCSS was significantly longer among patients in the post-2015 group versus the pre-2015 group (median BCSS: 39 [95% CI 38–42] vs 35 [95% CI 33–37] months; hazard ratio [HR] = 0.896, 95% CI 0.849–0.946; p < 0.001;”
> “The 48-month BCSS rate was 44.5% for the post-2015 group and 38.5% for the pre-2015 group”

Source: [Brufsky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11455714/)

<a id="topic-2.2.1.3-9"></a>

###### U.S. real-world overall survival with first-line CDK4/6 inhibitor plus aromatase inhibitor

> “Of 9146 eligible patients, 6831, 1279, and 1036 received palbociclib plus AI, ribociclib plus AI, or abemaciclib plus AI, respectively.”
> “After sIPTW, median OS was 54.6 months (95% CI 52.6-56.4 months) in the palbociclib group, 59.0 months (95% CI 50.9-66.1 months) in the ribociclib group, and 64.5 months (95% CI 55.4 months-not estimable) in the abemaciclib group.”

Source: [Rugo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11758200/)

<a id="topic-2.2.1.3-10"></a>

###### U.S. real-world outcomes of second-line therapy after progression on a first-line CDK4/6 inhibitor

> “A total of 839 patients received a documented second-line therapy after progression on first-line CDK4/6i treatment.”
> “The median unadjusted rwPFS and OS for those who received a CDK4/6i in the second-line setting were 8.25 months and 35.7 months, respectively”
> “The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.1.3-11"></a>

###### Systematic review: real-world progression-free survival after a first-line CDK4/6 inhibitor

> “Twenty records (9 full-text articles and 11 conference abstracts) encompassing 18 unique studies met the eligibility criteria and reported outcomes for second-line (2 L) treatments after 1 L CDK4/6i; no studies reported disaggregated outcomes in the third-line setting or beyond.”
> “The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.1.3-12"></a>

###### Second- and third-line real-world progression-free survival by intrinsic subtype, Spain

> “Median rwPFS-2L was 7.2 months in luminal IS vs. 6.1 in non-luminal (HR 1.40; 95% CI 0.86–2.30); the Basal-like (BL) subtype correlated with significantly shorter rwPFS-2L (HR 3.82; 95% CI 1.07–13.63).”
> “In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="topic-2.2.1.3-13"></a>

###### Acquired ESR1 mutations along the treatment course

> “Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease”
> “Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.”
> “In addition, ESR1 mutations usually occur with several concurrent genomic alterations, and together, these confer a globally worse prognosis”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

> “ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).”
> “Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.3-14"></a>

###### ESR1 mutation and overall survival after prior aromatase inhibitor, BOLERO-2

> “Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.”
> “These mutations were associated with shorter overall survival (wild-type, 32.1 months [95% CI, 28.09-36.40 months]; D538G, 25.99 months [95% CI, 19.19-32.36 months]; Y537S, 19.98 months [13.01-29.31 months]; both mutations, 15.15 months [95% CI, 10.87-27.43 months]).”

Source: [Chandarlapaty et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5063698/)

<a id="topic-2.2.1.3-15"></a>

###### Worldwide population-level survival trends in de novo and recurrent metastatic disease

> “For dnMBC, 13 of 14 studies reported improved OS or BCSS since 1995. In 2005–2009, the median OS was 26 months (range 24–30), a median gain of 6 months since 1995–1999 (range 0–9, 4 studies).”
> “For rMBC, one study reported no change in survival between 1998 and 2006 and 2007–2013 (median OS 23 months).”
> “Population-level improvements in OS for dnMBC have not been consistently observed in rMBC cohorts nor older women.”

Source: [Lord et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8804182/)

<a id="topic-2.2.1.3-16"></a>

###### Worldwide mortality, GLOBOCAN 2024

> “Among women, breast cancer is the most common cancer for both incidence and mortality worldwide, ranking first for incidence in 164 countries”
> “Mortality rates range from 20 to 25 per 100,000 in Melanesia, Micronesia/Polynesia, and Western Africa and from six to 10 per 100,000 in Eastern Asia and Central America.”

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.3-17"></a>

###### Worldwide survival gains in ER-positive/HER2-negative advanced disease

> “While important progress has been made, including the doubling of the median overall survival for two of the three ABC subtypes, the disease remains incurable for the vast majority of patients and inequities in access to the best diagnostic and therapeutic options and to high quality, multidisciplinary, evidence-based care have increased in the last decade.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

Additional sources: [Howlader et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29593010/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Estrogen receptor expression and dependence on estrogen receptor signaling

> “Upon activation by oestrogen, ER executes a transcriptional programme that drives proliferation and expansion of the mammary epithelia during puberty”
> “~70–80% of tumours that emerge from the mammary gland express ER and harbour some dependence on ER signalling for proliferation”
> “Although most ER+ tumours initially appear sensitive to anti-oestrogen agents, resistance can develop over time, characterized by clinical relapse, which typically involves the emergence of genetic and epigenetic alterations that allow for reactivation of ER signalling”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

<a id="topic-2.2.1.4-2"></a>

###### Ligand-dependent estrogen receptor activation

> “Upon binding to estrogen, the estrogen receptor (ER) dimerizes and translocates to the nucleus, where ER dimers bind coactivators (CoA) to form a transcriptionally active ER complex.”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-3"></a>

###### Activation function domains AF-1 and AF-2

> “ER consists of two transcriptional activation domains, the N-terminal ligand-independent activation function (AF)-1 and the C-terminal ligand-dependent AF-2 domains, a ligand-binding domain (LBD) also residing in the C-terminal region, and the DNA-binding and hinge domains, positioned in the core of the protein.”

Source: [Jeselsohn et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911210/)

<a id="topic-2.2.1.4-4"></a>

###### AF-1 activity and incomplete antagonism by selective estrogen receptor modulators

> “SERMs still allow for the engagement of ER with chromatin and therefore do not inhibit transcription driven by the N-terminal ER activation function-1 (AF1) domain”
> “As AF1 activity is sensitive to various cellular inputs, the impact of SERMs on ER transcriptional output depends on the tissue environment”
> “Selective ER degraders inhibit both LBD and AF1 domains by preventing recruitment of co-activators, immobilizing and destabilizing ER, leading to degradation.”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

<a id="topic-2.2.1.4-5"></a>

###### ESR1 ligand-binding domain mutations in the AF-2 region

> “All ESR1 mutations were located within the LBD/activation function-2 (AF-2) domain of the receptor and the majority occurred specifically at amino acids 537 and 538 of helix 12”
> “Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.”

Source: [Toy et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3903423/)

<a id="topic-2.2.1.4-6"></a>

###### Constitutive activity and reduced drug binding of mutant estrogen receptor

> “Whereas wild-type ESR1 (ESR1-WT) is bound by estrogen ligand to enable coactivator recruitment, LBD-mutated ESR1 (ESR1-MUT) is constitutively active and thus unaffected by AI depletion of estrogen”
> “For tamoxifen, ESR1-MUT has up to 30-fold decreased binding affinity (varying by specific mutation) and requires higher doses to inhibit transactivation function and cell proliferation”
> “For fulvestrant, ESR1-MUT has up to 40-fold decreased binding affinity and, like tamoxifen, requires an increased dose by an order of magnitude to inhibit transactivation function and cell expansion in culture and xenograft models”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.4-7"></a>

###### ESR1 mutations acquired under aromatase inhibitor therapy for metastatic disease

> “ESR1 mutations were found exclusively in patients with estrogen receptor positive breast cancer previously exposed to AI.”
> “ESR1 mutation prevalence differed markedly between patients that were first exposed to AI during the adjuvant and metastatic settings (5.8% (3/52) vs 36.4% (16/44) respectively, p=0.0002).”
> “ESR1 mutations are rarely acquired during adjuvant AI therapy, but are commonly selected by therapy for metastatic disease”

Source: [Schiavon et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4998737/)

<a id="topic-2.2.1.4-8"></a>

###### Prevalence of ESR1 mutations by prior endocrine therapy setting

> “The prevalence of ESR1 mutations in patients depends on prior duration and setting of endocrine therapy.”
> “Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease”
> “Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.4-9"></a>

###### Prevalence of ESR1 mutations in plasma after aromatase inhibitor exposure in BOLERO-2

> “Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.”

Source: [Chandarlapaty et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5063698/)

<a id="topic-2.2.1.4-10"></a>

###### Prevalence of ESR1 mutations by line of therapy in real-world genomic testing

> “ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).”
> “the prevalence of ESR1mut in TBx collected within 60 days before or after the initiation of 1st, 2nd, and 3rd lines of therapy was 8.1% (n = 175/2,154), 27.1% (n = 73/269), and 33.3% (n = 72/216), respectively.”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.4-11"></a>

###### Prevalence of ESR1 mutations before and after endocrine therapy

> “which are virtually absent in primary breast cancer but highly prevalent (20–40%) in anti-oestrogen-treated metastatic disease”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

<a id="topic-2.2.1.4-12"></a>

###### ESR1 mutation as one of several endocrine resistance mechanisms

> “About 50% of endocrine resistance cases are associated with an ESR1 mutation; other mechanisms, increasingly uncovered, include alterations in the PI3K-AKT-mTORC1, RAS-MAPK, and CDK4/6-RB-E2F pathways, and ESR1 loss, amplification, and translocation”
> “ESR1 fusions are rare but exhibit complete resistance to treatments targeting the LBD of ESR1 such as selective estrogen receptor modulators (SERMs) and degraders (SERDs), as these fusions lack the LBD”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.4-13"></a>

###### Ligand-independent estrogen receptor reactivation through growth factor signaling

> “Instead, endocrine resistance is commonly driven by ligand-independent ER reactivation”
> “Upon adaptation and/or resistance to antiestrogens, growth factor-driven mitogenic and survival pathways (i.e., PI3K/mTOR, RAS/RAF/MEK/ERK) can drive reactivation of ER transcription in the absence of estradiol.”
> “These resistant tumors are typically dependent upon both the aberrantly activated survival pathway and ER, and in most cases combined inhibition of both pathways is more effective”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-14"></a>

###### PI3K, AKT, and PTEN pathway alterations

> “Components of the PI3K pathway (including PIK3CA, PTEN, and AKT1) are frequently mutated in ER+ breast cancers”
> “Aberrant activation of the PI3K pathway promotes acquired resistance to estrogen depletion in preclinical models”
> “AKT1 and PTEN mutations are more frequent in advanced/metastatic ER+ breast cancers”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-15"></a>

###### Prevalence of PI3K, AKT, and PTEN alterations by line of therapy

> “1002 (17.3%) TBx and 503 (30.1%) LBx had an ESR1mut detected; 2,442 (42.2%) TBx and 564 (33.8%) LBx had a PIK3CAmut detected; 289 (5%) TBx and 70 (4.2%) LBx had an AKT1mut detected; and 602 (10.4%) TBx and 41 (2.5%) LBx had a PTEN alteration (mut or loss) detected.”
> “We observed that the prevalence of an alteration in the PI3K/AKT pathway in TBx collected in 1st, 2nd, and 3rd lines of therapy was 55.1% (n = 1,186/2,154), 48.3% (n = 130/269), and 54.6% (n = 118/216), respectively.”
> “Among patients with TBx in 1st (n = 2154), 2nd (n = 269), and 3rd (n = 216) lines, both ESR1mut and a PI3K/AKT pathway GA were detected in 4.4% (95), 8.2% (22), and 17.1% (37), respectively”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.4-16"></a>

###### Resistance to CDK4/6 inhibitors

> “Some of the somatic alterations described above have also been shown to promote resistance to CDK4/6i, including FGFR1 amplification, PTEN alterations, and ERBB2 mutations”
> “In contrast, RB1 and FAT1 alterations appear to be exclusively associated with resistance to CDK4/6 inhibitors and less to antiestrogens alone”
> “Acquired hotspot mutations in PIK3CA have been reported following progression on either fulvestrant alone or in combination with CDK4/6 inhibitors (CDK4/6i)”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-17"></a>

###### Estrogen receptor-independent growth and loss of estrogen receptor expression

> “Loss of ER expression occurs in a minority (~10%) of endocrine-resistant breast cancers”
> “In addition to ER, RTKs activate other transcription factors that promote ER-independent survival.”
> “Indeed, Razavi et al. reported that 60% of endocrine-resistant MBC lacked known somatic drivers of resistance”

Source: [Hanker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169993/)

<a id="topic-2.2.1.4-18"></a>

###### Estrogen receptor-dependent and estrogen receptor-independent routes of resistance

> “Still, these may be thought of as either (1) reactivating ER signalling despite drug administration or (2) bypassing ER to drive another oncogenic programme”
> “Interestingly, resistance mechanisms relating to active ER signalling are more typically observed in tumours that manifest with a period of apparent sensitivity followed by resistance, that is, resistance that is acquired under the pressure of therapy, whereas ER-independent mechanisms often appear in tumours that are intrinsically resistant.”
> “Pink and red: other cancers lose dependency on ER altogether.”

Source: [Will et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529099/)

Additional sources: [Fribbens et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27269946/); [Cabel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41260263/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Estrogen receptor testing by immunohistochemistry

> “The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.”
> “Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.”
> “Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.”
> “A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.”

Source: [Allison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928404/)

<a id="topic-2.2.1.5-2"></a>

###### HER2 testing and the distinction between immunohistochemistry 0 and 1+

> “The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.”
> “This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.”
> “Therefore, while it is premature to create new result categories of HER2 expression (eg, HER2-Low, HER2-Ultra-Low), best practices to distinguish IHC 0 from 1+ are now clinically relevant.”

Source: [Wolff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37284804/)

<a id="topic-2.2.1.5-3"></a>

###### Biopsy of metastatic disease and reassessment of receptor status

> “At first diagnosis of MBC, a biopsy is recommended to confirm histology and re-assess tumour biology, if feasible”
> “In case of important differences in ER, PgR and HER2 status between the primary tumour and recurrence, patients can generally be managed according to the receptor status of the recurrent disease biopsy [V, B].”
> “In patients who are not candidates for ET, re-assessment of HER2 status by immunohistochemistry and/or in situ hybridisation (HER2-low, -ultralow or -0) is recommended [I, A; ESCAT score: I-A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-4"></a>

###### Biopsy guidance for bone-only metastatic presentation

> “All patients with newly diagnosed lesions should have a biopsy, if clinically feasible, to confirm the presence of breast cancer and to assess the subtype of the recurrence.”
> “Biological markers (especially ER and HER2) should be reassessed at least once in the metastatic setting, even in case of a bone-only metastatic presentation.”
> “If a bone lesion is the biopsy site, it is preferable to biopsy a mixed lytic and sclerotic lesion rather than a pure sclerotic area to increase the chance of retrieving adequate high-quality cells to assess.”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.5-5"></a>

###### ASCO recommendation for ESR1 testing at recurrence or progression

> “To aid in treatment selection, the Expert Panel recommends routine testing for emergence of ESR1 mutations at recurrence or progression on ET (given with or without CDK4/6 inhibitor) in patients with ER-positive, HER2-negative MBC.”
> “Testing with a Clinical Laboratory Improvement Amendments–certified assay should be performed on blood or tissue obtained at the time of progression, as ESR1 mutations develop in response to selection pressure during treatment and are typically undetectable in the primary tumor.”
> “Blood-based ctDNA is preferred owing to greater sensitivity.”
> “Patients whose tumor or ctDNA tests remain ESR1 wild-type may warrant retesting at subsequent progression(s) to determine if an ESR1 mutation has arisen”

Source: [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)

<a id="topic-2.2.1.5-6"></a>

###### ESMO recommendation for ESR1 and PI3K pathway testing

> “Evaluation of ESR1 mutations [circulating tumour DNA (ctDNA) or tumour tissue] is recommended in ER-positive, HER2-negative MBC following progression on an aromatase inhibitor (AI) with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [I, A; ESCAT score: I-A].”
> “Evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway alterations (PIK3CA, PTEN and AKT1 mutations) using ctDNA or metastatic or primary tumour biopsies is recommended in ER-positive, HER2-negative MBC, mainly in the endocrine-resistant setting, if specific treatments are available [I, A; ESCAT score: I-A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-7"></a>

###### ABC8 recommendation for plasma ctDNA testing for ESR1 at progression

> “The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.”
> “The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound”
> “We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.5-8"></a>

###### Multigene panels on plasma or tissue

> “now explicitly supporting the use of multigene assays performed on plasma ctDNA and/or tissue, not only to facilitate enrollment into clinical trials but also to identify clinically actionable alterations, particularly ESR1 mutations and alterations in the PIK3CA/AKT/PTEN pathway”
> “in particular, plasma is preferred for ESR1 testing”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.5-9"></a>

###### Timing of tissue and liquid biopsy along the treatment course

> “Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines.”
> “Reflex TBx should be considered when ctDNA TF < 1%.”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.5-10"></a>

###### Detection technologies and polyclonality of ESR1 mutations

> “Sample sources include solid tissue biopsy, CTCs, and cell-free DNA (cfDNA); detection assays include next-generation sequencing (NGS) and droplet digital PCR (ddPCR), with ddPCR the most sensitive”
> “Thus, subclonality, polyclonality, and distinct effects of different ESR1 mutations demonstrate the utility inherent in liquid biopsy as compared to solid tissue sampling in characterizing the tumor ecosystem.”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.5-11"></a>

###### PIK3CA testing in plasma with tissue reflex

> “Candidates for a regimen with a phosphatidylinositol 3-kinase inhibitor and hormonal therapy should undergo testing for PIK3CA mutations using next-generation sequencing of tumor tissue or circulating tumor DNA (ctDNA) in plasma to determine eligibility for alpelisib plus fulvestrant.”
> “If no mutation is found in ctDNA, testing in tumor tissue, if available, should be used.”

Source: [Henry et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35759724/)

<a id="topic-2.2.1.5-12"></a>

###### Companion diagnostic: Guardant360 CDx for ESR1 mutations

> “Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes”
> “The current panel-track supplement was submitted to expand the intended use and indications for use of Guardant360® CDx to include a companion diagnostic indication for the detection of specific ESR1 mutation(s) (SNVs and V422 deletion) in patients with breast cancer who may benefit from treatment with INLURIYO (imlunestrant).”
> “Missense mutations between codons 310 and 547 of ESR1 will be reported in Category 1 as a companion diagnostic (CDx) for patients with breast cancer for ORSERDU (elacestrant).”
> “A negative result from a plasma specimen does not assure that the patient’s tumor is negative for genomic findings.”

Source: [FDA Guardant360 CDx SSED S021 (2025)](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S021B.pdf)

<a id="topic-2.2.1.5-13"></a>

###### Imaging for baseline staging

> “Computed tomography (CT) of the chest and abdomen and bone scintigraphy can be recommended as the minimum imaging work-up for baseline staging, as well as blood tests, including liver function tests [II, B].”
> “[18F]2-fluoro-2-deoxy-d-glucose–positron emission tomography (PET)–CT can also be recommended [II, B].”
> “CT or X-ray can be recommended for evaluation of impending fracture risk [V, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-14"></a>

###### Brain imaging

> “Brain imaging cannot be recommended for asymptomatic patients at initial MBC diagnosis or during disease monitoring [V, D].”
> “Brain imaging is recommended for symptomatic patients [II, A]. MRI can be recommended as the preferred technique [II, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-15"></a>

###### Response evaluation during treatment

> “Evaluation of response can be recommended every 2-4 months depending on patient symptoms, disease dynamics, location, extent of metastasis and type of treatment [V, B].”
> “Repeat bone scans may be considered for bone-only and bone-predominant metastases, noting that interpretation may be confounded by a possible flare during the first few months of treatment [III, C].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

Additional sources: [Bello et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42002527/); [Cabel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41260263/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Asymptomatic presentation

> “Metastatic cancer does not always cause symptoms.”
> “When symptoms do occur, what they are like and how often you have them will depend on the size and location of the metastatic tumors.”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-2"></a>

###### Asymptomatic patients in a real-world HR-positive, HER2-negative cohort

> “Overall, physicians reported that 30.9% (n = 506) of patients were asymptomatic”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-3"></a>

###### Site-dependent signs and symptoms of metastatic breast cancer

> “They may be related to the primary tumour (i.e., a palpable mass in the breast or axilla) or to the secondary site of disease: skeletal pain in bone metastases, respiratory symptoms in lung or pleural disease, abdominal pain in peritoneal involvement and neurological symptoms in brain lesions.”

Source: [Benvenuti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10136132/)

<a id="topic-2.2.1.6-4"></a>

###### Bone metastases: pain and fractures

> “pain and fractures, when cancer has spread to the bone”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-5"></a>

###### Bone metastases: chronic pain from expanding lesions and pathologic fracture

> “Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain.”
> “Bone metastases are a common cause of chronic pain, with pain resulting directly from expanding lesions, pathologic fracture, or damage to adjacent structures.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-6"></a>

###### Bone metastases: bone pain as the most frequent physician-reported symptom

> “Bone pain was the most common physician-reported symptom, affecting 30.3% (n = 496) of patients, followed by change in appetite (13.2%, n = 216) and weight loss (11.6%, n = 190).”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-7"></a>

###### Bone metastases: frequency in advanced disease

> “In advanced stages of breast cancer, about 65–75% of patients eventually develop BM”

Source: [Zhang et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832676/)

<a id="topic-2.2.1.6-8"></a>

###### Neurological symptoms: spinal cord compression

> “Spinal cord compression occurs in 5%–20% of cancer patients at autopsy and is a medical emergency requiring prompt evaluation and treatment”
> “Patients should be evaluated for impending cord compression if there are complaints of back pain because bone metastases are present in 95% of cases.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-9"></a>

###### Central nervous system metastases: headache, seizures, and dizziness

> “headache, seizures, or dizziness, when cancer has spread to the brain”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-10"></a>

###### Central nervous system metastases: leptomeningeal disease

> “Leptomeningeal disease (LMD) is an aggressive complication of ABC with tumor cells infiltrating the leptomeninges, subarachnoid space, and CSF”
> “LMD is confirmed by positive CSF cytology or can be considered as probable (typical neurological signs and symptoms plus typical neuroimaging findings) or possible (atypical clinical and typical neuroimaging findings)”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.6-11"></a>

###### Pulmonary and hepatic metastases: dyspnea, jaundice, and abdominal swelling

> “shortness of breath, when cancer has spread to the lung”
> “jaundice or swelling in the belly, when cancer has spread to the liver”

Source: [National Cancer Institute Metastatic Cancer (2026)](https://www.cancer.gov/types/metastatic-cancer)

<a id="topic-2.2.1.6-12"></a>

###### Respiratory symptoms: shortness of breath by treatment class

> “Shortness of breath was reported by 63.2% of those who received ET monotherapy (n = 24) and 43.4% who received ET+CDK4/6i”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-13"></a>

###### Visceral crisis: organ dysfunction from rapid progression

> “Visceral crisis is usually defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention”
> “The ABC guidelines further clarified visceral crisis as defined in liver as rapidly increasing bilirubin >1.5x ULN in the absence of an obstruction, and in lung as rapidly increasing dyspnea at rest in the absence of pleural effusion”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.6-14"></a>

###### Visceral crisis: frequency at diagnosis of advanced disease

> “Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10–15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative.”

Source: [Benvenuti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10136132/)

<a id="topic-2.2.1.6-15"></a>

###### Peritoneal metastases: abdominal pain, nausea, and ascites

> “Peritoneal carcinomatosis is more common in patients with invasive lobular carcinoma”
> “Patients may present with non-specific symptoms such as abdominal pain, decreased appetite, nausea, vomiting, weight loss, increased abdominal girth. Ascites is present in 50 % of patients.”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.6-16"></a>

###### Constitutional symptoms: fatigue

> “Fatigue is the most commonly reported symptom in cancer patients, with an estimated prevalence of 25%–99% during treatment and 20%–35% off treatment”
> “Potential contributing factors include the tumor burden, pain, difficulty sleeping, anemia, poor nutrition, inactivity, and other comorbid conditions.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-17"></a>

###### Constitutional and psychological symptoms reported by patients with HR-positive, HER2-negative metastatic disease

> “Of the 319 patients who completed the EORTC-QLQ-C30/BR23, the most frequently-reported issues were tiredness (85.6%, n = 273), worrying about future health (75.9%, n = 242), and general worry (75.9%, n = 242; Table 2).”
> “By treatment class, pain was reported by 80.8% of those who received chemotherapy monotherapy (n = 42), compared with 51.1% of those who received other targeted therapies (n = 24) and 63.6% who received ET+CDK4/6i (n = 110).”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.6-18"></a>

###### Psychological symptoms: depression and sleep disturbance

> “Common vegetative symptoms of depression (fatigue, loss of appetite, insomnia) may be difficult to differentiate from symptoms related to metastases.”
> “Fatigue and depression are often associated with sleep problems, whereas pain and menopausal vasomotor symptoms may interfere with sleep quantity and quality.”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="topic-2.2.1.6-19"></a>

###### Locoregional symptoms: lymphedema

> “Lymphedema may develop in the upper extremity and/or trunk of the primary tumor site and can be especially disabling if associated with infection or local recurrence”

Source: [Irvin et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3228166/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Skeletal-related events in patients with bone metastases

> “BM is associated with accelerated bone resorption leading to increased morbidity due to a range of skeletal-related events (SREs) including bone pain (BP), pathological fracture (PF), spinal cord compression (SCC), tumor-induced hypercalcemia (TIH) and surgery or radiation therapy (RT) to bone”
> “Studies have demonstrated that at least one SRE occurs in nearly 50% of patients with bone metastases of breast cancer”
> “In randomized trials in advanced breast cancer, one of the major SREs occurs on average every 3–6 months after the onset of BM.”

Source: [Zhang et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832676/)

<a id="topic-2.2.1.7-2"></a>

###### Prevention of skeletal-related events with bone-modifying agents

> “Patients with breast cancer who have evidence of bone metastases should be treated with BMAs.”
> “The analgesic effects of BMAs are modest, and they should not be used alone for bone pain.”

Source: [Van Poznak et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29035643/)

<a id="topic-2.2.1.7-3"></a>

###### ESMO recommendations on bone metastases and skeletal-related events

> “A multidisciplinary approach is recommended to manage patients with bone metastases and to prevent skeletal-related events (SREs) [V, A].”
> “Bone-modifying agents (BMAs) such as bisphosphonates or denosumab are recommended for patients with bone metastases, regardless of symptoms [I, A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.7-4"></a>

###### Visceral crisis: prognosis

> “The diagnosis of visceral crisis in metastatic breast cancer is associated with poor prognosis.”
> “Sbitti et al. showed a median Overall Survival (mOS) of 4.7 weeks in a retrospective cohort of 35 patients with hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer and visceral crisis pre-treated with two hormonal therapy lines, of whom 77 % had liver metastases.”
> “Thus, the type of organic involvement in patients with VC is an established prognostic factor, with hepatic involvement being more associated with worse mOS.”

Source: [Andrade et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112279/)

<a id="topic-2.2.1.7-5"></a>

###### Central nervous system metastases: incidence by subtype and line of therapy

> “Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation.”
> “For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2- disease, 23% for HR+/HER2+ disease, 34% for HR-/HER2+ disease, and 22% for triple-negative breast cancer (TNBC).”
> “Brain metastases incidence increases per line of therapy for every MBC subtype.”

Source: [Sammons et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40163696/)

<a id="topic-2.2.1.7-6"></a>

###### Central nervous system metastases: pooled incidence in HR-positive, HER2-negative disease

> “Four studies including 14656 patients reported the incidence of brain metastases specifically in patients with HR+/HER2− MBC.”
> “Pooled cumulative incidence of brain metastases among this subgroup was 0.15 (95% CI: 0.078–0.27), with a median follow-up of 33.0 months (IQR: 31.9–36.2).”

Source: [Kuksis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8168821/)

<a id="topic-2.2.1.7-7"></a>

###### Central nervous system metastases: detection by screening MRI and ABC8 position

> “Data from a non-randomized, prospective screening study in patients with ABC reveal that approximately one-quarter of patients across all subtypes (HR+/HER2-negative, TNBC, and HER2+) who undergo a baseline and 6-month screening MRI will be diagnosed with brain metastases”
> “As we await these data, the existing evidence base, though limited, provides rationale to consider screening in patients at high risk of developing brain metastases and in situations where the knowledge of brain metastases status would impact the choice of systemic therapy.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.7-8"></a>

###### Central nervous system metastases: rising incidence with longer survival

> “The incidence of brain metastases in breast cancer patients is increasing mainly due to improved systemic therapies resulting in more durable control of extracranial metastatic disease and prolonged survival.”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.7-9"></a>

###### Disease progression: shorter benefit from endocrine monotherapy after first line

> “Although most HR-positive breast cancers benefit from first-line ET, most eventually become endocrine-resistant.”
> “Second-line ET monotherapy has a median progression-free survival (PFS) of only 2–6 months, compared to 1–4 years for first-line ET”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.7-10"></a>

###### Treatment toxicities over sequential lines: assessment beyond adverse event frequency

> “Assessment of treatment-related toxicity should extend beyond the frequency and severity of clinician-reported adverse events.”
> “Rates of treatment discontinuation due to toxicity should be considered alongside patient-reported outcomes (PROs) and validated measures of health-related quality of life, including the specific domains assessed and the completeness of their reporting.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.7-11"></a>

###### Treatment toxicities over sequential lines: vasomotor symptoms and alopecia

> “Vasomotor symptoms (VMS; also known as hot flashes) are common side effects of endocrine therapy, in particular in young women receiving LHRH analogs.”
> “Alopecia is a common distressing treatment toxicity that negatively impacts body image, quality of life and psycho-social functioning.”
> “However, hair loss may occur with ADCs, CDK4/6 inhibitors and endocrine therapy (male-pattern androgenetic alopecia).”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.7-12"></a>

###### Treatment toxicities over sequential lines: interstitial lung disease and cognitive impairment

> “In the treatment of breast cancer, ILD has been associated with antibody drug conjugates, mTOR inhibitors, HER-2/EGFR targeted oral tyrosine kinase inhibitors, PD-1 or PD-L1 inhibitors, radiation therapy and rarely, CDK4/6 inhibitors”
> “Cognitive complaints are usually subtle or moderate, and most frequently related to ChT. However, other treatments, such as ET, targeted agents, and immunotherapy may also have an impact in cognitive function”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.7-13"></a>

###### Treatment toxicities over sequential lines: patient-reported side effects

> “Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.”
> “The only symptom that worsened in over 10% of the overall cohort was bone pain severity”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

Additional sources: [Atre et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38816556/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Patient-reported symptoms, side effects, and quality of life in 321 participants with HR+/HER2- metastatic breast cancer in Europe and the United States

> “Data were derived from the Adelphi Real World Advanced Breast Cancer Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with HR+/HER2- mBC receiving treatment, conducted in Europe and the United States between August 2022 and February 2023.”
> “Overall, 298 physicians provided data on 1,642 patients, of which 321 patients self-reported data. Tiredness (85.6%), general worry (75.9%), and worry about future health (75.9%) were the most common patient-reported symptoms and side effects overall. Physicians reported bone pain (30.3%) and appetite changes (13.2%) as the most frequent patient symptoms, while estimating that most patients experienced no side effects (55.1%).”
> “Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.8.1-2"></a>

###### Global health status and quality of life in 1250 participants receiving palbociclib plus endocrine therapy in the POLARIS real-world cohort

> “Patients received palbociclib plus endocrine therapy as first-line, second-line or later line of therapy.”
> “Between January 2017 and January 2023, 1250 patients were enrolled and received ≥ 1 palbociclib dose.”
> “For Question 29 (GHS), the proportion of patients with a favorable response significantly increased by ∼13% to 69.3% by month 6, which was maintained at month 12 (68.6%) and month 18 (70.0%). For Question 30 (QoL), the proportion of patients with a favorable response significantly increased by ∼9% to 74.5% by month 6, which was maintained at month 12 (75.0%) and month 18 (73.4%).”

Source: [Rocque et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12596709/)

<a id="topic-2.2.1.8.1-3"></a>

###### Pain and EQ-5D-3L utility by metastatic site and pain severity in 739 participants in the United States and Europe

> “Overall, 173 oncologists and 739 patients participated.”
> “The mean (SD) health utility index was 0.73 (0.29) for the total population while the mean (SD) self-reported general health status was 62.0 (20.7)”
> “There was a significant difference in the mean health utility index related to metastatic sites, with mean (SD) index for patients with visceral and bone, bone only and visceral only metastases reported as 0.62 (0.33), 0.68 (0.34) and 0.78 (0.26), respectively”
> “Patients on chemotherapy reported significantly higher proportions of moderate/extreme levels of anxiety/depression (66.7%) and significantly lower general health status (60.7) compared with those on endocrine therapy (53.1% and 64.4, respectively).”

Source: [Wood et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5703387/)

| Worst pain severity | Mean (SD) health utility index |
| --- | --- |
| Mild (1-4) | “0.81 (0.21)” |
| Moderate (5-6) | “0.63 (0.27)” |
| Severe (7-10) | “0.40 (0.45)” |

Source: [Wood et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5703387/)

<a id="topic-2.2.1.8.1-4"></a>

###### Health-state utilities for stable, responding, and progressive disease: standard gamble study of 100 members of the UK general public

> “One hundred members of the general public rated them using standard gamble to determine health state utility.”
> “Stable disease on treatment had a utility value of 0.72, with a corresponding gain of +0.07 following a treatment response and a decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile neutropenia).”
> “The base state (stable disease with no side effects) had a utility value of 0.715. Moving to responding disease from stable on treatment produced a significant utility gain (+0.075). Moving from stable disease to progressive disease led to a significant decrement in utility (−0.272).”

Source: [Lloyd et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360509/)

<a id="topic-2.2.1.8.1-5"></a>

###### Structured review of health utility elicitation in advanced or metastatic breast cancer

> “A total of 768 publications were identified in the searches, and 26 publications, comprising 18 journal articles and eight submissions to HTA bodies, were included in the evidence review.”
> “the TTO-derived utilities for nine breast cancer health states were collected from two different cohorts, one in the Netherlands and one in Sweden. Of these, the Swedish sample rated progressive and stable disease health states (0.61 and 0.81, respectively) higher than the Dutch sample (0.49 and 0.69, respectively).”
> “Most submissions to HTA bodies obtained utility values from the literature rather than exploring the HRQOL data obtained during clinical development.”

Source: [Hao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4922814/)

<a id="topic-2.2.1.8.1-6"></a>

###### Symptom burden, activity impairment, and work productivity in 152 participants in the US VIRGO observational cohort

> “This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study.”
> “Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8%-52.0% of patients. Mean percent daily activity impairment was 30% for study patients, and WP impairment ranged from 20% to 40% across indices in employed patients (n, 58).”

Source: [Cleeland et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25193423/)

<a id="topic-2.2.1.8.1-7"></a>

###### Time spent receiving health care during the first 3 months of treatment for metastatic breast cancer

> “Average total time spent on health care ranged from 7% to 10% of all days included within the initial 3 months of treatment, depending on treatment. The greatest time contributions were time spent traveling for care and on inpatient services.”
> “Patients receiving infusion/injection treatments, compared with those receiving oral therapy, spent more time in ambulatory care. Health care time was higher for patients receiving chemotherapeutic agents compared to those receiving hormonal agents.”

Source: [Rocque et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7666754/)

<a id="topic-2.2.1.8.1-8"></a>

###### Patient perspectives on progression-free survival and quality of life

> “Virtual roundtables in Europe and the United States and interviews in Japan with breast cancer patients, patient advocates, and thought leaders.”
> “Lengthened OS combined with no worsening or improvement in QoL remain the most important endpoints for mBC patients. Time when the disease is not progressing is meaningful to patients when coupled with improvements in QoL and no added treatment toxicity.”

Source: [Mertz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9307669/)

<a id="topic-2.2.1.8.1-9"></a>

###### Patient-reported outcomes in EMBER-3: imlunestrant, imlunestrant plus abemaciclib, and fulvestrant or exemestane

> “Most (72.3%) fulvestrant-treated patients reported injection site reactions at any time. Diarrhea frequency was consistently higher in the combination arm of imlunestrant–abemaciclib.”
> “GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant–abemaciclib group.”

Source: [Curigliano et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13091516/)

<a id="topic-2.2.1.8.1-10"></a>

###### Patient-reported outcomes in CAPItello-291: capivasertib plus fulvestrant versus placebo plus fulvestrant

> “Median time to deterioration in EORTC QLQ-C30 GHS/QOL was 24·9 months (95% CI 13·8 to not reached) in the capivasertib-fulvestrant group and 12·0 months (10·2 to 15·7) in the placebo-fulvestrant group (hazard ratio [HR] 0·70, 95% CI 0·53 to 0·92).”
> “Time to deterioration HRs for all EORTC QLQ-C30 and QLQ-BR23 subscale scores showed little difference between the treatment groups, except for diarrhoea, which was worse in the capivasertib-fulvestrant group than in the placebo-fulvestrant group (HR 2·75, 95% CI 2·01-3·81).”

Source: [Oliveira et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/39214106/)

<a id="topic-2.2.1.8.1-11"></a>

###### Patient-reported outcomes in SOLAR-1: alpelisib plus fulvestrant versus placebo plus fulvestrant

> “Time to 10% deterioration for Global Health Status/QoL was similar between arms (hazard ratio, 1.03; 95% CI, 0.72 to 1.48). Compared with placebo, deterioration in social functioning and in diarrhea, appetite loss, nausea or vomiting, and fatigue symptom subscales occurred with alpelisib.”

Source: [Ciruelos et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8210974/)

<a id="topic-2.2.1.8.1-12"></a>

###### Patient-reported outcomes in SERENA-6: switch to camizestrant at ESR1 mutation emergence during first-line therapy

> “Switching to camizestrant-CDK4/6i delayed TTD and reduced the risk of deterioration in patient-reported cancer symptoms [pain (hazard ratio 0.57, 95% confidence interval 0.37-0.86), fatigue (0.75, 0.46-1.24), shortness of breath/dyspnoea (0.52, 0.28-0.93), breast symptoms (0.59, 0.28-1.24) and arm symptoms (0.69, 0.34-1.39)] and functioning [physical (0.74, 0.44-1.24), role (0.73, 0.48-1.10) and emotional (0.51, 0.29-0.87)] compared with AI-CDK4/6i.”

Source: [Mayer et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41125211/)

<a id="topic-2.2.1.8.1-13"></a>

###### Health-related quality of life with first-line versus second-line CDK4/6 inhibitor use in SONIA

> “HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL 5-dimensions 5-level questionnaires at up to 11 time points over the course of both treatment lines (follow-up) until SONIA treatment discontinuation.”
> “No clinically or statistically significant differences in HRQOL were observed between treatment arms during follow-up. The estimated mean difference in FACT-B total score (CDK4/6i in second-line as reference) was -0.66 (95% confidence interval [CI] = -2.14 to 0.82; P = .39).”

Source: [Wortelboer et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41270788/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Health care resource utilization and costs per patient per month by line of therapy in 3203 premenopausal women with HR+/HER2- metastatic breast cancer, US commercial claims

> “A total of 3203 patients received first-line, 2194 received second-line, and 1242 received third-line therapy for mBC. Mean number of IP days PPP6 M were 1.6, 1.3, and 1.5 days in the first, second, and third lines, respectively. Mean number of days with OP services PPP6 M was 31.4, 30.9, and 23.3 in the first, second, and third lines, respectively.”
> “Among patients receiving ET, mean total healthcare costs were $6521, $4440, and $4555 PPPM in the first, second, and third line, respectively. Among patients receiving chemotherapy, mean total healthcare costs were $16,842, $12,868, and $16,129 PPPM in the first, second, and third line, respectively.”

Source: [Gauthier et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29556908/)

<a id="topic-2.2.1.8.2-2"></a>

###### All-cause costs per patient per month and treatment patterns by line in 5563 privately insured participants with HR+/HER2- metastatic breast cancer before CDK4/6 inhibitors

> “Among 5,563 eligible patients, endocrine therapy was the most common first-line (1L) therapy; its utilization trended downward from 63% (1L) to 23% (4L), with a simultaneous increase in chemotherapy use, 25% (1L) to 50% (4L).”
> “The average per patient monthly all-cause costs were $14,424. The 12-month indirect costs for short-term disability were substantially higher in MBC patients ($10,397) than in matched noncancer patients ($394).”

Source: [Goyal et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32755262/)

<a id="topic-2.2.1.8.2-3"></a>

###### Anticancer and supportive care drug costs by subtype in 15 215 participants in a US nationwide database, 2011 to 2021

> “The mean total per-patient treatment and supportive care drug cost using publicly available Medicare prices was $334 812 for patients with HR-positive and ERBB2-positive MBC, $284 609 for patients with HR-negative and ERBB2-positive MBC, $104 774 for patients with HR-positive and ERBB2-negative MBC, and $54 355 for patients with TNBC.”
> “From 2011 to 2019 (most recent complete year 1 data are for patients diagnosed in 2019), annual costs in year 1 increased from $12 986 to $80 563 for ERBB2-negative and HR-positive MBC, $99 997 to $156 712 for ERBB2-positive and HR-positive MBC, and $31 397 to $53 775 for TNBC.”
> “Second, our study focused on outpatient treatment and did not account for other medical costs, such as surgery, radiation, imaging, and hospital stays.”

Source: [Jaber Chehayeb et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9709649/)

<a id="topic-2.2.1.8.2-4"></a>

###### Resource utilization and costs in the year after first-line CDK4/6 inhibitor initiation in 901 Medicare-enrolled participants

> “901 patients met the inclusion criteria with a mean age of 74 years (SD = 6.84). Nearly 24% (n = 214) had an IP admission in the 6 months following CDK4/6i initiation.”
> “Roughly 30% (n = 271) of patients had an ED visit, with a mean of 2.1 (SD = 1.54) visits per patient among those who had a visit.”
> “Mean total health care costs over the 1-year period following CDK4/6is were $62,228 (95% CI = 52,281-73,029) per patient with the main drivers being OP services ($31,686 [95% CI = 27,168-36,925]) and pharmacy costs ($22,727 [95% CI = 19,273-25,931]).”

Source: [Behan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695835/)

<a id="topic-2.2.1.8.2-5"></a>

###### Projected lifetime health care costs after first-line CDK4/6 inhibitor plus aromatase inhibitor in a US Medicare-eligible population

> “Total lifetime health care costs were also similar ($865,000 [95% CR = $807,400-$925,000], $866,800 [95% CR = $786,000-$965,000], and $901,000 [95% CR = $809,000-$1,004,600], respectively).”
> “All-cause medical costs and CDK4/6i drug costs were based on an analysis of patients aged 65 years and older in Optum Clinformatics DataMart.”

Source: [Sun et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467758/)

<a id="topic-2.2.1.8.2-6"></a>

###### Cost of disease progression in 5709 participants with metastatic breast cancer, US commercial and Medicare Advantage claims

> “Of 5,709 patients with mBC, 3,707 patients with mCRC, and 5,201 patients with mLC, 56.8% of patients with mBC, 58.1% of those with mCRC, and 80.3% of those with mLC patients had evidence of disease progression over 12 months.”
> “Per‐patient‐per‐month costs, which accounted for variable follow‐up time, were almost twice as high among progressors versus nonprogressors in patients with mBC, mCRC, and mLC. In each of the three cancer types, delays in progression were associated with lower health care costs.”

Source: [Reyes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6738320/)

<a id="topic-2.2.1.8.2-7"></a>

###### End-of-life costs and resource utilization in the last 6 months, 3878 participants in US commercial claims

> “Of the 3,878 females included, 18.5% (n = 718) met the criteria for EOL.”
> “In adjusted analyses, the EOL cohort had 4.15 times higher 6-month total healthcare costs (EOL, $72,112 vs NEOL, $17,137; p < 0.001). NEOL month-to-month mean total healthcare costs fluctuated between $2336-$3145, while EOL costs increased steadily from $8,956 in the sixth month prior to death to $19,326 in the last month of life.”
> “EOL month-to-month costs increased precipitously in the last 2 months of life and were driven by acute inpatient care.”

Source: [Bramley et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27248201/)

<a id="topic-2.2.1.8.2-8"></a>

###### Cancer-attributable medical costs by phase of care and stage at diagnosis, SEER-Medicare

> “Annualized average cancer-attributable costs for medical care (Medicare Parts A and B) and oral prescription drugs (Medicare Part D) were estimated by subtracting costs between cancer patients and matched controls. Costs are reported in 2019 US dollars.”
> “Overall annualized average costs were highest in the EOL-cancer death phase, followed by the initial and continuing phases”

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

| Breast cancer, stage at diagnosis | Initial phase | Continuing phase | End-of-life phase, cancer death |
| --- | --- | --- | --- |
| Distant, medical services (thousand 2019 US dollars) | “$67.4” | “$22.3” | “$91.9” |
| All stages, medical services (thousand 2019 US dollars) | “$33.7” | “$3.5” | “$73.2” |

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

<a id="topic-2.2.1.8.2-9"></a>

###### Projected US prevalence and total medical and productivity costs of metastatic breast cancer, 2015 to 2030

> “In 2030, we estimated there would be 246 194 prevalent cases of mBC, an increase of 54.8% from the 2015 estimate of 158 997. We estimated total costs (medical and productivity) of mBC across all age groups and phases of care were $63.4 billion (95% sensitivity range = $59.4-$67.4 billion) in 2015 and would increase to $152.4 billion (95% sensitivity range = $111.6-$220.4 billion) in 2030, an increase of 140%.”

Source: [Gogate et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8364673/)

<a id="topic-2.2.1.8.2-10"></a>

###### Health care contact days in the year after diagnosis among Medicare beneficiaries with metastatic breast cancer

> “In the year after diagnosis, beneficiaries with colorectal cancer had the highest mean (SD) contact days (62.9 [48.1]), followed by those with lung (60.2 [47.0]), breast (48.7 [47.9]), and prostate (40.1 [42.4]) cancers.”
> “Across all cancer types, mean contact days increased from 2008 to 2019 with a prominent increase in ambulatory days from 2016 onward; the largest increase in contact days was observed for breast cancer (44.9 [95% CI, 38.7-52.2] to 57.6 [95% CI, 46.9-70.8]).”

Source: [Gupta et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690425/)

<a id="topic-2.2.1.8.2-11"></a>

###### Encounter days in the first year of treatment among 2949 SEER-Medicare participants aged 67 years or older

> “We assessed time toxicity using the number of encounter days patients interacted with the healthcare system per 100 days, within the first year of starting cancer treatment.”
> “Patients with more than three comorbidities had significantly higher encounter days compared to those without comorbidities [RR 1.36 (95% CI 1.26, 1.46)]. Receipt of radiotherapy [RR: 1.45 95% CI (1.37, 1.54)] was associated with more encounter days compared to not receiving radiotherapy”

Source: [Atre et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38816556/)

<a id="topic-2.2.1.8.2-12"></a>

###### Systematic review of direct and indirect costs of breast cancer by stage

> “Across cost categories, cost ranges tended to be higher in the US than any other country. Metastatic breast cancer was associated with higher costs than earlier-stage cancer. When indirect costs were accounted for, particularly in terms of productivity loss, they tended to be higher than any other estimated direct cost (e.g., diagnosis, drug, and other medical costs).”

Source: [Franklin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11213812/)

<a id="topic-2.2.1.8.2-13"></a>

###### Phase-specific costs per patient per month after first-line CDK4/6 inhibitor in 5435 participants, Japanese nationwide claims

> “Among 5435 patients (median age 72.3 years), active treatment phases showed drug-dominated cost structures: first-line per-patient per-month (PPPM) cost was 482,936 Japanese yen (JPY) (drug 85%–90%), second-line 361,615 JPY (81%), and extended chemotherapy 255,922 JPY (66%). A marked inversion occurred in the palliative phase (PPPM 233,824 JPY; drug 11%, inpatient 70%) and terminal phase (PPPM 412,149 JPY; drug 17%, inpatient 69%).”
> “Death-anchored analysis of 1111 decedents identified a transition 2 months before death, when inpatient costs first exceeded drug costs.”

Source: [Kashiwa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13723614/)

Additional sources: [Goyal et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31060392/); [Allen (2010)](https://pubmed.ncbi.nlm.nih.gov/20873957/); [Sorensen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22617734/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver work changes and quality of life in 345 informal caregivers in the United States, United Kingdom, and Germany

> “We conducted a one-time, cross-sectional survey of 345 informal caregivers of people living with mBC in the United States, United Kingdom, and Germany in December 2021.”
> “One in three caregivers changed work status after onset of caregiving, either reducing working hours (12 %), stopping work altogether (13 %), or increasing working hours (8 %). Caregivers who reduced hours or stopped working reported better QoL overall with total CQOLC scores of 71.8 and 65.3, compared to those who maintained or increased work hours (CQOLC scores of 61.3 and 54.4, respectively, [p < 0.001]).”

Source: [Comerford et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39631724/)

<a id="topic-2.2.1.8.3-2"></a>

###### Indirect costs of productivity loss for patients and family members, US employer claims

> “The MarketScan Health and Productivity Management database (2005-2009) was used.”
> “MBC patients had more sick leave cost than controls ($2383 ± $5539 vs. $1282 ± $2083, p < 0.05). Controlling for covariates, MBC patients incurred 47% more short-term disability costs vs EBC patients (p = 0.009).”
> “MBC patients' families incurred 39.7% (p = 0.06) higher indirect costs compared to EBC patients' families after controlling for key covariates.”

Source: [Wan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23866016/)

<a id="topic-2.2.1.8.3-3"></a>

###### Systematic review of cancer treatment and work productivity of patients and caregivers

> “Of 978 potential citations, 62 articles or abstracts were included. Forty-six studies (74.2%) evaluated patient-related productivity; 10 studies (16.1%) focused on caregivers, and 6 studies (9.7%) were a combination.”
> “The most commonly studied cancer was breast cancer (53.2%).”
> “Metastatic patients’ family members had higher leave days and associated costs than matched patients.”

Source: [Kamal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397748/)

<a id="topic-2.2.1.8.3-4"></a>

###### Workdays missed and indirect costs among employees with newly diagnosed metastatic versus non-metastatic cancer, US claims

> “The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year.”

Source: [Cong et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9596506/)

<a id="topic-2.2.1.8.3-5"></a>

###### Financial hardship by insurance status in 1054 women with metastatic breast cancer, US national survey

> “Participants responded from 41 states (N = 1054; median age: 44 years). Overall, 30% were uninsured.”
> “In adjusted analyses, uninsured participants were more likely than insured participants to report contact by debt collectors (adjusted risk ratio [aRR]: 2.38 [2.06, 2.76]) and being unable to meet monthly expenses (aRR: 2.11 [1.68, 2.66]). Financial distress was reported more frequently by insured participants.”
> “Young adult women with metastatic cancer reported a high burden of financial toxicity. Importantly, insurance does not protect against financial distress; however, the uninsured are the most materially vulnerable.”

Source: [Wheeler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10242847/)

<a id="topic-2.2.1.8.3-6"></a>

###### Drivers of financial burden and cost-coping behaviors: qualitative interviews with patients and caregiver representatives

> “A total of N=11 MBC patients or caregiver representatives participated in the study.”
> “Both medical and non-medical costs drove financial burden among participants. All participants reported challenges navigating their health insurance and applying for financial assistance. Regardless of gaining access to assistance, financial burden persisted for nearly all patients and resulted in cost-coping behaviors.”
> “Even when MBC patients accessed assistance, excess financial burden persisted necessitating use of financial coping-behaviors such as altering medication use, maintaining employment, and taking on debt.”

Source: [Waters et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129926/)

<a id="topic-2.2.1.8.3-7"></a>

###### Financial toxicity in 145 women with metastatic breast cancer at a US outpatient clinic

> “145 women with metastatic breast cancer receiving care at an urban outpatient breast cancer clinic.”
> “Financial toxicity is common among women with metastatic breast cancer and more common among low-income women with the disease. In addition, financial toxicity is correlated with worse quality of life and overall cancer-related distress.”

Source: [Rosenzweig et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30547962/)

<a id="topic-2.2.1.8.3-8"></a>

###### Pooled rate of financial toxicity in breast cancer: meta-analysis of 66 studies

> “Sixty-six studies involving 29 426 participants with breast cancer were enrolled in our study.”
> “The pooled FT rate was 39.3% (95% CI, 32.4%-46.6%) in HICs and 72.3% (95% CI, 56.8%-83.8%) in LMICs.”

Source: [Yin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12831935/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Medicare payment for liquid biopsy and tissue genomic sequencing panels, Clinical Laboratory Fee Schedule fourth-quarter file

| Code | Short description in the file | Rate in the file (U.S. dollars) |
| --- | --- | --- |
| 0242U | “Trgt gen seq alys pnl 55-74” | “05000.00” |
| 0239U | “Trgt gen seq alys pnl 311+” | “03500.00” |
| 0326U | “Trgt gen seq alys pnl 83+” | “05000.00” |
| 81455 | “So/hl 51/>gsap dna/dna&rna” | “02919.60” |

Source: [CMS Clinical Laboratory Fee Schedule file 26CLABQ4 (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

> “Note: Including a code or payment amount for a particular clinical diagnostic laboratory test doesn't imply Medicare will cover the test.”
> “CY 2026 Q4 Release: Updated for October 2026.”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files)

<a id="topic-2.2.1.8.4-2"></a>

###### Advanced Diagnostic Laboratory Test status and initial-period payment for Guardant360 CDx and FoundationOne Liquid CDx

| Test code | Laboratory | Test name | Payment amount during new ADLT initial period |
| --- | --- | --- | --- |
| 0242U | “Guardant Health, Inc.” | “Guardant360 CDx” | “$5,000.00” |
| 0239U | “Foundation Medicine, Inc.” | “FoundationOne Liquid CDx” | “$3,500.00” |

Source: [CMS ADLT list (2026)](https://cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)

<a id="topic-2.2.1.8.4-3"></a>

###### Medicare national coverage of next-generation sequencing companion diagnostics in advanced cancer

> “Effective for services performed on or after March 16, 2018, the Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, when ordered by a treating physician, and when all of the following requirements are met:”
> “Patient has: either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and not been previously tested with the same test using NGS for the same cancer genetic content, and decided to seek further cancer treatment (e.g., therapeutic chemotherapy).”
> “The diagnostic laboratory test using NGS must have: Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and, an FDA-approved or -cleared indication for use in that patient’s cancer; and, results provided to the treating physician for management of the patient using a report template to specify treatment options.”

Source: [CMS National Coverage Determination 90.2 (2020)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372)

<a id="topic-2.2.1.8.4-4"></a>

###### State biomarker testing insurance coverage laws

> “Cost and lack of insurance coverage are common barriers to testing because insurance coverage varies across commercial payers, Medicare, and Medicaid.”
> “Fifteen states have passed legislation related to biomarker testing since 2021”
> “All laws apply to commercial payers; in 12 states, the laws also apply to Medicaid.”
> “Most laws (n = 11) require coverage of biomarker testing broadly without regard to condition. Four states (Arkansas, California, Louisiana, and Nevada) specify coverage of cancer biomarkers, with California specifying coverage for testing for stage III or IV cancer only.”

Source: [Lin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11590753/)

<a id="topic-2.2.1.8.4-5"></a>

###### Managed care perspectives on ESR1 and circulating tumor DNA testing costs and coverage

> “Key insight: A primary consideration of payers in aBC is that the optimal biomarker testing parameters are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care such as via treatment pathways.”
> “Participants also recognized that although the cost of additional biomarker testing may not be realized by the provider or patient, it could be a cost-of-care consideration for payers including employer groups.”
> “Payer participants expressed concern with regular, potentially costly testing if it does not result in actionable information for making treatment decisions.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)

<a id="topic-2.2.1.8.4-6"></a>

###### Coverage and out-of-pocket cost barriers to next-generation sequencing reported by US stakeholders in metastatic breast cancer

> “This study revealed that despite the awareness and recognition of the value proposition of NGS-based molecular profiling in mBC, inconsistent payer coverage, high out of pocket costs for patients, and challenges in managing reimbursement and prior authorization processes can lead to suboptimal utilization of NGS, which can subsequently lead to suboptimal treatment decisions where approved therapies exist.”
> “Interestingly, many payers (33%) were not aware of the current somatic biomarker testing recommendations from NCCN guidelines.”

Source: [Cadirov et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12564138/)

<a id="topic-2.2.1.8.4-7"></a>

###### ESR1 testing rates by line of therapy in US practice

> “Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups.”

Source: [Liao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13710441/)

<a id="topic-2.2.1.8.4-8"></a>

###### Specimen type and turnaround time of ESR1 tests during first-line therapy in US practice

> “Among 7772 patients with mBC in the FHRD who initiated 1 L therapy, tumor ESR1 mutation status was evaluated for 222 (3%) patients at baseline (≤ 90 days before 1 L) and 1355 (17%) during 1 L.”
> “Most (60%) tests during 1 L used tissue specimens, while the remaining 40% were liquid biopsies, and the median time from specimen collection to result reporting in 1 L was 28 (IQR:10–84) days.”

Source: [Meisel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13558280/)

Additional sources: [Bello et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42002527/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Oral Selective Estrogen Receptor Degraders and Estrogen Receptor Degraders

<a id="topic-2.2.2.1.1-1"></a>

###### Guideline recommendation: NCCN, elacestrant and imlunestrant for ESR1-mutated disease

> “After a prior line of AI with or without CDK4/6 inhibitor therapy (in adjuvant or metastatic setting), options for ESR-1 mutated tumors include elacestrant or imlunestrant.”
> “Therefore, the NCCN panel recommends elacestrant as an option after a prior line of AI a with CDK4/6 inhibitor therapy (in adjuvant or metastatic setting) (Figure 5).”
> “The NCCN Panel recommends imlunestrant after a prior line of AI with or without CDK4/6 inhibitor therapy (in adjuvant or metastatic setting) (Figure 5).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.1-2"></a>

###### Guideline recommendation: NCCN, imlunestrant plus abemaciclib and vepdegestrant

> “noting that the combination of imlunestrant and abemaciclib may be most effective in those with ESR1 mutations and no prior CDK4/6 inhibitor.”
> “The NCCN panel has included vepdegestrant as an option after a prior line of endocrine therapy in the metastatic setting for patients with ESR1-mutated breast cancer (Figure 5).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.1-3"></a>

###### Guideline recommendation: ABC8, oral SERD class

> “Since the approval of elacestrant based on the EMERALD trial [ 33 ], the class of oral SERDs has expanded with new agents now supported by phase 3 evidence. Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.”
> “Camizestrant showed encouraging results in the SERENA-6 trial using a ctDNA-guided switch strategy upon emergence of ESR1 mutations , though the clinical utility of treatment modification without radiological progression remains to be established [ 35 ].”
> “The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.1-4"></a>

###### Guideline background: ASCO 2021, ESR1 testing before oral SERD approvals

> “There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. Existing data suggest reduced efficacy of AIs compared with the selective estrogen receptor degrader fulvestrant in patients who have tumor or circulating tumor DNA (ctDNA) with ESR1 mutations (type: informal consensus; evidence quality: insufficient; strength of recommendation: moderate).”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.1-5"></a>

###### Comparator regulatory information: elacestrant

> “ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test”
> “with disease progression following at least one line of endocrine therapy.”
> “The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.2.2.1.1-6"></a>

###### Elacestrant, EMERALD: trial population and comparator

> “Patients were required to have disease progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.”
> “investigator’s choice of endocrine therapy (n=239), which included fulvestrant (n=166), or an aromatase inhibitor (n=73; anastrozole, letrozole or exemestane).”
> “An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### Elacestrant, EMERALD: progression-free survival

> “PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).”
> “Similarly, 12-month PFS rates were 22.3% (95% CI, 15.2 to 29.4) versus 9.4% (95% CI, 4.0 to 14.8), respectively, in all patients versus 26.8% (95% CI, 16.2 to 37.4) and 8.2% (95% CI, 1.3 to 15.1), respectively, in patients with ESR1 mutation.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.1-8"></a>

###### Elacestrant, EMERALD: FDA review of the ESR1-mutated subgroup

> “The median PFS was 3.8 months (95% CI, 2.2 to 7.3) in the elacestrant arm and 1.9 months (95% CI, 1.9 to 2.1) in the SOC arm.”
> “By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.1.1-9"></a>

###### Elacestrant, EMERALD: duration of prior CDK4/6 inhibitor therapy

> “In patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63).”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.1.1-10"></a>

###### Elacestrant, EMERALD: safety

> “Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.1-11"></a>

###### Comparator regulatory information: imlunestrant

> “as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy”
> “in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.2.2.1.1-12"></a>

###### Imlunestrant, EMBER-3: FDA approval of monotherapy

> “In the ESR1 mutated population (n=256), a statistically significant difference in investigator-assessed PFS for imlunestrant compared to investigator’s choice of endocrine therapy was observed. The median PFS was 5.5 months (95% CI: 3.9, 7.4) in the imlunestrant arm and 3.8 months (95% CI: 3.7, 5.5) in the investigator's choice arm (hazard ratio 0.62 [95% CI: 0.46, 0.82]; p-value 0.0008).”

Source: [FDA imlunestrant approval notice (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)

<a id="topic-2.2.2.1.1-13"></a>

###### Imlunestrant, EMBER-3: primary results

> “Overall, 874 patients underwent randomization, with 331 assigned to imlunestrant, 330 to standard therapy, and 213 to imlunestrant–abemaciclib.”
> “In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).”
> “The incidence of grade 3 or higher adverse events was 17.1% with imlunestrant, 20.7% with standard therapy, and 48.6% with imlunestrant–abemaciclib.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.1-14"></a>

###### Imlunestrant, EMBER-3: updated overall survival

> “In patients with ESR1 m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].”

Source: [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)

<a id="topic-2.2.2.1.1-15"></a>

###### Comparator regulatory information: vepdegestrant

> “VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.”

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.1-16"></a>

###### Vepdegestrant, VERITAC-2: FDA approval

> “On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader”
> “Patients were required to have disease progression on one to two lines of endocrine therapy, including one line with a CDK4/6 inhibitor.”
> “Median PFS was 5 months (95% CI: 3.7, 7.4) in the vepdegestrant arm and 2.1 months (95% CI: 1.9, 3.5) in the fulvestrant arm (hazard ratio 0.57 [95% CI: 0.42, 0.77]; p-value 0.0001). ORR was 19% (95% CI: 12, 27) and 4% (95% CI: 1.6, 10) in the respective arms.”
> “The recommended vepdegestrant dose is 200 mg taken orally once daily with food until disease progression or unacceptable toxicity.”

Source: [FDA vepdegestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)

<a id="topic-2.2.2.1.1-17"></a>

###### Vepdegestrant, VERITAC-2: primary results

> “Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).”
> “Adverse events of grade 3 or higher occurred in 23.4% of the patients in the vepdegestrant group and in 17.6% of the patients in the fulvestrant group. Adverse events led to treatment discontinuation in 2.9% and 0.7% of the patients, respectively.”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.1.1-18"></a>

###### Comparator regulatory information: camizestrant

> “ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test”
> “This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation.”

Source: [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.1-19"></a>

###### Camizestrant, SERENA-6: first-line switch at ESR1 mutation detection

> “All patients were required to be currently receiving treatment of an AI in combination with a CDK4/6 inhibitor for ≥ 6 months as the initial endocrine based treatment with no evidence of disease progression as per investigator assessment.”
> “Median PFS was 16 months (95% CI: 12.7, 18.2) in the camizestrant and CDK4/6 inhibitor arm and 9.2 months (95% CI: 7.2, 9.5) in the AI and CDK4/6 inhibitor arm (Hazard ratio 0.44 [95% CI: 0.31, 0.60]; p-value < 0.00001). At the time of the PFS analysis, OS data were not mature.”

Source: [FDA camizestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative)

<a id="topic-2.2.2.1.1-20"></a>

###### Camizestrant, SERENA-4: first-line trial in unselected patients

> “The SERENA-4 Phase III trial of AstraZeneca’s Etcamah (camizestrant) in combination with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, did not meet the primary endpoint of progression-free survival (PFS), however a numerical improvement was observed in the upfront 1st-line treatment of patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer who have not received any systemic treatment for advanced disease.”

Source: [AstraZeneca SERENA-4 update announcement (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/update-serena-4-phase-iii-trial.html)

<a id="topic-2.2.2.1.1-21"></a>

###### Giredestrant plus everolimus, evERA: primary results

> “Patients were randomized 1:1 to giredestrant plus everolimus (giredestrant-everolimus) or standard endocrine therapy (i.e., exemestane, fulvestrant, or tamoxifen) plus everolimus (standard endocrine therapy-everolimus).”
> “median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).”
> “The most common adverse events in both groups were stomatitis (47.3% and 48.9%, respectively), diarrhea (26.9% and 22.6%), and anemia (23.6% and 21.0%).”

Source: [Mayer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674676/)

<a id="topic-2.2.2.1.1-22"></a>

###### Giredestrant plus everolimus: regulatory status

> “the United States (U.S.) Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence or progression on a prior endocrine-based regimen. The FDA is expected to make a decision on the approval by 18 December 2026.”

Source: [Roche giredestrant New Drug Application acceptance announcement (2026)](https://www.roche.com/media/releases/med-cor-2026-02-20)

Additional sources: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext); [Bidard et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454637/); [Oliveira et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39481395/); [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 PI3K, AKT, and mTOR Pathway Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline recommendation: NCCN, PIK3CA, AKT1, or PTEN alterations

> “For patients with alterations in PIK3CA/AKT1/PTEN who have disease progression on at least one endocrine-based regimen in the metastatic setting or recurrence on adjuvant endocrine therapy + CDK4/6 inhibitor, the panel recommends fulvestrant in combination with either alpelisib or capivasertib (Figures 4 and 5).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.2-2"></a>

###### Guideline recommendation: NCCN, everolimus combinations

> “Based on the evidence from the BOLERO-2 trial, the NCCN panel has included everolimus + exemestane as an option for patients who fulfill the entry criteria for BOLERO-2. Tamoxifen or fulvestrant in combination with everolimus have also been included as options. The NCCN panel also notes that if there is disease progression while on an everolimus-containing regimen, there are no data to support an additional line of therapy with another everolimus regimen (Figure 4).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.2-3"></a>

###### Guideline recommendation: ABC8, PI3K/AKT/mTOR pathway inhibitor class

> “The EPIK-B5 trial confirmed that alpelisib + fulvestrant retains meaningful activity after CDK4/6i-based therapy in PIK3CA-mutated disease (median PFS improvement of 4.6 months; HR: 0.52), consolidating this combination as a valid option in the absence of contraindications [ 36 ].”
> “Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management [ 39 ]. The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.”
> “As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.2-4"></a>

###### Guideline recommendation: ASCO 2021, alpelisib and everolimus

> “Alpelisib in combination with ET should be offered to postmenopausal patients in combination with fulvestrant, and to male patients, with HR-positive, HER2-negative, PIK3CA-mutated, ABC, or MBC following prior ET including an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.”
> “Thus, everolimus may be an option in second or subsequent lines of endocrine-based therapy, although the clinical benefits in contemporary practice in patients treated with CDK4/6 inhibitors are not well defined.”
> “There are no data for the use of alpelisib after everolimus, or vice versa, to guide clinical recommendations.”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.2-5"></a>

###### Comparator regulatory information: capivasertib

> “TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-authorized test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.”

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### Capivasertib, CAPItello-291: progression-free survival

> “Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer.”
> “In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).”
> “Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.2.2.1.2-7"></a>

###### Capivasertib, CAPItello-291: biomarker-negative subgroup and overall survival

> “An exploratory analysis of PFS in the 313 (44%) patients whose tumors did not have a PIK3CA/AKT1/PTEN-alteration showed a HR of 0.79 (95% CI: 0.61, 1.02), indicating that the difference in the overall population was primarily attributed to the results seen in the population of patients whose tumors have PIK3CA/AKT1/PTEN-alteration.”
> “At the prespecified final analysis of OS, there was no significant difference in OS between the TRUQAP with fulvestrant arm and the placebo with fulvestrant arm, with HR 0.83 (95% CI: 0.63, 1.10) in the PIK3CA/AKT1/PTEN-altered subgroup.”

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

###### Comparator regulatory information: alpelisib

> “is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen.”
> “Overall, 60% of enrolled patients had tumors with one or more PIK3CA mutations in tissue, 50% had liver/lung metastases, and 6% had previously been treated with a CDK4/6 inhibitor.”

Source: [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf)

<a id="topic-2.2.2.1.2-9"></a>

###### Alpelisib, SOLAR-1: progression-free survival and toxicity

> “In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001)”
> “In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%).”
> “The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively.”

Source: [André et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31091374/)

<a id="topic-2.2.2.1.2-10"></a>

###### Alpelisib, SOLAR-1: overall survival

> “In the PIK3CA-mutated cohort (n = 341), median OS [95% confidence interval (CI)] was 39.3 months (34.1-44.9) for alpelisib-fulvestrant and 31.4 months (26.8-41.3) for placebo-fulvestrant [hazard ratio (HR) = 0.86 (95% CI, 0.64-1.15; P = 0.15)]. OS results did not cross the prespecified efficacy boundary.”

Source: [André et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33246021/)

<a id="topic-2.2.2.1.2-11"></a>

###### Alpelisib after a CDK4/6 inhibitor: BYLieve

> “Patients receiving alpelisib and fulvestrant after an AI and a CDK4/6 inhibitor had a median PFS of 7.3 months and 50.4% were alive without disease progression at 6 months (n = 121).”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.2-12"></a>

###### Comparator regulatory information: inavolisib (first-line, endocrine-resistant disease)

> “ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy”

Source: [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf)

<a id="topic-2.2.2.1.2-13"></a>

###### Inavolisib, INAVO120: progression-free survival

> “The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001).”

Source: [Turner et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39476340/)

<a id="topic-2.2.2.1.2-14"></a>

###### Inavolisib, INAVO120: overall survival

> “After a median follow-up of 34.2 months in the inavolisib group and 32.3 months in the placebo group, the median overall survival was 34.0 months (95% confidence interval [CI], 28.4 to 44.8) with inavolisib and 27.0 months (95% CI, 22.8 to 38.7) with placebo (hazard ratio for death, 0.67; 95% CI, 0.48 to 0.94; P = 0.02 [prespecified boundary for statistical significance, P<0.0469]).”
> “Adverse events led to discontinuation of inavolisib in 6.8% of patients and discontinuation of placebo in 0.6%.”

Source: [Jhaveri et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13496148/)

<a id="topic-2.2.2.1.2-15"></a>

###### Inavolisib: NCCN limitation on sequencing

> “A key limitation of the trial is the lack of cross-over, which is relevant because PIK3CA-pathway inhibitors are known to have significant activity in later line settings. Thus, it is unknown whether treatment with inavolisib in the first-line versus in a later line is truly superior.”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.2-16"></a>

###### Comparator regulatory information: gedatolisib

> “On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.”
> “There was a statistically significant improvement in PFS for Arm A vs Arm C, with a median PFS of 9.3 months (95% CI: 7.2, 16.6) in Arm A and 2.0 months (95% CI: 1.8, 2.3) in Arm C (hazard ratio [HR] 0.24 [95% CI: 0.17, 0.35]; p-value <0.0001). There was also a statistically significant improvement in PFS for Arm B vs Arm C with a median PFS of 7.4 months (95% CI: 5.5, 9.9) in Arm B and 2.0 months (95% CI: 1.8, 2.3) in Arm C (HR 0.33 [95% CI: 0.24, 0.48]; p-value <0.0001).”
> “At the time of the PFS analysis, OS data were not mature with 25% deaths in the overall population.”

Source: [FDA gedatolisib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally)

<a id="topic-2.2.2.1.2-17"></a>

###### Gedatolisib, VIKTORIA-1: safety

> “Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.2.2.1.2-18"></a>

###### Comparator regulatory information: everolimus

> “is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole.”

Source: [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)

<a id="topic-2.2.2.1.2-19"></a>

###### Everolimus, BOLERO-2: progression-free survival and toxicity

> “The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).”
> “Median progression-free survival was 10.6 months and 4.1 months, respectively, according to central assessment (hazard ratio, 0.36; 95% CI, 0.27 to 0.47; P<0.001).”

Source: [Baselga et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5705195/)

<a id="topic-2.2.2.1.2-20"></a>

###### Everolimus, BOLERO-2: overall survival

> “Median OS in patients receiving EVE + EXE was 31.0 months [95% confidence interval (CI) 28.0–34.6 months] compared with 26.6 months (95% CI 22.6–33.1 months) in patients receiving PBO + EXE (hazard ratio = 0.89; 95% CI 0.73–1.10; log-rank P = 0.14).”

Source: [Piccart et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/)

Additional sources: [Rugo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39637900/); [Dilawari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11588547/); [Burstein et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38478799/); [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 CDK4/6 Inhibitors After Progression on a CDK4/6 Inhibitor

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline recommendation: NCCN, another CDK4/6 inhibitor after progression

> “The panel notes that if there is disease progression while on CDK4/6 inhibitor therapy, there are limited data to support an additional line of therapy with another CDK4/6 inhibitor-containing regimen (Figure 4).”
> “The panel recommends treatment with fulvestrant + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib), if CDK4/6 inhibitor was not previously used (category 1).”
> “postMONARCH and MAINTAIN have not shown a OS benefit.”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.3-2"></a>

###### Guideline recommendation: ABC8, CDK4/6 inhibition beyond progression

> “In view of the modest absolute benefit, the suboptimal control arm, and the availability of multiple biomarker-driven options in the post-CDK4/6i setting, the panel considers continued CDK4/6i beyond progression a less preferred strategy, reserving it for patients without access to other targeted therapies and in whom prior CDK4/6i benefit exceeded 12 months; when used, both the CDK4/6i and the endocrine agent should be changed.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.3-3"></a>

###### Guideline recommendation: ASCO 2021, fulvestrant plus a CDK4/6 inhibitor

> “Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting (type: evidence-based, benefits outweigh harms; evidence quality: high; strength of recommendation: strong).”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.3-4"></a>

###### Comparator regulatory information: abemaciclib

> “in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.”

Source: [Verzenio prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208716s022lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### Abemaciclib plus fulvestrant, postMONARCH: progression-free survival

> “At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001).”
> “Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015).”

Source: [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)

<a id="topic-2.2.2.1.3-6"></a>

###### Abemaciclib plus fulvestrant, postMONARCH: overall survival

> “Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR 0.80, 95% CI 0.60-1.06, P = 0.11, boundary for significance not reached).”
> “Updated PFS was consistent with the primary analysis (HR 0.78, 95% CI 0.62-0.99, nominal P = 0.039).”

Source: [Kalinsky et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42926108/)

<a id="topic-2.2.2.1.3-7"></a>

###### Ribociclib with switched endocrine therapy, MAINTAIN

> “Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006.”
> “At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo.”

Source: [Kalinsky et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37207300/)

<a id="topic-2.2.2.1.3-8"></a>

###### Palbociclib continued with fulvestrant, PACE

> “Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62).”
> “The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI.”

Source: [Mayer et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38513188/)

<a id="topic-2.2.2.1.3-9"></a>

###### Imlunestrant plus abemaciclib, EMBER-3: combination arm

> “Among 426 patients in the comparison of imlunestrant–abemaciclib with imlunestrant, the median progression-free survival was 9.4 months and 5.5 months, respectively (hazard ratio, 0.57; 95% CI, 0.44 to 0.73; P<0.001).”
> “However, most patients (65%) in the imlunestrant–abemaciclib group in our trial had received a CDK4/6 inhibitor previously, and the treatment effect of imlunestrant–abemaciclib (hazard ratio for progression or death, 0.51) in these patients was consistent with that in the overall population, and the median progression-free survival was 9.1 months.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.3-10"></a>

###### Imlunestrant plus abemaciclib, EMBER-3: ESR1-mutated subgroup in the approval

> “In an exploratory subgroup analysis in 159 patients with ESR1 mutated tumors for the combination, the PFS HR estimate was 0.53 (95% CI: 0.35, 0.80). Median PFS in patients with ESR1 mutated tumors was 11.1 months (95% CI: 7.4, 13.7) in the imlunestrant and abemaciclib arm and 5.5 months (95% CI: 3.8, 7.2) in the imlunestrant alone arm.”
> “At the time of interim analysis, OS data was immature with 35% of deaths in patients with ESR1 mutated tumors.”

Source: [FDA imlunestrant and abemaciclib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or)

<a id="topic-2.2.2.1.3-11"></a>

###### Imlunestrant plus abemaciclib: NCCN subgroup with prior CDK4/6 inhibitor

> “In those previously treated with a CDK4/6 inhibitor with ESR1-mutated tumors, the median PFS with doublet (n=53) versus the single agent (n=72) was 11.1 versus 5.4 months, respectively (HR, 0.44; 95% CI, 0.28–0.70). The grade ≥3 toxicities were higher with the combination therapy, seen in 49% versus 17%.”
> “Although the combination showed a PFS benefit in the overall population, it is noteworthy that the trial design did not include a comparison with the established combination of fulvestrant + abemaciclib.”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.3-12"></a>

###### Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib: indirect treatment comparison

> “Though not powered for formal hypothesis testing, PFS favored imlunestrant + abemaciclib versus fulvestrant + abemaciclib across all three ITC methods. Hazard ratios (95% confidence intervals) for Bucher, MAIC, and PSM were 0.77 (0.58-1.04), 0.77 (0.55-1.06), and 0.83 (0.56-1.22), respectively.”

Source: [Jhaveri et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12972957/)

Additional sources: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Fulvestrant, Aromatase Inhibitors, and Tamoxifen

<a id="topic-2.2.2.1.4-1"></a>

###### Guideline recommendation: NCCN, endocrine monotherapy

> “AIs as monotherapy are options as subsequent-line therapy. The 3 AIs (anastrozole, letrozole, and exemestane) have shown similar efficacy in the second-line setting.”
> “Patients who have received a prior nonsteroidal AI may benefit from a steroidal AI as a subsequent line of therapy or vice versa.”
> “An analysis of 2 randomized studies of first-line treatment with anastrozole followed by second-line tamoxifen and vice versa showed that tamoxifen is effective as a second-line option.”
> “The clinical benefit rates of fulvestrant versus exemestane in a phase III trial of postmenopausal patients with HR-positive advanced breast cancer who experienced disease progression on prior nonsteroidal AI therapy were observed to be comparable (32.2% vs 31.5%; P=.853).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.4-2"></a>

###### Guideline recommendation: NCCN, fulvestrant dose

> “The PFS was superior with the fulvestrant 500 mg regimen (HR, 0.80; 95% CI, 0.68–0.94; P=.006),74 indicating an increased duration of response (DOR) with the higher dose of fulvestrant.”
> “Median OS was 26.4 versus 22.3 months (HR, 0.81; 95% CI, 0.69–0.96; P=.02).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.4-3"></a>

###### Comparator regulatory information: fulvestrant

> “HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.”
> “The recommended dose of FASLODEX is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter”

Source: [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)

<a id="topic-2.2.2.1.4-4"></a>

###### Comparator regulatory information: exemestane

> “AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy”
> “The recommended dose of AROMASIN in early and advanced breast cancer is one 25 mg tablet once daily after a meal.”

Source: [Aromasin prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020753s025lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

###### OPERA-01 control arm: standard-of-care endocrine monotherapy

> “Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm. The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy”
> “Fulvestrant was recommended to patients who have not previously received fulvestrant.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.1.4-6"></a>

###### Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm

> “However, the clinical activity of endocrine monotherapy in patients who have received prior CDK4/6 or mammalian target of rapamycin inhibition is limited, with a median progression-free survival (PFS) of approximately 2 months, highlighting a major unmet clinical need in the field.”
> “SOC treatment was per investigator's choice of fulvestrant, anastrozole, letrozole, or exemestane monotherapy and dosed according to the labeling.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.4-7"></a>

###### Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm in ESR1-mutated disease

> “The median PFS was 3.8 months (95% CI, 2.2 to 7.3) in the elacestrant arm and 1.9 months (95% CI, 1.9 to 2.1) in the SOC arm.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.1.4-8"></a>

###### Fulvestrant or exemestane: EMBER-3 control arm

> “Patients received INLURIYO 400 mg orally, once daily (n=327), or standard of care (n=324) consisting of either fulvestrant (n=292) or exemestane (n=32).”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.2.2.1.4-9"></a>

###### Fulvestrant or exemestane: EMBER-3 control arm outcomes

> “Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy.”
> “In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.4-10"></a>

###### Fulvestrant: VERITAC-2 control arm outcomes

> “Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).”
> “Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.1.4-11"></a>

###### Fulvestrant: CAPItello-291 control arm outcomes

> “In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.2.2.1.4-12"></a>

###### Fulvestrant: VIKTORIA-1 control arm outcomes

> “The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.2.2.1.4-13"></a>

###### Endocrine monotherapy in the second line: real-world progression-free survival

> “the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”
> “The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

Additional sources: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 PARP Inhibitors for Germline BRCA1 or BRCA2 Variants

<a id="topic-2.2.2.1.5-1"></a>

###### PARP inhibitor recommendations in second-line treatment: ESMO 2026 guideline

> “Poly (ADP-ribose) polymerase inhibitor (PARPi) monotherapy is recommended for patients with a germline BRCA1/2 mutation [I, A].”
> “Options include olaparib (ESMO-MCBS v2.0 score: 4) or talazoparib (ESMO-MCBS v2.0 score: 3).”
> “Olaparib or talazoparib can be recommended for patients with a germline PALB2 mutation [II, B; not European Medicines Agency (EMA) or Food and Drug Administration (FDA) approved].”
> “For patients with tumours harbouring somatic pathogenic or likely pathogenic BRCA1/2 mutations, PARPi monotherapy can also be recommended [II, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.1.5-2"></a>

###### PARP inhibitor recommendation for hormone receptor-positive disease: ASCO 2021 guideline

> “Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy.”

Source: [Moy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34324366/)

<a id="topic-2.2.2.1.5-3"></a>

###### PARP inhibitors versus nonplatinum chemotherapy in BRCA1/2 carriers: ASCO, ASTRO, and SSO 2020 guideline

> “Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers.”
> “Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/2 carriers.”

Source: [Tung et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32243226/)

<a id="topic-2.2.2.1.5-4"></a>

###### Comparator regulatory information: olaparib

> “Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.”
> “The recommended dosage of Lynparza is 300 mg taken orally twice daily, with or without food.”
> “Patients with hormone receptor-positive disease must have progressed on at least 1 endocrine therapy (adjuvant or metastatic), or have disease that the treating healthcare provider believed to be inappropriate for endocrine therapy.”
> “Discontinuation due to an adverse reaction occurred in 5% of patients receiving Lynparza.”

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

###### Comparator regulatory information: talazoparib

> “TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.”
> “The median duration of study treatment was 6.1 months in patients who received TALZENNA and 3.9 months in patients who received chemotherapy.”
> “Serious adverse reactions of TALZENNA occurred in 32% of patients.”
> “Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients.”

Source: [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

###### Prevalence of germline BRCA1 or BRCA2 variants in breast cancer: OlympiAD final analysis

> “Approximately 5% of all breast cancer patients carry a germline deleterious mutation in BRCA1 and/or BRCA2 (BRCAm), with higher rates among those with human epidermal growth factor receptor 2 (HER2)-negative disease”

Source: [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/)

<a id="topic-2.2.2.1.5-7"></a>

###### Olaparib versus chemotherapy: OlympiAD progression-free survival, response, and safety

> “Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive standard therapy.”
> “Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).”
> “The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group.”
> “The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the standard-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively.”

Source: [Robson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28578601/)

<a id="topic-2.2.2.1.5-8"></a>

###### Olaparib versus chemotherapy: OlympiAD final overall survival

> “At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66–1.23; P = 0.513); median follow-up was 25.3 and 26.3 months, respectively.”
> “receptor status (triple negative: 0.93, 0.62–1.43; hormone receptor positive: 0.86, 0.55–1.36)”
> “While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease.”

Source: [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/)

<a id="topic-2.2.2.1.5-9"></a>

###### Talazoparib versus chemotherapy: EMBRACA progression-free survival, response, and safety

> “Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy.”
> “Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001).”
> “The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001).”
> “Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively.”

Source: [Litton et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30110579/)

<a id="topic-2.2.2.1.5-10"></a>

###### Talazoparib versus chemotherapy: EMBRACA final overall survival

> “As the population was either triple-negative or hormone receptor-positive within EMBRACA, the effect of talazoparib on OS in these two subgroups was generally consistent, with HR 0.899 (95% CI 0.634–1.276) for triple-negative patients and HR 0.827 (95% CI 0.597–1.143) for hormone receptor-positive patients.”
> “Altogether, a similar percentage of patients received subsequent systemic antineoplastic therapy in the talazoparib and chemotherapy groups (80.8% and 76.4%, respectively)”

Source: [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Antibody-Drug Conjugates

<a id="topic-2.2.2.1.6-1"></a>

###### Antibody-drug conjugate recommendations in third-line treatment and beyond: ESMO 2026 guideline

> “ChT or antibody–drug conjugates (ADCs) can be recommended for patients with tumours considered endocrine-resistant or refractory when targeted agents have already been used or ruled out due to lack of therapeutically relevant molecular alterations [V, B].”
> “Trastuzumab deruxtecan (T-DXd) is recommended for patients with HER2-low or -ultralow disease after at least two lines of ET for MBC (or after one line of ET if progression occurred within 24 months of adjuvant ET or within 6 months of ET–CDK4/6 inhibitor for MBC) [I, A; ESMO-MCBS v2.0 score: 3].”
> “Sacituzumab govitecan can be recommended for patients with ER-positive, HER2-negative MBC after at least one line of ChT [I, B; ESMO-MCBS v2.0 score: 4].”
> “Datopotamab deruxtecan (Dato-DXd) can also be recommended for patients with ER-positive, HER2-negative MBC who have received at least one prior line of ChT [I, B; ESMO-MCBS v2.0 score: 3].”
> “T-DXd is recommended for patients with HER2-low MBC after at least one line of ChT if not already used [I, A; ESMO-MCBS v2.0 score: 4].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.1.6-2"></a>

###### Antibody-drug conjugate positioning and sequencing: ABC8 consensus 2026

> “In the ADC landscape, DESTINY-Breast06 showed that T-DXd can be an option for patients with HER2-low disease when the decision to initiate cytotoxic therapy is made, now earlier in the treatment sequence, as first-line cytotoxic therapy after progression on endocrine therapy and for whom further endocrine therapy was considered unsuitable, based on a 5.1-month improvement in median PFS over physician's choice chemotherapy (HR: 0.62), OS showed no statistically significant improvement”
> “For patients with HER2 ultra-low disease, the available data remain limited and further evidence is required before a recommendation can be made.”
> “In view of the modest PFS improvement, the absence of mature OS data, the side effect profile, and the availability of other treatment options, Dato-DXd in this setting is not a preferred option at present.”
> “Sacituzumab govitecan has moved to a less favored position in this subtype following the negative results of ASCENT-07, which failed to demonstrate superiority over single-agent chemotherapy as first-line cytotoxic therapy in ER+/HER2-negative ABC (median PFS by BICR: 8.3 months in both arms; HR: 0.85)”
> “In the absence of validated predictive biomarkers and robust evidence from prospective clinical trials, routine sequencing of ADCs in this setting cannot currently be recommended.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.6-3"></a>

###### Trastuzumab deruxtecan for HER2-low disease: ASCO 2022 rapid recommendation update

> “Patients with HER2 IHC 1+ or 2+ and ISH-negative metastatic breast cancer who have received at least one prior chemotherapy for metastatic disease, and if hormone receptor–positive are refractory to endocrine therapy, should be offered treatment with trastuzumab deruxtecan (Type: evidence based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).”

Source: [Moy et al. (2022)](https://ascopubs.org/doi/10.1200/JCO.22.01533)

<a id="topic-2.2.2.1.6-4"></a>

###### Sacituzumab govitecan for hormone receptor-positive disease: ASCO 2023 rapid recommendation update

> “Patients with hormone receptor–positive HER2-negative metastatic breast cancer who are refractory to endocrine therapy and have received at least two prior lines of chemotherapy for metastatic disease may be offered SG.”
> “Key grade ≥ 3 treatment-related adverse events with SG were diarrhea (5%) and neutropenic complications including febrile neutropenia (4%) and neutropenic colitis (2%).”

Source: [Moy et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02807)

<a id="topic-2.2.2.1.6-5"></a>

###### Comparator regulatory information: trastuzumab deruxtecan

> “Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting”
> “HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy”
> “Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU.”

Source: [Enhertu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761139s041s043lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

###### Comparator regulatory information: datopotamab deruxtecan

> “human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.”
> “In the pooled safety population [see Adverse Reactions (6.1)], ocular adverse reactions occurred in 38% of patients treated with DATROWAY.”
> “The most common (≥5%) ocular adverse reactions were dry eye (18%), keratitis (16%), increased lacrimation (6%), and conjunctivitis (5%).”

Source: [Datroway prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761394s003lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

###### Comparator regulatory information: sacituzumab govitecan

> “TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.”
> “TRODELVY can cause severe, life-threatening, or fatal neutropenia.”
> “TRODELVY can cause severe diarrhea.”

Source: [Trodelvy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761115s064lbl.pdf)

<a id="topic-2.2.2.1.6-8"></a>

###### Trastuzumab deruxtecan after chemotherapy in HER2-low disease: DESTINY-Breast04

> “Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor–positive disease and 63 (11.3%) had hormone receptor–negative disease.”
> “In the hormone receptor–positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician’s choice group (hazard ratio for disease progression or death, 0.51; P<0.001) and overall survival was 23.9 months and 17.5 months, respectively (hazard ratio for death, 0.64; P=0.003).”
> “Among patients who had received previous treatment with CDK4/6 inhibitors, the median progression-free survival was 10.0 months in the trastuzumab deruxtecan group; without previous CDK4/6 inhibitor treatment, it was 11.7 months.”
> “Adjudicated, drug-related interstitial lung disease/pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events.”

Source: [Modi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/)

<a id="topic-2.2.2.1.6-9"></a>

###### Trastuzumab deruxtecan in HER2-low disease: DESTINY-Breast04 long-term survival

> “For the HR+ cohort, the median OS was 23.9 months (95% CI 21.7–25.2) in the T-DXd arm and 17.6 months (95% CI 15.1–20.2) in the TPC arm (hazard ratio 0.69; 95% CI 0.55–0.87)”
> “Grade ≥3 TEAEs occurred in 202 patients (54.4%) in the T-DXd arm and in 116 patients (67.4%) in the TPC arm.”
> “The most common TEAEs associated with drug discontinuation were investigator-assessed interstitial lung disease (ILD) and/or pneumonitis at 10.2% in the T-DXd arm and peripheral sensory neuropathy at 2.3% in the TPC arm.”

Source: [Modi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705423/)

<a id="topic-2.2.2.1.6-10"></a>

###### Trastuzumab deruxtecan after endocrine therapy in HER2-low or HER2-ultralow disease: DESTINY-Breast06

> “Of the 866 patients who underwent randomization, 713 had HER2-low disease, and 153 had HER2-ultralow disease.”
> “Among the patients with HER2-low disease, the median progression-free survival was 13.2 months (95% confidence interval [CI], 11.4 to 15.2) in the trastuzumab deruxtecan group and 8.1 months (95% CI, 7.0 to 9.0) in the chemotherapy group (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75; P<0.001); the results were consistent in the exploratory HER2-ultralow population.”
> “Adverse events of grade 3 or higher occurred in 52.8% of the patients in the trastuzumab deruxtecan group and in 44.4% of those in the chemotherapy group.”
> “Adjudicated interstitial lung disease or pneumonitis occurred in 49 patients (11.3%; three events were grade 5 in severity) and in 1 patient (0.2%; grade 2), respectively.”

Source: [Bardia et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39282896/)

<a id="topic-2.2.2.1.6-11"></a>

###### Trastuzumab deruxtecan by time to progression on first-line CDK4/6 inhibitor: DESTINY-Breast06 subgroup analysis

> “Median PFS (95% confidence interval) favored T-DXd versus TPC regardless of time to progression (TTP) on prior first-line endocrine therapy (ET) + cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i): <6 months: 14.0 (11.2-15.9) versus 6.5 (4.2-8.4) months for T-DXd versus TPC; 6-12 months: 13.2 (8.6-16.4) versus 6.9 (4.3-10.4) months; >12 months: 12.9 (9.8-17.1) versus 8.2 (6.9-10.9) months.”

Source: [Curigliano et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41780642/)

<a id="topic-2.2.2.1.6-12"></a>

###### Trastuzumab deruxtecan after endocrine therapy: FDA approval summary

> “Random assignment was 1:1 to T-DXd or investigator's choice of chemotherapy (paclitaxel, nab-paclitaxel, or capecitabine).”
> “The trial also met its key secondary end point, PFS by BICR in the overall population, with a HR of 0.64 (95% CI, 0.54 to 0.76, P < .0001).”
> “This is the first indication specifying the category of HER2-ultralow expression in breast cancer, and an assay to select patients for this category was approved contemporaneously.”

Source: [Dilawari et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40763319/)

<a id="topic-2.2.2.1.6-13"></a>

###### Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 progression-free survival and safety

> “Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367).”
> “The median PFS by BICR was 6.9 months (95% CI, 5.7 to 7.4) with Dato-DXd versus 4.9 months (95% CI, 4.2 to 5.5) with ICC.”
> “The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8% v 44.7%).”
> “The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.”

Source: [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/)

<a id="topic-2.2.2.1.6-14"></a>

###### Datopotamab deruxtecan versus chemotherapy: TROPION-Breast01 final overall survival

> “At data cut-off, median follow-up was 22.8 months.”
> “OS for the Dato-DXd versus ICC arm did not reach statistical significance (hazard ratio 1.01, 95% confidence interval 0.83-1.22, P = 0.9445).”
> “Use of ADCs (trastuzumab deruxtecan and sacituzumab govitecan) as subsequent therapy was imbalanced: 12.3% in the Dato-DXd arm versus 24.0% in the ICC arm.”

Source: [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/)

<a id="topic-2.2.2.1.6-15"></a>

###### Datopotamab deruxtecan: FDA approval summary

> “TB01 demonstrated a 2-month improvement in median PFS for Dato-DXd compared to ICC (6.9 months vs. 4.9 months, respectively; stratified hazard ratio (HR) 0.63 (95% CI: 0.52, 0.76; p<0.0001).”
> “The OS endpoint was not met; at the final analysis (FA) of OS, the median OS was 18.6 months in the Dato-DXd arm and 18.3 months in the ICC arm (HR: 1.01, 95% CI: 0.83, 1.22).”
> “The most commonly reported adverse reactions (≥20%) with Dato-DXd were stomatitis, nausea, fatigue, alopecia, constipation, dry eye, keratitis, and vomiting.”

Source: [Royce et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12393668/)

<a id="topic-2.2.2.1.6-16"></a>

###### Sacituzumab govitecan versus chemotherapy: TROPiCS-02 progression-free survival

> “The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease.”
> “The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively.”
> “Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).”

Source: [Rugo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36027558/)

<a id="topic-2.2.2.1.6-17"></a>

###### Sacituzumab govitecan versus chemotherapy: TROPiCS-02 final overall survival

> “Overall survival was significantly improved with sacituzumab govitecan versus chemotherapy (median 14·4 months [95% CI 13·0-15·7] vs 11·2 months [10·1-12·7]; hazard ratio [HR] 0·79, 95% CI 0·65-0·96; p=0·020); survival benefit was consistent across Trop-2 expression-level subgroups.”
> “ORR was significantly improved with sacituzumab govitecan compared with chemotherapy (57 [21%] patients vs 38 [14%]; odds ratio 1·63 [95% CI 1·03-2·56]; p=0·035)”
> “One fatal adverse event (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.”

Source: [Rugo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37633306/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Chemotherapy

<a id="topic-2.2.2.1.7-1"></a>

###### Chemotherapy recommendations in third-line treatment and beyond: ESMO 2026 guideline

> “At least two lines of endocrine-based therapy can be recommended before moving to non-endocrine-based therapy in endocrine-sensitive disease [V, B].”
> “Sequential single-agent ChT is recommended over combination strategies [II, A].”
> “Combination ChT is recommended when a rapid response is needed due to imminent organ failure [V, A].”
> “Capecitabine, capecitabine–bevacizumab (not EMA or FDA approved in this line), taxane or taxane–bevacizumab (not EMA or FDA approved in this line), may be considered [I, C].”
> “If capecitabine is used, dihydropyrimidine dehydrogenase testing is recommended before treatment is initiated [V, A].”
> “Rechallenge with anthracyclines or taxanes (liposomal anthracyclines or protein-bound paclitaxel, if available) can be recommended beyond third-line treatment in patients with a disease-free interval (DFI) ≥12 months [II, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.1.7-2"></a>

###### Single-agent chemotherapy for endocrine-pretreated disease: ASCO 2021 guideline

> “Patients with HR-positive human epidermal growth factor receptor 2-negative MBC for whom chemotherapy is being considered should be offered single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease.”
> “Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy.”

Source: [Moy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34324366/)

<a id="topic-2.2.2.1.7-3"></a>

###### Comparator regulatory information: capecitabine

> “treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated.”
> “Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary.”
> “Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with oral vitamin K antagonists, such as warfarin”

Source: [Xeloda prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020896s052lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

###### Comparator regulatory information: eribulin

> “HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.”
> “Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting”
> “In Study 1, Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients with metastatic breast cancer (MBC).”

Source: [Halaven prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201532s023lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

###### Comparator regulatory information: paclitaxel protein-bound

> “ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.”
> “Prior therapy should have included an anthracycline unless clinically contraindicated.”

Source: [Abraxane prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

###### Eribulin versus treatment of physician's choice: EMBRACE

> “762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC).”
> “Overall survival was significantly improved in women assigned to eribulin (median 13·1 months, 95% CI 11·8-14·3) compared with TPC (10·6 months, 9·3-12·5; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·041).”
> “Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in 24 (5%) of 503 patients.”

Source: [Cortes et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21376385/)

<a id="topic-2.2.2.1.7-7"></a>

###### Eribulin versus capecitabine: Study 301

> “Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056).”
> “Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30).”
> “Objective response rates were 11.0% for eribulin and 11.5% for capecitabine.”

Source: [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)

<a id="topic-2.2.2.1.7-8"></a>

###### Eribulin in hormone receptor-positive disease: pooled analysis of two phase 3 trials

> “Indeed, women with HER2-negative or triple-negative disease gained a particular benefit; the effects in patients with HER2-negative but hormone-receptor-positive disease were somewhat less robust.”

Source: [Twelves et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4243003/)

<a id="topic-2.2.2.1.7-9"></a>

###### Chemotherapy compared with endocrine-based therapy: network meta-analysis

> “We identified 2689 published results and 140 studies (comprising 50 029 patients) were included in the analysis.”
> “No chemotherapy or hormone therapy regimen was significantly better than palbociclib plus letrozole for progression-free survival.”
> “Moreover, no chemotherapy regimen with or without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of progression-free survival.”

Source: [Giuliano et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31494037/)

<a id="topic-2.2.2.1.7-10"></a>

###### Single-agent chemotherapy in the control arm of a contemporary trial: TROPION-Breast01

> “The median PFS of 4.9 months in the ICC arm of TROPION-Breast01 was generally consistent with previous reports for single-agent chemotherapy.”

Source: [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/)

<a id="topic-2.2.2.1.7-11"></a>

###### Chemotherapy after first-line CDK4/6 inhibitor in practice: systematic review of real-world evidence

> “The weighted average median rwPFS for chemotherapy was 6.1 months (n = 499 total patients), calculated using data from 7 studies reporting median rwPFS values ranging from 3.7 months (n = 249)”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.2.1.7-12"></a>

###### Chemotherapy use and outcomes in second and third lines: SOLTI-1801 CDK-PREDICT

> “In the second-line setting (n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).”
> “Targeted agents were frequent in 2L (51%) and capecitabine in 3L (36%), while endocrine monotherapy yielded poorest rwPFS.”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

Additional sources: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Limitations of Current Therapies

<a id="topic-2.2.2.1.8-1"></a>

###### Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor

The oral estrogen receptor degraders approved after progression on endocrine therapy (elacestrant, imlunestrant, and vepdegestrant) are indicated for ESR1-mutated disease, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. Without ESR1 mutations, the progression-free survival hazard ratio for elacestrant was 0.86 (95% CI 0.63 to 1.19) in 250 participants (52%) in EMERALD, and median progression-free survival in EMBER-3 was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In ESR1-mutated tumors, the ABC8 consensus describes “modest absolute clinical benefit” across the oral SERDs, with hazard ratios generally in the 0.55 to 0.62 range. In EMERALD, median progression-free survival was 2.8 versus 1.9 months in the overall population and 3.8 versus 1.9 months in the ESR1 mutation cohort. In the control arms of VERITAC-2 and EMBER-3, median progression-free survival was 2.1 months with fulvestrant among 270 participants with ESR1 mutations and 3.8 months with standard therapy among participants with ESR1 mutations, respectively. In real-world studies after a first-line CDK4/6 inhibitor, the weighted average median progression-free survival was 3.9 months with single-agent endocrine therapy and 6.1 months with chemotherapy, and in a second cohort, median second-line real-world progression-free survival with endocrine monotherapy was 5.0 months (n = 27).

Fulvestrant 500 mg is administered as two 5 mL intramuscular injections on Days 1, 15, 29, and once monthly thereafter, and injection site pain was reported in 11.6% of participants in the fulvestrant 500 mg group. Hyperglycemia was reported in 65% of participants treated with alpelisib, and increased fasting glucose occurred in 37% of participants treated with capivasertib and 85% of participants treated with inavolisib; adverse events led to discontinuation in 25.0% of participants receiving alpelisib (4.2% with placebo) and 13.0% of participants receiving capivasertib (2.3% with placebo). Overall survival was not significantly improved with capivasertib plus fulvestrant (hazard ratio 0.83 in the PIK3CA/AKT1/PTEN-altered subgroup), alpelisib plus fulvestrant in the PIK3CA-mutated cohort (39.3 versus 31.4 months), everolimus plus exemestane (31.0 versus 26.6 months), abemaciclib plus fulvestrant (32.1 versus 24.6 months), or imlunestrant in ESR1-mutated disease (34.5 versus 23.1 months, boundary for significance not reached). The ABC8 consensus does not recommend rechallenge with a second oral SERD or a second PI3K/AKT/mTOR inhibitor outside clinical trials, and states that following progression on a CDK4/6 inhibitor “the optimal sequence remains undefined”.

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf); [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf); [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf); [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/); [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/); [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/); [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/); [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/); [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/); [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf); [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf); [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf); [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf); [André et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31091374/); [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/); [André et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33246021/); [Piccart et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/); [Kalinsky et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42926108/); [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)

<a id="topic-2.2.2.1.8-2"></a>

###### Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy

Olaparib and talazoparib are indicated for germline BRCA-mutated, HER2-negative disease, and approximately 5% of all breast cancer patients carry a germline deleterious BRCA1 and/or BRCA2 mutation. Neither improved overall survival significantly over chemotherapy: median overall survival was 19.3 months with olaparib and 17.1 months with chemotherapy (hazard ratio 0.90; 0.86 in hormone receptor-positive participants), and the overall survival hazard ratio with talazoparib was 0.827 in hormone receptor-positive participants. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of participants receiving trastuzumab deruxtecan in DESTINY-Breast04, and adjudicated interstitial lung disease or pneumonitis in 11.3% in DESTINY-Breast06; ocular adverse reactions occurred in 38% of participants treated with datopotamab deruxtecan in the pooled safety population; and grade 3 or higher treatment-related neutropenia occurred in 51% of participants receiving sacituzumab govitecan in TROPiCS-02. Overall survival with datopotamab deruxtecan was not significantly different from chemotherapy (hazard ratio 1.01), and the ABC8 consensus states that routine sequencing of antibody-drug conjugates in this setting “cannot currently be recommended”. In the TROPION-Breast01 control arm, single-agent chemotherapy produced a median progression-free survival of 4.9 months, with grade 3 or higher treatment-related adverse events in 44.7% of participants, and eribulin was not superior to capecitabine for overall survival (median 15.9 versus 14.5 months) or progression-free survival (4.1 versus 4.2 months).

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf); [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf); [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/); [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/); [Modi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/); [Bardia et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39282896/); [Datroway prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761394s003lbl.pdf); [Rugo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36027558/); [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/); [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/); [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/); [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)

<a id="topic-2.2.2.1.8-3"></a>

###### ESR1 mutation restriction of oral endocrine therapy: elacestrant label

> “Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with ORSERDU based on the presence of ESR1 mutation(s) in plasma specimen using an FDA-authorized test”
> “An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.2.2.1.8-4"></a>

###### ESR1 mutation restriction of oral endocrine therapy: imlunestrant label

> “Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with INLURIYO based on the presence of ESR1 mutation(s) in a plasma specimen using an FDA-authorized test”
> “a PFS improvement was not demonstrated for INLURIYO monotherapy compared to investigator’s choice of endocrine therapy in either the overall or ESR1m not detected populations, indicating that the benefit for INLURIYO monotherapy was only observed in the ESR1m population.”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.2.2.1.8-5"></a>

###### ESR1 mutation restriction of oral endocrine therapy: vepdegestrant label

> “Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with VEPPANU based on the presence of ESR1 mutation(s) in plasma specimen using an FDA-authorized test”
> “A statistically significant difference in PFS by BICR was observed for the patients whose tumors had ESR1 mutations for VEPPANU compared with fulvestrant.”

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.8-6"></a>

###### No progression-free survival difference without ESR1 mutation: EMBER-3

> “In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)”
> “Among patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with ESR1 mutations but not in the overall population.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.8-7"></a>

###### Modest absolute benefit of oral SERDs: ABC8 consensus 2026

> “Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.”
> “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.”
> “The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.”
> “As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.8-8"></a>

###### Short progression-free survival with endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm

> “Because of the initial drop in PFS in both arms, median PFS may not be a sufficient measure of efficacy in the overall population (2.8 months v 1.9 months) or ESR1 mutation cohort (3.8 months v 1.9 months).”
> “In a recent phase II trial, fulvestrant was associated with a median PFS of 1.9 months and a CBR of 13.7%.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.8-9"></a>

###### Short progression-free survival with fulvestrant after a CDK4/6 inhibitor: VERITAC-2 control arm

> “Patients were required to have disease progression on one to two lines of endocrine therapy, including one line with a CDK4/6 inhibitor.”
> “Median PFS was 5 months (95% CI: 3.7, 7.4) in the vepdegestrant arm and 2.1 months (95% CI: 1.9, 3.5) in the fulvestrant arm (hazard ratio 0.57 [95% CI: 0.42, 0.77]; p-value 0.0001).”
> “OS was immature with 16% of deaths in this population at the time of the PFS analysis.”

Source: [FDA vepdegestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)

<a id="topic-2.2.2.1.8-10"></a>

###### Short progression-free survival with standard endocrine therapy: EMBER-3 control arm

> “Among patients with ESR1 mutations, the median progression-free survival was 5.5 months (95% confidence interval [CI], 3.9 to 7.4) in the imlunestrant group, as compared with 3.8 months (95% CI, 3.7 to 5.5) in the standard-therapy group”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.8-11"></a>

###### Intramuscular administration of fulvestrant: fulvestrant label

> “The recommended dose of FASLODEX is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter”
> “Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy have been reported with FASLODEX injection.”
> “The most frequently reported adverse reactions in the FASLODEX 500 mg group were injection site pain (11.6% of patients), nausea (9.7% of patients), and bone pain (9.4% of patients)”

Source: [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)

<a id="topic-2.2.2.1.8-12"></a>

###### Pharmacologic limitations of fulvestrant: review

> “Clinical challenges with fulvestrant can be related to pharmacologic limitations, including the absence of oral bioavailability,”
> “Pharmacologic limitations regarding the bioavailability of fulvestrant have prompted strong interest in an orally bioavailable alternative.”

Source: [Lloyd et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9340905/)

<a id="topic-2.2.2.1.8-13"></a>

###### Oral route compared with intramuscular fulvestrant: ABC8 consensus 2026

> “The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant.”
> “Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.8-14"></a>

###### Hyperglycemia with PI3K inhibition: alpelisib label

> “Severe hyperglycemia, in some cases associated with hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or ketoacidosis has occurred in patients treated with PIQRAY.”
> “Hyperglycemia was reported in 65% of patients treated with PIQRAY.”
> “In the 187 patients with hyperglycemia, 87% (163/187) were managed with anti-hyperglycemic medication”

Source: [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf)

<a id="topic-2.2.2.1.8-15"></a>

###### Hyperglycemia with AKT inhibition: capivasertib label

> “TRUQAP can cause severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes.”
> “Increased fasting glucose from baseline occurred in 37% of patients treated with TRUQAP, including 11% of patients with Grade 2 (FG > 160 to 250 mg/dL), 2% with Grade 3 (FG > 250 to 500 mg/dL), and 1.1% with Grade 4 (FG > 500 mg/dL) events.”
> “The safety of TRUQAP has not been established in patients with Type 1 diabetes or Type 2 diabetes that is uncontrolled or requiring insulin at baseline as these patients were excluded from clinical studies”

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.2.2.1.8-16"></a>

###### Hyperglycemia with PI3K-alpha inhibition: inavolisib label

> “Increased fasting glucose occurred in 85% of patients treated with ITOVEBI, including 22% of patients with Grade 2 (FPG > 160 to 250 mg/dL), 12% with Grade 3 (FPG > 250 to 500 mg/dL), and 0.6% with Grade 4 (FPG > 500 mg/dL) events.”
> “In INAVO120, 46% (74/162) of patients who received ITOVEBI were treated with oral anti-hyperglycemic medications and 7% (11/162) were treated with insulin to manage increased fasting glucose.”
> “Hyperglycemia led to dose interruption in 28%, to dose reduction in 2.5%, and to discontinuation of ITOVEBI in 1.2% of patients.”

Source: [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf)

<a id="topic-2.2.2.1.8-17"></a>

###### Short real-world progression-free survival after first-line CDK4/6 inhibitor: US Flatiron cohort

> “Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively.”
> “The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.2.1.8-18"></a>

###### Short real-world progression-free survival in second and third lines: SOLTI-1801 CDK-PREDICT

> “Median rwPFS-2L was 5.0 months for endocrine monotherapy (n = 27), 7.0 months for targeted therapies (n = 65), 7.4 months for capecitabine (n = 12), and 8.7 months for other chemotherapy agents (n = 21).”
> “In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).”
> “Endocrine monotherapy was consistently associated with the shortest rwPFS across lines, reinforcing its limited role in this setting.”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="topic-2.2.2.1.8-19"></a>

###### Short real-world progression-free survival in second line: systematic review of real-world evidence

> “The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”
> “no studies reported disaggregated outcomes in the third-line setting or beyond”
> “The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.2.1.8-20"></a>

###### Overall survival not statistically improved: EMBER-3 interim overall survival

> “In patients with ESR1m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].”

Source: [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)

<a id="topic-2.2.2.1.8-21"></a>

###### Overall survival not statistically improved: PARP inhibitor trials

> “In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy, although subsequent treatments may have impacted analysis.”

Source: [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/)

<a id="topic-2.2.2.1.8-22"></a>

###### Overall survival not statistically improved: datopotamab deruxtecan

> “While there was no statistically significant improvement in the dual primary endpoint of OS with Dato-DXd versus ICC, subsequent ADC treatment may have affected OS results.”

Source: [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/)

<a id="topic-2.2.2.1.8-23"></a>

###### Overall survival not statistically improved: eribulin versus capecitabine

> “In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.”

Source: [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)

<a id="topic-2.2.2.1.8-24"></a>

###### Inevitable endocrine resistance and uncertain sequencing: reviews

> “Endocrine resistance inevitably develops in the metastatic setting, often mediated by acquired ESR1 mutations that promote ligand-independent ER activation and reduce sensitivity to standard antiestrogens.”
> “Their optimal integration and sequencing in practice remain uncertain, and for tumors harboring dual ESR1 and PIK3CA mutations, with multiple biomarker-guided options available, the best treatment strategies are unclear.”
> “With several oral SERDs emerging contemporaneously, data are needed to assess their relative efficacy, safety, and potential interchangeability.”

Source: [Lloyd et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42413061/)

<a id="topic-2.2.2.1.8-25"></a>

###### Resistance to anti-oestrogen therapy: review

> “Resistance to anti-oestrogen agents inevitably occurs, mediated by oestrogen receptor (ER)-dependent or ER-independent mechanisms that drive tumour progression.”

Source: [Lloyd et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39179659/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated place in therapy

Palazestrant has no approved indication. The company plans to submit a new drug application in 2027 for monotherapy in second- and third-line ER+/HER2- metastatic breast cancer and anticipates commercial launch in 2028. The FDA Fast Track designation covers ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. In OPERA-01, participants whose disease advanced after at least one endocrine therapy given with a CDK4/6 inhibitor are enrolled “regardless of ESR1 mutation status” and, in Part 2, randomized 1:1 to palazestrant 90 mg once daily or investigator's choice of standard-of-care endocrine therapy (fulvestrant, letrozole, anastrozole, or exemestane). The company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. The approved oral agents in the same setting, elacestrant, imlunestrant, and vepdegestrant, are each indicated only for ESR1-mutated disease after at least one line of endocrine therapy, and the NCCN guideline lists elacestrant, imlunestrant, or vepdegestrant for ESR1-mutated tumors, aromatase inhibitor monotherapy as a subsequent-line option, and fulvestrant with alpelisib or capivasertib for PIK3CA, AKT1, or PTEN alterations. The ESMO 2026 guideline states that at least two lines of endocrine-based therapy can be recommended before non-endocrine therapy in endocrine-sensitive disease and that a fulvestrant–CDK4/6 inhibitor switch or, to a lesser extent, fulvestrant monotherapy may be considered in the absence of targetable alterations. The ABC8 consensus recommends switching the endocrine mechanism of action when resistance emerges, reports oral SERD hazard ratios of 0.55 to 0.62 in ESR1-mutated tumors, and states that “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials”. In one cohort treated after first-line CDK4/6 inhibitor therapy, second-line treatment was cytotoxic chemotherapy in 29.7% of 839 participants, endocrine monotherapy in 12.4%, and continued CDK4/6 inhibitor in 36.0%. Palazestrant is taken orally once daily, whereas fulvestrant is given as two intramuscular injections every 28 days, with injections “mainly requiring in-office administration”. The company plans a field force of approximately 75 to 100 representatives “to cover U.S. breast oncologists” and is studying palazestrant with ribociclib in the first line in OPERA-02, with the goal of positioning it as the “endocrine therapy of choice in the first-line setting”.

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06); [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm); [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and); [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/); [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf); [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf); [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf); [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml); [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext); [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/); [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/); [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.2-2"></a>

###### Proposed initial line of therapy: monotherapy in the second- and third-line setting

> “We are currently evaluating palazestrant in a pivotal Phase 3 trial, called OPERA-01, as a monotherapy in the second- and third-line setting of ER+/HER2- advanced or metastatic breast cancer.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-3"></a>

###### Company positioning for both ESR1-mutated and ESR1 wild-type tumors

> “Palazestrant monotherapy in 2/3L ER+/HER2- MBC offers our first opportunity for market entry in 2028”
> “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-4"></a>

###### Population named in the Fast Track designation

> “In patients with ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-5"></a>

###### Company estimates of United States incidence and market size in the second- and third-line setting

> “Annual U.S. incidence estimated at ~40K”
> “U.S. market potential of ~$3-5B”
> “Olema internal estimate of US market.”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-6"></a>

###### Planned commercial launch and prescriber audience

> “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”
> “Anticipated targeted field force of ~75–100 reps to cover U.S. breast oncologists”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-7"></a>

###### Company positioning as an endocrine backbone and first-line combination partner

> “We believe palazestrant’s oral formulation and dual mechanism of action directly address the limitations of current endocrine therapies, such as fulvestrant, aromatase inhibitors and tamoxifen, and position palazestrant as a potential endocrine therapy of choice for the treatment of ER+ breast cancers.”
> “Our goal is to successfully demonstrate improved efficacy and a favorable tolerability profile in combination with other targeted therapies to position palazestrant as the endocrine therapy of choice in the first-line setting for advanced or metastatic ER+/HER2- breast cancer.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-8"></a>

###### Planned first-line use with ribociclib (OPERA-02)

> “These data further support our thesis that palazestrant possesses key characteristics to make it a potential backbone endocrine therapy of preference for ER+/HER2- breast cancer, while also supporting the ongoing pivotal Phase 3 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- MBC, called OPERA-02.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.2.2.2-9"></a>

###### Company description of endocrine sequencing in metastatic disease

> “When moving a patient from one line of therapy to the next, the standard of care is to switch to an endocrine agent with a different mechanism of action depending upon last therapy, co-morbidities, and individual patient characteristics.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-10"></a>

###### ESMO guideline sequence for second-line and later endocrine-based therapy

> “Selection of second-line therapy (endocrine or non-endocrine) based on disease aggressiveness, disease extent, organ function, progression-free survival on prior ET, somatic and germline mutation status and the associated toxicity profile, can be recommended [V, B].”
> “Elacestrant [I, A; ESMO-MCBS v2.0 score: 3] or imlunestrant [I, A; ESMO-MCBS v2.0 score: 3] are recommended for patients with ESR1-mutated MBC after at least one line of ET, who preferably had a prolonged response to previous CDK4/6 inhibitor therapy.”
> “Fulvestrant–CDK4/6 inhibitor switch [II, C] or fulvestrant monotherapy (to a lesser extent) [I, C; ESMO-MCBS v2.0 score: 1] may be considered in the absence of targetable alterations.”
> “At least two lines of endocrine-based therapy can be recommended before moving to non-endocrine-based therapy in endocrine-sensitive disease [V, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.2-11"></a>

###### ABC8 consensus on switching endocrine mechanism and oral SERD sequencing

> “In general, when resistance emerges, switching the mechanism of action of endocrine therapy, with or without adding targeted treatment, is recommended.”
> “The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.2-12"></a>

###### Endocrine-based regimens preferred after a CDK4/6 inhibitor

> “After a CDK4/6i and ET, oncologists typically treat patients with sequential ET-based regimens as long as possible because these are usually associated with less toxicity than chemotherapy.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.2-13"></a>

###### Oral once-daily administration and the outpatient care setting

> “Palazestrant is a new oral ET taken once daily that may be effective against tumors with or without a mutation in ESR1.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.2-14"></a>

###### Intramuscular fulvestrant requires in-office administration

> “Furthermore, the injections can be painful and burdensome to patients, mainly requiring in-office administration, and oral options may be preferred.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.2-15"></a>

###### Company description of fulvestrant administration

> “Fulvestrant is administered every 28 days in two 5 ml intramuscular injections into the buttocks.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-16"></a>

###### Real-world second-line treatment after first-line CDK4/6 inhibitor in the United States

> “Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively. Fulvestrant was the most commonly prescribed endocrine monotherapy (70 patients, 8.3%).”
> “Three hundred two (36.0%) of patients continued a CDK4/6i.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.2.2-17"></a>

###### Real-world second- and third-line treatment after first-line CDK4/6 inhibitor in a European cohort

> “In the second-line setting ( n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).”
> “In the third-line setting ( n = 95), treatment options were more heterogeneous, including endocrine monotherapy (2%; n = 2), targeted therapies (29%; n = 27), capecitabine (36%; n = 34), other chemotherapy (26%; n = 25), and ADCs (7%; n = 7).”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Palazestrant phase 2 results by ESR1 status at 120 mg (OP-1250-001)

> “Across all 86 patients, the median progression-free survival (PFS) was 4.6 months and the clinical benefit rate (CBR), was 40% with a 6-month PFS rate of 38%. In patients with an ESR1 mutation, the median PFS was 5.6 months and the CBR was 52% with a 6-month PFS rate of 46%. In ESR1 wild-type patients, the median PFS was 3.5 months and the CBR was 32% with a 6-month PFS rate of 35%.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.3-2"></a>

###### Palazestrant results by ESR1 status in the second- and third-line subset (OP-1250-001)

> “In a subset analysis of 49 patients that received palazestrant as a second- or third-line therapy with or without prior chemotherapy, the median PFS was 7.2 months and the CBR was 48% across all patients with a 6-month PFS rate of 54%. In patients with an ESR1 mutation, the median PFS was 7.3 months and CBR was 59% with a 6-month PFS rate of 62%. In ESR1 wild-type patients the median PFS was 5.5 months and the CBR was 38% with a 6-month PFS rate of 44%.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.3-3"></a>

###### Palazestrant plus ribociclib by ESR1 status after a prior CDK4/6 inhibitor (OP-1250-003)

> “Median PFS was 12.2 months for those who received prior treatment with CDK4/6i, including 9.2 months for patients with ESR1 wild-type tumors and 13.8 months for patients with tumors with ESR1 mutations.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.3-4"></a>

###### Investigator interpretation of ESR1-dependent benefit across the class

> “Recent studies showed that imlunestrant may be beneficial only for cancers harboring ESR1 mutations”
> “Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.2.2.3-5"></a>

###### Elacestrant in tumors without a detected ESR1 mutation (EMERALD, FDA review)

> “In an exploratory analysis of PFS in the ESR1-mut-nd subgroup, the HR was 0.86 (95% CI, 0.63 to 1.19), with the median PFS of 1.9 months (95% CI, 1.9 to 3.6) in the elacestrant arm and 2.0 months (95% CI, 1.9 to 2.2) in the SOC arm.”
> “By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.3-6"></a>

###### Imlunestrant by ESR1 status (EMBER-3)

> “In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)”
> “In addition, the treatment effect of imlunestrant–abemaciclib was similar in patients with or without ESR1 or PI3K pathway mutations.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.3-7"></a>

###### Vepdegestrant by ESR1 status (VERITAC-2)

> “Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).”
> “Among patients with ER-positive, HER2-negative advanced breast cancer, vepdegestrant was associated with significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations but not in the full patient population.”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.3-8"></a>

###### Giredestrant plus everolimus by ESR1 status (evERA)

> “Among 207 patients with ESR1 -mutated tumors, median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).”

Source: [Mayer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674676/)

<a id="topic-2.2.2.3-9"></a>

###### Consistency of oral SERD hazard ratios in ESR1-mutated tumors

> “Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.3-10"></a>

###### Duration of prior endocrine therapy plus CDK4/6 inhibitor (EMERALD)

> “In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63).”
> “The P value for interaction between elacestrant treatment and prior ET+CDK4/6i duration (<12 vs. ≥12 months) was statistically significant”
> “Prior ET+CDK4/6i ≥12 months may help identify patients with ESR1-mutated tumors that remain endocrine-sensitive to elacestrant, enabling ET sequencing in the second line before other targeted therapies and drug combinations, and may delay chemotherapy-based regimens, including antibody–drug conjugates.”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.3-11"></a>

###### PIK3CA co-mutation with ESR1 mutation (EMERALD)

> “Among patients with PIK3CA- and ESR1-mutated tumors, the mPFS with elacestrant was 5.5 versus 1.9 months with SOC (HR, 0.42; 95% CI, 0.18–0.94).”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.3-12"></a>

###### Concurrent ESR1 and PI3K pathway mutations with elacestrant in routine practice

> “Disease with dual ESR1 and PI3K pathway mutations (PIK3CA, AKT1, and PTEN) had a median TTNT of 5.2 months.”
> “Higher ESR1 polyclonality (≥4 alterations; 11% of patients) correlated with a shorter TTNT of 5.2 months (hazard ratio, 1.44; 95% confidence interval, 1.01–2.06), but efficacy was consistent across ESR1 alleles (e.g., Y537S and D538G).”

Source: [Lloyd et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770935/)

<a id="topic-2.2.2.3-13"></a>

###### Visceral and bone metastases (EMERALD)

> “ESR1 mutations are associated with visceral metastases and endocrine resistance”
> “In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases)”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.3-14"></a>

###### Visceral and liver metastases with elacestrant in routine practice

> “In patients with coexisting ESR1- and PI3K-pathway–mutated tumors, mTTNT was 6.3 months (95% CI, 4.8–7.9).”
> “mTTNT was 7.9 months (95% CI, 7.1–9.8) in all patients and was also sustained in patients with no prior fulvestrant [12.9 months (95% CI, 7.2–not reached)], no prior chemotherapy [8.4 months (95% CI, 7.1–13.3)], visceral metastasis [7.9 months (95% CI, 7.0–9.9)], and liver metastases [7.2 months (95% CI, 6.3–9.0)].”

Source: [Rugo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770937/)

<a id="topic-2.2.2.3-15"></a>

###### Abemaciclib plus fulvestrant across ESR1 and PIK3CA subgroups (postMONARCH)

> “Consistent abemaciclib treatment effect was observed across the most prevalent biomarker subgroups”
> “HR, 0.79 (95% CI, 0.54 to 1.15) ESR1 detected versus 0.78 (95% CI, 0.54 to 1.12) not detected; HR, 0.76 (95% CI, 0.50 to 1.14) PIK3CA detected versus 0.80 (95% CI, 0.57 to 1.12) not detected.”

Source: [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)

<a id="topic-2.2.2.3-16"></a>

###### ESR1 mutation prevalence by line of therapy

> “ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).”
> “Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### ESMO recommendation for ESR1 testing after progression on an aromatase inhibitor

> “Evaluation of ESR1 mutations [circulating tumour DNA (ctDNA) or tumour tissue] is recommended in ER-positive, HER2-negative MBC following progression on an aromatase inhibitor (AI) with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [I, A; ESCAT score: I-A].”
> “Evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway alterations (PIK3CA, PTEN and AKT1 mutations) using ctDNA or metastatic or primary tumour biopsies is recommended in ER-positive, HER2-negative MBC, mainly in the endocrine-resistant setting, if specific treatments are available [I, A; ESCAT score: I-A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.4-2"></a>

###### ABC8 consensus on ctDNA testing at each progression and retesting

> “The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.”
> “The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound and consistent with both regulatory developments and real-world clinic-genomic data”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.4-3"></a>

###### ABC8 consensus against ctDNA as a test of disease progression

> “We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.4-4"></a>

###### Liquid biopsy for acquired alterations in second and later lines

> “Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines. Reflex TBx should be considered when ctDNA TF < 1%.”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.2.4-5"></a>

###### ESMO guideline interval for response assessment

> “Evaluation of response can be recommended every 2-4 months depending on patient symptoms, disease dynamics, location, extent of metastasis and type of treatment [V, B].”
> “Shortening of disease monitoring intervals cannot be recommended as there is no evidence of an overall survival benefit and there is potential for emotional and financial harm [IV, D].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.4-6"></a>

###### Managed care practices for ESR1 testing and ctDNA monitoring

> “A primary consideration of payers related to aBC is that the optimal biomarker testing parameters, including ctDNA-based monitoring for ESR1m aBC, are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care.”
> “Key insights include that community oncologists and patients may benefit from support, for example, with treatment pathways and patient navigators.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)

<a id="topic-2.2.2.4-7"></a>

###### Prior authorization practices suggested by managed care stakeholders

> “They also indicated that many payers are already working to reduce prior authorization burden through practices such as auto-approvals (eg, for requests in concordance with biomarker testing guidelines), extending authorization duration (eg, from 12 to 24 months), and allowing gold carding, which relaxes prior authorization requirements for providers who have a demonstrated history of complying with coverage criteria.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)

<a id="topic-2.2.2.4-8"></a>

###### ASCO and ONS safety standards for oral antineoplastic therapy

> “A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy.”
> “The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home.”

Source: [Neuss et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27868581/)

<a id="topic-2.2.2.4-9"></a>

###### ASCO and ONS 2024 standards update including home administration

> “The standards presented here include clarification and expansion of existing standards to include home administration and other changes in processes of ordering, preparing, and administering antineoplastic therapy; the advent of immune effector cellular therapy; the importance of social determinants of health; fertility preservation; and pregnancy avoidance.”

Source: [Siegel et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38776491/)

<a id="topic-2.2.2.4-10"></a>

###### Adherence to oral anticancer therapy with a smartphone application (randomized trial)

> “Study groups did not differ across any outcome measure, with an overall mean adherence of 78.81% (SD, 26.66%) per electronic pill caps.”
> “Although the mobile app may not improve outcomes for all patients prescribed oral cancer therapy, the intervention may be beneficial for those with certain risk factors, such as difficulties with adherence or anxiety.”

Source: [Greer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32023526/)

<a id="topic-2.2.2.4-11"></a>

###### Adherence interventions for oral therapy in breast cancer (systematic review)

> “Thirty-six studies met the inclusion criteria and involved a total sample of 28,528 BC patients.”
> “The use of reminders, monitoring patients' medication-taking behaviors and giving feedback were the most frequently implemented techniques in those interventions that resulted significant.”

Source: [Pezzolato et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37571974/)

<a id="topic-2.2.2.4-12"></a>

###### CMS Enhancing Oncology Model scope for breast cancer

> “Unlike OCM, EOM focuses on beneficiaries receiving systemic initiating cancer therapy, and will not include beneficiaries who receive hormonal therapy only.”
> “Subject to certain exceptions, EOM includes the following seven cancer types for beneficiaries undergoing systemic initiating cancer therapy: high-risk breast cancer, chronic leukemia, small intestine/colorectal cancer, lung cancer, lymphoma, multiple myeloma, and high-intensity prostate cancer.”

Source: [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)

<a id="topic-2.2.2.4-13"></a>

###### CMS Enhancing Oncology Model care redesign activities

> “The eight EOM PRAs are: Provide beneficiaries 24/7 access to an appropriate clinician with real-time access to the EOM participant’s medical records; Provide patient navigation, as appropriate, to EOM beneficiaries; Document a care plan for each EOM beneficiary that contains the 13 components of the Institute of Medicine (IOM) Care Management Plan, as applicable to the EOM beneficiary; Treat beneficiaries with therapies in a manner consistent with nationally recognized clinical guidelines; Identify EOM beneficiary health-related social needs using a health-related social needs screening (HRSN) tool; Collect and monitor electronic Patient Reported Outcomes (ePROs); Utilize data for continuous quality improvement (CQI); and Use Certified EHR Technology (CEHRT) as specified in 42 CFR § 414.1415(a).”

Source: [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)

Additional sources: [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### FDA alignment on the 90 mg dose for OPERA-01 Part 2 and OPERA-02

> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial in second- and third-line estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”
> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-2.2.2.5-2"></a>

###### Randomized dose selection in OPERA-01 Part 1

> “The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated with palazestrant 90 mg and 120 mg in Part 1.”
> “Safety, efficacy, and PRO outcomes at the non-selected dose”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

> “There was no clinically significant difference in exposure between 90 mg and 120 mg doses.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.2.2.5-3"></a>

###### REMS and post-approval requirements described by the company

> “For example, the FDA may require a REMS in order to approve palazestrant, which could entail requirements for a medication guide, physician training, and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools.”
> “Prior to seeking accelerated approval for palazestrant or OP-3136, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.2.2.5-4"></a>

###### Post-marketing requirements or commitments

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### Post-approval safety reporting and surveillance described by the company

> “Any regulatory approvals that we may receive for palazestrant, OP-3136, or any product candidate we develop in the future, will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.2.2.6-2"></a>

###### Post-approval monitoring requirements

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### OPERA-01 planned primary endpoint

> “The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.7-2"></a>

###### OPERA-01 stated rationale and expected benefit

> “More effective ETs that can overcome resistance are needed to improve clinical outcomes and maintain quality of life by delaying chemotherapy.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.7-3"></a>

###### Company statement of the OPERA-01 design objective

> “OPERA-01 Phase 3 monotherapy trial designed to show superior efficacy in ESR1 mutant and ESR1 wild-type tumors”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.7-4"></a>

###### Observed palazestrant monotherapy outcomes and stated expected benefit (OP-1250-001)

> “In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall.”
> “Palazestrant could result in prolongation of time on endocrine therapy, thereby increasing time to disease progression and delaying the transition to cytotoxic chemotherapy.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.2.2.7-5"></a>

###### Standard endocrine therapy outcomes in the EMERALD control arm

> “Accordingly, 6-month PFS rates were 34.3% (95% CI, 27.2 to 41.5) versus 20.4% (95% CI, 14.1 to 26.7) for the elacestrant versus SOC arms, respectively, in all patients and 40.8% (95% CI, 30.1 to 51.4) versus 19.1% (95% CI, 10.5 to 27.8), respectively, in patients with ESR1 mutation.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.7-6"></a>

###### Fulvestrant outcomes by duration of prior CDK4/6 inhibitor (EMERALD)

> “In those patients who received fulvestrant, the mPFS ranged from 1.9 to 2.1 months across the subgroups evaluated based on prior ET+CDK4/6i duration”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.7-7"></a>

###### Standard endocrine therapy and imlunestrant outcomes in ESR1-mutated disease (EMBER-3)

> “Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.7-8"></a>

###### Fulvestrant and vepdegestrant outcomes in ESR1-mutated disease (VERITAC-2)

> “Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.7-9"></a>

###### Fulvestrant control arm outcomes in a PIK3CA wild-type population (VIKTORIA-1)

> “The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.2.2.7-10"></a>

###### Fulvestrant control arm outcomes after an aromatase inhibitor with or without a CDK4/6 inhibitor (CAPItello-291)

> “Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer. In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.2.2.7-11"></a>

###### Fulvestrant with and without abemaciclib after progression on a CDK4/6 inhibitor (postMONARCH)

> “At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37%”

Source: [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)

<a id="topic-2.2.2.7-12"></a>

###### Real-world progression-free survival with second-line therapy after first-line CDK4/6 inhibitor (systematic review)

> “The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”
> “The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.2.7-13"></a>

###### Real-world progression-free survival with second-line therapy in the United States

> “The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.2.7-14"></a>

###### Real-world second-line progression-free survival by treatment group in a European cohort

> “Median rwPFS-2L was 5.0 months for endocrine monotherapy ( n = 27), 7.0 months for targeted therapies ( n = 65), 7.4 months for capecitabine ( n = 12), and 8.7 months for other chemotherapy agents ( n = 21).”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="topic-2.2.2.7-15"></a>

###### Real-world time to next treatment with oral SERD monotherapy in ESR1-mutated disease

> “The median TTNT was 6.4 months, and the time-to-treatment-discontinuation was 4.6 months. In those with ≤1 prior lines of metastatic therapy, the TTNT was 8.8 months, compared with 6.0 months in the third-line setting.”

Source: [Lloyd et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770935/)

<a id="topic-2.2.2.7-16"></a>

###### Real-world time to next treatment with elacestrant by prior lines of endocrine therapy

> “Median TTNT (mTTNT) was 8.2 months [95% confidence interval (CI), 6.3–13.0] in patients with 1 to 2 prior lines and 7.5 months (95% CI, 7.1–9.9) in those with ≥3 prior lines of ET.”

Source: [Rugo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770937/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
